

PT Therapeutic agent for treating transcription factor-related illnesses

PT such as proliferative malignancies, comprises an oligonucleotide for
 XX regulating transcription factor function -
 PS Claim 15; Page 34; 43pp; English.

CC This sequence represents a STAT5 (signal transducer and activator of
 CC transcription 5) protein binding sequence. The invention relates to a
 CC therapeutic agent comprising an effective amount of an oligonucleotide
 CC (1) for modulating the function of transcription factors and a
 CC pharmaceutical acceptable carrier. The oligonucleotides can be used in a
 CC method of removing malignant cells in vitro. The oligonucleotides can be
 CC used in compositions to inhibit transcription factors in illnesses where
 CC transcription factors play a role, especially proliferative malignancies,
 CC neoplastic diseases, and immunological and inflammatory disorders.

XX Sequence 21 BP; 8 A; 3 C; 3 G; 7 T; 0 other;

Query Match 100.0%; Score 21; DB 21; Length 21;
 Best Local Similarity 100.0%; Pred. No. 2.5;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 AGATTCTAGGAATTCATC 21
 DB 1 AGATTCTAGGAATTCATC 21

RESULT 2

AAV46012
 ID AAV46012 standard; DNA; 20 BP.

XX AAV46012:

XX 15-OCT-1998 (first entry)

XX Immune Adjuvant STAYS.

XX Immune system; adjuvant; vaccine; canker; prophylactic; pathogenicity;

XX modulator; tolerance; regulatory; helper cell; antigen; immunoglobulin;

XX Ig class; autoimmune response; T-cell; B-cell; tumor; ss.

XX Class Bacteria.

XX EPR55184-A1.

XX 29-JUL-1998.

XX 23-JAN-1997; 97EP-0101019.

XX 23-JAN-1997; 97EP-0101019.

XX (HEG/) HEGS K.

XX (LIPF/) LIPFORD G B.

XX (WAGN/) WAGNER H.

XX Heeg K, Lipford GB, Wagner H;

XX WPI: 1998-389630/34.

XX Adjuvant composition comprises polynucleotide fragment and antigen
 XX - used as vaccine to treat or prevent e.g. cancer or pathogen
 XX infections and to modulate immune response e.g. tolerance break and
 XX regulation of TH1/TH2 cells

XX Example 5; Page 9; 28pp; English.

XX AAV45993-V46019 are fragments of bacterial polynucleotides which are
 XX used as immune adjuvants for inclusion into vaccines to treat cancer and
 XX for prophylaxis and/or treatment of conditions caused by pathogenic
 XX micro-organisms. The polynucleotide is used for modulation of an immune
 XX response and the modulation is selected from the group break of
 XX tolerance, regulation of TH1/TH2 helper cell responses, switch of Ig
 XX classes, treatment of autoimmune responses and induction of tolerances.
 XX DNA oligomers are used to enhance the reactivity of immune cells to

CC viral, bacterial and parasitic antigens, to break tolerance in anergic T
 CC and B cells e.g. against tumour antigens, as adjuvants in vaccination
 CC against tumour-defined antigens and immunostimulatory substances in an
 CC immune response against tumours and to suppress immune reactions of the
 CC innate and acquired immune system. The composition is inexpensive and
 CC stable and does not cause lethal shock, which happens with prior art
 CC bacterial sequences.

XX Sequence 20 BP; 7 A; 3 C; 3 G; 7 T; 0 other;

Query Match 85.7%; Score 18; DB 19; Length 20;
 Best Local Similarity 100.0%; Pred. No. 59;
 Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 AGATTCTAGGAATTCATC 18
 DB 1 AGATTCTAGGAATTCATC 18

RESULT 3

AAI39155
 ID AAI39155 standard; DNA; 20 BP.

XX AAI39155;

XX 05-SEP-2002 (first entry)

XX Murine Toll-like receptor related CpG DNA SEQ ID No 30.

XX Murine Toll-like receptor; TLR9; TLR7; TLR8; ISNA; ds.

XX Unidentified.

XX W0200222809-A2.

XX 21-MAR-2002.

XX 17-SEP-2001; 2001WO-US29229.

XX 15-SEP-2000; 2000US-2330/5P.

XX 23-JAN-2001; 2001US-263657P.

XX 17-MAY-2001; 2001US-291726P.

XX 22-JUN-2001; 2001US-300210P.

XX (COLE-) COLEY PHARM GMBH.

XX Bauer S, Lipford G, Wagner H;

XX WPI: 2002-393964/42.

XX New isolated murine Toll-like receptor (TLR)9, TLR7, TLR8 polypeptides,
 XX useful for identifying species specificity of immunostimulatory nucleic
 XX acid and identifying immunostimulatory nucleic acids -
 XX Disclosure; Page 76; 195pp; English.

XX The invention relates to isolated murine Toll-like receptors (TLR)9,
 XX TLR7 and TLR8 polypeptides. These polypeptides comprise fully defined
 XX sequences of 1032, 1050 or 1032 amino acids as given in specification, or
 XX their fragments, where TLR9, TLR7 and TLR8 polypeptides or their
 XX fragments have an amino acid sequence which is identical to human TLR9,
 XX TLR7 or TLR8 polypeptides or their fragment except for at least one amino
 XX acid of a murine TLR polypeptide. The isolated nucleic acids of the
 XX invention are useful for inhibiting TLR9 signalling activity in a cell.
 XX TLR7, TLR8 and TLR9 polypeptides are useful for identifying nucleic acid
 XX molecules which interact with a TLR polypeptide or its fragment. The
 XX TLR7, TLR8 and TLR9 polypeptides are also useful for identifying ISNA. The
 XX signalling activity of a test compound (that is not a nucleic acid, and
 XX is a polypeptide or a part of a combinatorial library of compounds) with
 XX an ISNA. The TLR7, TLR8 and TLR9 polypeptides are also useful for
 XX identifying species specificity of an ISNA. The isolated nucleic acids of
 XX the invention are useful as probes or primers. This polynucleotide

CC sequence represents DNA relating to the isolated Toll-like receptors of
CC the invention.

SO Sequence 20 BP; 7 A; 3 C; 3 G; 8 T; 0 other;

Query Match 85.7%; Score 18; DB 24; Length 20;

Best Local Similarity 100.0%; Pred. No. 59;

Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 AGATTCTAGCAATTCAA 18
DB 1 AGATTCTAGCAATTCAA 18

RESULT 4
AAA54479
ID AAA54479 standard; DNA; 100 BP.

AAA54479;

11-APR-2001 (first entry)

DNA fragment comprising STAT transcription factors.

DE zcytor 10 cytokine receptor; cytokine; receptor; antibody; ligand;
KW binding; detection; modulation; recombinant cell;
KW haematopoietic cell; lymphoid cell; myeloid cell; lymph;
KW immune system; blood; bone; inflammatory response; inflammation;
KW spleen; human; primer; ss.

Synthetic.

WO200068381-A1.

16-NOV-2000.

11-MAY-2000; 2000WO-US12924.

11-MAY-1999; 99US-0309861.

(ZYMO) ZYMOGENETICS INC.

Presnell SR, Foster DC, Hammond AK, Lok S;

WPI, 2001-016096/02.

DR New cytokine receptor mouse zcytor 10, useful for detecting ligands
PT that stimulate proliferation or development of haematopoietic,
PT lymphoid and myeloid cells

Example 19; Page 128; 134pp; English.

XX Isolating a nucleotide which encodes the zcytor 10 cytokine
CC receptor enables the production of recombinant cells expressing the
CC receptor. Those cells can then be used to detect the presence of a
CC modulator of zcytor10 protein by culturing the cells in the presence
CC of a test ligand and comparing levels of activity of mouse zcytor10
CC in the presence and absence of the test sample. Similarly, detection
CC of zcytor10 receptor ligand within a test sample can be achieved.
CC The method comprising contacting a test sample containing an amino
CC acid sequence from Cys15 or Gly25 to Pro230 of the zcytor 10
CC cytokine receptor and detecting the binding of the polypeptide to a
CC ligand in the sample. Specified peptide fragments of the zcytor 10
CC cytokine receptor and the methods described are used to identify
CC ligands that stimulate the proliferation and/or development of
CC haematopoietic, lymphoid and myeloid cells. Peptide fragments of
CC the cytokine receptor are useful for treating lymphoid, immune,
CC inflammatory, splenic, blood or bone disorders and for generating
CC antibodies directed against the receptor. An exemplary luciferase
CC mammalian expression vector is the K2134 plasmid which was
CC constructed with two complementary oligonucleotides (AAA54479,
CC AAA54480) which comprise STAT transcription factors from 4 genes
CC (a modified c-fos sis element, the p21 SIE1 from the p21 WAF1

CC gene, the mammary gland response element of the Beta-casein gene
CC and a STAT inducible element of the Fcg RI gene.

SO Sequence 100 BP; 24 A; 33 C; 17 G; 26 T; 0 other;

Query Match 85.7%; Score 18; DB 22; Length 100;

Best Local Similarity 100.0%; Pred. No. 63;

Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 AGATTCTAGCAATTCAA 18
DB 67 AGATTCTAGCAATTCAA 84

RESULT 5
AAA54480/c
ID AAA54480 standard; DNA; 100 BP.

AAA54480;

11-APR-2001 (first entry)

DNA fragment comprising STAT transcription factors.

DE zcytor 10 cytokine receptor; cytokine; receptor; antibody; ligand;
KW binding; detection; modulation; recombinant cell;
KW haematopoietic cell; lymphoid cell; myeloid cell; lymph;
KW immune system; blood; bone; inflammatory response; inflammation;
KW spleen; human; primer; ss.

Synthetic.

WO200068381-A1.

16-NOV-2000.

11-MAY-2000; 2000WO-US12924.

11-MAY-1999; 99US-0309861.

(ZYMO) ZYMOGENETICS INC.

Presnell SR, Foster DC, Hammond AK, Lok S;

WPI, 2001-016096/02.

DR New cytokine receptor mouse zcytor 10, useful for detecting ligands
PT that stimulate proliferation or development of haematopoietic,
PT lymphoid and myeloid cells

Example 19; Page 128; 134pp; English.

XX Isolating a nucleotide which encodes the zcytor 10 cytokine
CC receptor enables the production of recombinant cells expressing the
CC receptor. Those cells can then be used to detect the presence of a
CC modulator of zcytor10 protein by culturing the cells in the presence
CC of a test ligand and comparing levels of activity of mouse zcytor10
CC in the presence and absence of the test sample. Similarly, detection
CC of zcytor10 receptor ligand within a test sample can be achieved.
CC The method comprising contacting a test sample containing an amino
CC acid sequence from Cys15 or Gly25 to Pro230 of the zcytor 10
CC cytokine receptor and detecting the binding of the polypeptide to a
CC ligand in the sample. Specified peptide fragments of the zcytor 10
CC cytokine receptor and the methods described are used to identify
CC ligands that stimulate the proliferation and/or development of
CC haematopoietic, lymphoid and myeloid cells. Peptide fragments of
CC the cytokine receptor are useful for treating lymphoid, immune,
CC inflammatory, splenic, blood or bone disorders and for generating
CC antibodies directed against the receptor. An exemplary luciferase
CC mammalian expression vector is the K2134 plasmid which was
CC constructed with two complementary oligonucleotides (AAA54479,
CC AAA54480) which comprise STAT transcription factors from 4 genes
CC (a modified c-fos sis element, the p21 SIE1 from the p21 WAF1

CC gene, the mammary gland response element of the beta-casein gene
CC and a 5'ATG inducible element of the FcgRI gene.

XX Sequence 100 BP; 26 A; 17 C; 33 G; 24 T; 0 other;

Query Match 85.7%; Score 18; DB 24; Length 100;
Best Local Similarity 100.0%; Pred. No. 63;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGATTCTAGCAATTCAA 18
DB 38 AGATTCTAGCAATTCAA 21

RESULT 6
ID ABA93801 standard; DNA; 100 BP.

XX ABA93801;

DT 01-MAY-2002 (first entry)

DE K2134 plasmid construction oligonucleotide SEQ ID NO:43

XX Zcytor17; chromosome 5; 5q11; cytokine receptor; immunomodulatory;
XX antiinflammatory; antiviral; antirheumatic; antiarthritic; cytostatic;
XX muscular; lymphoid; immune; inflammatory; splenic; blood; bone;
XX infection; immunosuppression; cytotoxicity; leukopenia; Crohn's disease;
XX autoimmune disease; rheumatoid arthritis; multiple sclerosis; cancer;
XX inflammatory disease; pancreatitis; inflammatory bowel disease;
XX PCR primer; probe; ss.

OS Synthetic.

PN WO200200721-A2.

PD 03-JAN-2002.

PF 26-JUN-2001; 2001WO-US20484.

PR 26-JUN-2000; 2000US-214282P.

PR 29-JUN-2000; 2000US-214955P.

PR 08-FEB-2001; 2001US-267963P.

PA (ZYMO) ZYMOGENETICS INC.

PI Sprecher CA, Presnell SR, Gao Z, Whitmore TE, Kuijper JL;

PI Maurer MF;

DR WPI; 2002-090519/12.

XX Example 19; Page 190; 235pp; English.

XX The present invention describes a cytokine receptor designated zcytor17.

XX zcytor17 has immunomodulatory, antiinflammatory, antiviral, cytostatic,

XX antirheumatic, antiarthritic and muscular activities. The zcytor17

XX proteins are useful for treating and diagnosing lymphoid, immune,

XX inflammatory, splenic, blood or bone disorders. Agonists or

XX anti-zcytor17 antibodies are useful in stimulating cell-mediated

XX immunity and for stimulating lymphocyte proliferation, such as in the

XX treatment of infections involving immunosuppression, including certain

XX viral infections. They are also useful for inducing cytotoxicity and

XX for treating leukopenias. Antagonist of zcytor17 polypeptides are useful

XX for treating autoimmune diseases (e.g. rheumatoid arthritis and multiple

XX sclerosis), inflammatory diseases (e.g. Crohn's disease), cancer,

XX pancreatitis, and inflammatory bowel disease. Zcytor17 was mapped to

CC chromosome 5, specifically to the 5q11 chromosomal region. ABA93767 to

CC ABA93843 and ABB05730 to ABB05745 represent sequences used in the

CC exemplification of the present invention.

XX Sequence 100 BP; 24 A; 33 C; 17 G; 26 T; 0 other;

Query Match 85.7%; Score 18; DB 24; Length 100;
Best Local Similarity 100.0%; Pred. No. 63;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGATTCTAGCAATTCAA 18
DB 67 AGATTCTAGCAATTCAA 84

RESULT 7
ID ABA93802/C
XX ABA93802; standard; DNA; 100 BP.

XX ABA93802;

DT 01-MAY-2002 (first entry)

DE K2134 plasmid construction oligonucleotide SEQ ID NO:44.

XX Zcytor17; chromosome 5; 5q11; cytokine receptor; immunomodulatory;
XX antiinflammatory; antiviral; antirheumatic; antiarthritic; cytostatic;
XX muscular; lymphoid; immune; inflammatory; splenic; blood; bone;
XX infection; immunosuppression; cytotoxicity; leukopenia; Crohn's disease;
XX autoimmune disease; rheumatoid arthritis; multiple sclerosis; cancer;
XX inflammatory disease; pancreatitis; inflammatory bowel disease;
XX PCR primer; probe; ss.

OS Synthetic.

PN WO200200721-A2.

PD 03-JAN-2002.

PF 26-JUN-2001; 2001WO-US20484.

PR 26-JUN-2000; 2000US-214282P.

PR 29-JUN-2000; 2000US-214955P.

PR 08-FEB-2001; 2001US-267963P.

PA (ZYMO) ZYMOGENETICS INC.

PI Sprecher CA, Presnell SR, Gao Z, Whitmore TE, Kuijper JL;

PI Maurer MF;

DR WPI; 2002-090519/12.

XX Example 19; Page 190; 235pp; English.

XX The present invention describes a cytokine receptor designated zcytor17.

XX zcytor17 has immunomodulatory, antiinflammatory, antiviral, cytostatic,

XX antirheumatic, antiarthritic and muscular activities. The zcytor17

XX proteins are useful for treating and diagnosing lymphoid, immune,

XX inflammatory, splenic, blood or bone disorders. Agonists or

XX anti-zcytor17 antibodies are useful in stimulating cell-mediated

XX immunity and for stimulating lymphocyte proliferation, such as in the

XX treatment of infections involving immunosuppression, including certain

XX viral infections. They are also useful for inducing cytotoxicity and

XX for treating leukopenias. Antagonist of zcytor17 polypeptides are useful

XX for treating autoimmune diseases (e.g. rheumatoid arthritis and multiple

XX sclerosis), inflammatory diseases (e.g. Crohn's disease), cancer,

CC pancreatitis, and inflammatory bowel disease. Zcytor17 was mapped to

CC chromosome 5, specifically to the 5q11 chromosomal region. ABA93767 to

CC ABA93843 and ABB05730 to ABB05745 represent sequences used in the

CC exemplification of the present invention.

XX Sequence 100 BP; 26 A; 17 C; 33 G; 24 T; 0 other;

Query Match 85.7%; Score 18; DB 24; Length 100;
Best Local Similarity 100.0%; Pred. No. 63;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 AGATTCTAGCAATTCAA 18
|||||
DB 38 AGATTCTAGCAATTCAA 21

RESULT 8
AAS20691
ID AAS20691 standard; DNA; 100 BP.
AC AAS20691;
XX
XX 09-APR-2002 (first entry)
DE Plasmid K2 134 oligonucleotide ZC12749.
XX
XX Cytokine; zaiaphall ligand; zaiaphall receptor; NK cell progenitor;
KW natural killer cell proliferation; T-cell proliferation;
KW B-cell proliferation; anti-tumour response; immune system;
KW immunostimulant; cytostatic; primer; ss.
XX
XX Synthetic.
XX US6307024-B1.
XX 23-OCT-2001.
XX 09-MAR-2000; 2000US-0522217.
XX
XX 09-MAR-1999; 99US-123547P.
XX 11-MAR-1999; 99US-123904P.
XX 01-JUL-1999; 99US-142013P.
XX
XX (ZYMO) ZYMOGENETICS INC.
XX
XX Novak JE, Presnell SR, Sprecher CA, Foster DC, Holly RD, Gross JA;
PI Johnston JV, Nelson AJ, Dillon SR, Hammond AK;
XX
XX WFI; 2002-040208/05.
XX
XX New zaiaphall ligand polypeptides and polynucleotides, useful for
PT stimulating proliferation, activation, differentiation and/or induction
PT of inhibition of specialized cell function, or for stimulating an
PT antigenic response -
XX
XX Example 20; Column 149-150; 105pp; English.
XX
XX The present invention relates to the isolation of a novel cytokine,
CC zaiaphall ligand and the polynucleotide encoding it. The invention
CC also gives the sequence for the zaiaphall receptor and the polynucleotide
CC encoding it. The zaiaphall ligand polypeptide stimulates proliferation of
CC natural killer (NK) cells or NK cell progenitors, the activation of NK
CC cells, proliferation of T-cells, proliferation of B-cells stimulated
CC with anti-CD40 antibodies, stimulates an antigenic response in a mammal,
CC and reduces proliferation of B-cells stimulated with anti-IgM antibodies.
CC The zaiaphall ligand polypeptide is also useful in preparing antibodies
CC that bind to zaiaphall ligand epitopes. The zaiaphall ligand
CC polynucleotides can be used as probes or primers to clone regions
CC of a zaiaphall ligand gene, and in gene therapy. Zaiaphall ligand may
CC also be used to identify inhibitors of its activity, to enhance the
CC generation of anti-tumour responses with or without the infusion of
CC donor lymphocytes, and to activate or stimulate the immune system.
CC The present sequence represents an oligonucleotide used to construct
CC plasmid K2 134 in the methods of the present invention.
XX
XX Sequence 100 BP; 25 A; 32 C; 17 G; 26 T; 0 other;
SO

Query Match 85.7%; Score 18; DB 24; Length 100;
Best Local Similarity 100.0%; Pred. No. 63;

Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 AGATTCTAGCAATTCAA 18
|||||
DB 67 AGATTCTAGCAATTCAA 84

RESULT 9
AAS20692/c
ID AAS20692 standard; DNA; 100 BP.
AC AAS20692;
XX
XX 09-APR-2002 (first entry)
DE Plasmid K2 134 oligonucleotide ZC12748.
XX
XX Cytokine; zaiaphall ligand; zaiaphall receptor; NK cell progenitor;
KW natural killer cell proliferation; T-cell proliferation;
KW B-cell proliferation; anti-tumour response; immune system;
KW immunostimulant; cytostatic; primer; ss.
XX
XX Synthetic.
XX US6307024-B1.
XX 23-OCT-2001.
XX 09-MAR-2000; 2000US-0522217.
XX
XX 09-MAR-1999; 99US-123547P.
XX 11-MAR-1999; 99US-123904P.
XX 01-JUL-1999; 99US-142013P.
XX
XX (ZYMO) ZYMOGENETICS INC.
XX
XX Novak JE, Presnell SR, Sprecher CA, Foster DC, Holly RD, Gross JA;
PI Johnston JV, Nelson AJ, Dillon SR, Hammond AK;
XX
XX WFI; 2002-040208/05.
XX
XX New zaiaphall ligand polypeptides and polynucleotides, useful for
PT stimulating proliferation, activation, differentiation and/or induction
PT of inhibition of specialized cell function, or for stimulating an
PT antigenic response -
XX
XX Example 20; Column 149-151; 105pp; English.
XX
XX The present invention relates to the isolation of a novel cytokine,
CC zaiaphall ligand and the polynucleotide encoding it. The invention
CC also gives the sequence for the zaiaphall receptor and the polynucleotide
CC encoding it. The zaiaphall ligand polypeptide stimulates proliferation of
CC natural killer (NK) cells or NK cell progenitors, the activation of NK
CC cells, proliferation of T-cells, proliferation of B-cells stimulated
CC with anti-CD40 antibodies, stimulates an antigenic response in a mammal,
CC and reduces proliferation of B-cells stimulated with anti-IgM antibodies.
CC The zaiaphall ligand polypeptide is also useful in preparing antibodies
CC that bind to zaiaphall ligand epitopes. The zaiaphall ligand
CC polynucleotides can be used as probes or primers to clone regions
CC of a zaiaphall ligand gene, and in gene therapy. Zaiaphall ligand may
CC also be used to identify inhibitors of its activity, to enhance the
CC generation of anti-tumour responses with or without the infusion of
CC donor lymphocytes, and to activate or stimulate the immune system.
CC The present sequence represents an oligonucleotide used to construct
CC plasmid K2 134 in the methods of the present invention.
XX
XX Sequence 100 BP; 26 A; 17 C; 32 G; 25 T; 0 other;
SO

Query Match 85.7%; Score 18; DB 24; Length 100;
Best Local Similarity 100.0%; Pred. No. 63;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 AGATTCTAGCAATTCAA 18

Db 38 AGATTCTAGCAATTCAA 21
|||||

RESULT 10
AAD22953
ID AAD22953 standard; DNA: 100 BP.

AC AAD22953;

XX 26-FEB-2002 (first entry)

DE BAF3/K2134/zalpal1 cell line constructing ZC12.749 oligonucleotide.

XX Zalpal1; cytokine receptor; immunosuppressive; cytostatic; haemostatic;
XX inflammatory disorder; cell proliferation; immune disorder; cancer; SLE;
KW systemic lupus erythematosus; myasthenia gravis; rheumatoid arthritis;
KW diabetes; autoimmune disease; multiple sclerosis; ulcerative colitis;
KW inflammatory bowel disease; sepsis; Crohn's disease; viral infection;
KW asthma; ss.

XX Unidentified.

PN WO200177171-A2.

PD 18-OCT-2001.

PE 03-APR-2001; 2001WO-US10872.

XX 05-APR-2000; 2000US-194731P.

PR 28-JUL-2000; 2000US-222121P.

XX (ZYMO) ZYMOGENETICS INC.

PI Sprecher CA, Novak JE, West JM, Presnell SR, Holly RD, Nelson AJ;

DR WPI; 2002-025898/03.

XX Novel soluble receptor polypeptides and polynucleotides used as
PT cytokine antagonist for stimulating ligand activity-induced
PT proliferation of hematopoietic cells and for suppressing immune
PT response in a mammal

XX Example 19; Page 213; 243pp; English.

XX The invention relates to an isolated soluble zalpal1 cytokine receptor
CC polypeptide and their cDNA molecules. Zalpa proteins are useful for
CC inhibiting or antagonising the ligand activity-induced proliferation of
CC hematopoietic cells and hematopoietic cell progenitors preferably
CC lymphoid cells which are natural killer cells or cytotoxic T cells.
CC Zalpa is useful for treating immune and inflammatory disorders, for
CC reducing proliferation of neoplastic B or T cells, for suppressing an
CC immune response in a mammal exposed to an antigen or pathogen. Zalpa is
CC useful for treating diseases that require immune regulation including
CC autoimmune diseases such as rheumatoid arthritis, multiple sclerosis,
CC myasthenia gravis, systemic lupus erythematosus (SLE) and diabetes;
CC asthma, ulcerative colitis, inflammatory bowel disease, Crohn's disease,
CC sepsis, viral infection (dengue virus infection) and cancer. The present
CC sequence is an oligonucleotide used for BAF3/K2134/zalpal1 cell line
CC construction.

XX Sequence 100 BP; 24 A; 33 C; 17 G; 26 T; 0 other;

Query Match 85.7%; Score 18; DB 24; Length 100;
Best Local Similarity 100.0%; Pred. No. 63;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGATTCTAGCAATTCAA 18
ID |||||||
DB 67 AGATTCTAGCAATTCAA 84

RESULT 11

AAD22954/C
ID AAD22954 standard; DNA: 100 BP.

AC AAD22954;

XX 26-FEB-2002 (first entry)

DE BAF3/K2134/zalpal1 cell line constructing ZC12.748 oligonucleotide.

XX Zalpal1; cytokine receptor; immunosuppressive; cytostatic; haemostatic;
XX inflammatory disorder; cell proliferation; immune disorder; cancer; SLE;
KW systemic lupus erythematosus; myasthenia gravis; rheumatoid arthritis;
KW diabetes; autoimmune disease; multiple sclerosis; ulcerative colitis;
KW inflammatory bowel disease; sepsis; Crohn's disease; viral infection;
KW asthma; ss.

XX Unidentified.

PN WO200177171-A2.

PD 18-OCT-2001.

PE 03-APR-2001; 2001WO-US10872.

PR 05-APR-2000; 2000US-194731P.

PR 28-JUL-2000; 2000US-222121P.

XX (ZYMO) ZYMOGENETICS INC.

PI Sprecher CA, Novak JE, West JM, Presnell SR, Holly RD, Nelson AJ;

DR WPI; 2002-025898/03.

XX Novel soluble receptor polypeptides and polynucleotides used as
PT cytokine antagonist for stimulating ligand activity-induced
PT proliferation of hematopoietic cells and for suppressing immune
PT response in a mammal

XX Example 19; Page 213; 243pp; English.

XX The invention relates to an isolated soluble zalpal1 cytokine receptor
CC polypeptide and their cDNA molecules. Zalpa proteins are useful for
CC inhibiting or antagonising the ligand activity-induced proliferation of
CC hematopoietic cells and hematopoietic cell progenitors preferably
CC lymphoid cells which are natural killer cells or cytotoxic T cells.
CC Zalpa is useful for treating immune and inflammatory disorders, for
CC reducing proliferation of neoplastic B or T cells, for suppressing an
CC immune response in a mammal exposed to an antigen or pathogen. Zalpa is
CC useful for treating diseases that require immune regulation including
CC autoimmune diseases such as rheumatoid arthritis, multiple sclerosis,
CC myasthenia gravis, systemic lupus erythematosus (SLE) and diabetes;
CC asthma, ulcerative colitis, inflammatory bowel disease, Crohn's disease,
CC sepsis, viral infection (dengue virus infection) and cancer. The present
CC sequence is an oligonucleotide used for BAF3/K2134/zalpal1 cell line
CC construction.

XX Sequence 100 BP; 26 A; 17 C; 33 G; 24 T; 0 other;

Query Match 85.7%; Score 18; DB 24; Length 100;
Best Local Similarity 100.0%; Pred. No. 63;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGATTCTAGCAATTCAA 18
ID |||||||
DB 38 AGATTCTAGCAATTCAA 21

RESULT 12
ABK88204/C
ID ABK88204 standard; DNA: 33 BP.

XX ABK88204;

07-OCT-2002 (first entry)

Human cytochrome bcl core protein cDNA specific PCR primer #2.

Cytochrome bcl; primer: ss; core protein III2. 21; cancer; HIV; human immunodeficiency virus; human; PCR.

Homo sapiens.

CN1340524-A.

20-MAR-2002.

31-AUG-2000; 2000CN-0119831.

31-AUG-2000; 2000CN-0119831.

(BODE-) BODE GENE DEV CO LTD SHANGHAI

Mao Y, Xie Y;

WPI; 2002-436418/47.

Polypeptide-human cytochrome bcl compound core protein II 12.21 and polynucleotide for coding it -

Example 4; Page 19 (disclosure); 34pp; Chinese.

This invention relates to the cDNA and protein sequences of a novel polypeptide-human cytochrome bcl compounds core protein III2. 21. The invention also comprises a method for producing the protein by recombinant DNA technology and a method for the application of the polypeptide in treating diseases such as cancer, HIV infection, etc. The invention also discloses an antagonist against this polypeptide and its therapeutic action, and the application of the polynucleotide to coding this new human cytochrome bcl compound core protein III2.21. The present sequence represents a PCR primer used to clone the human cytochrome bcl compound core protein III2.21 cDNA of the invention.

Sequence 33 BP; 10 A; 10 C; 4 G; 9 T; 0 other;

Query Match 76.2%; Score 16; DB 24; Length 33;

Best Local Similarity 100.0%; Pred. No. 5e+02; Mismatches 0; Indels 0; Gaps 0;

Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

1 AGATTCTAGGAATTC 16

19 AGATTCTAGGAATTC 4

RESULT 13

AA131609

AA131609 standard; DNA; 51 BP.

24-JAN-2002 (first entry)

Human SNP oligonucleotide #4817.

Immunosuppressive; immunostimulatory; anti-inflammatory; cytostatic; neuroprotective; antimicrobial; gene therapy; vaccine; enzyme; cancer; amyloid protein; angiotensin; apoptosis related protein; cadherin; cyclin; polymerase; oncogene; histone; kinase; colony stimulating factor; complement related protein; cytochrome; kinase; cytokine; interferon; interleukin; G-protein coupled receptor; thioesterase; inflammation; multifactorial disease; autoimmune disease; infection; nervous system disease; ss.

Homo sapiens.

WO200147944-A2.

05-JUL-2001.

28-DEC-2000; 2000WO-US35498.

28-DEC-1999; 99US-0173419.

27-DEC-2000; 2000US-0173419.

(CURA-) CURAGEN CORP.

Shinkets RA, Leach M;

WPI; 2001-465210/50.

Polymorphic nucleic acids encoding e.g. amylases, cyclins, polymerases, oncogenes and histones, useful for diagnosing and treating, e.g. cancer, autoimmune diseases and infections -

Claim 1; Page 2773; 4143pp; English.

The present invention relates to oligonucleotides encoding polymorphic variants of proteins related to amylases, amyloid proteins, angiotensin, apoptosis related proteins, cadherin, cyclin, polymerase, oncogenes, histones, kinases, colony stimulating factors, complement related proteins, cytochromes, kinases, cytokines, interferons, interleukins, G-protein coupled receptors and thioesterases. The present sequence is one such oligonucleotide. The oligonucleotides and the peptides encoded by them may be used in the prevention, diagnosis and treatment of diseases associated with/inappropriate expression of the proteins listed above. Disorders that may be prevented, diagnosed and/or treated include multifactorial diseases with a genetic component, such as autoimmune diseases (e.g. rheumatoid arthritis, multiple sclerosis, diabetes, systemic lupus erythematosus and Grave's disease), inflammation, cancer (e.g. cancers of the bladder, brain, breast, colon and kidney, leukaemia), diseases of the nervous system and an infection of pathogenic organisms.

Sequence 51 BP; 22 A; 6 C; 8 G; 15 T; 0 other;

Query Match 73.3%; Score 15.4; DB 22; Length 51;

Best Local Similarity 94.1%; Pred. No. 9.5e+02; Mismatches 1; Indels 0; Gaps 0;

Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

3 ATTCTAGGAATTCANA 19

9 ATTCTAGGAATTCANA 25

RESULT 14

ABL53039/C

ABL53039 standard; DNA; 41 BP.

29-MAY-2002 (first entry)

Oligonucleotide JCA 325.

Virucide; vaccine; food and mouth disease; PI region; capsid; 3C protease; ds.

Foot and mouth disease virus.

WO200200251-A1.

03-JAN-2002.

27-JUN-2001; 2001WO-FR02842.

29-JUN-2000; 2000FR-0008437.

(MERI-) MERTAL.

King A, Burman A, Audonnet J, Lombard M;

XX DR WPI, 2002-130837/17.
 XX PT Stable, potent effective vaccines against foot-and-mouth disease,
 XX PT comprises recombinantly produced empty virus capsids as antigens -
 XX
 PS Example 7, Page 29; 79pp; French.
 CC The present invention relates to a vaccine against foot and mouth disease
 CC (FMD) comprising (in addition to a veterinary vehicle or excipient) an
 CC antigen consisting of empty FMD virus capsids, obtained by expression in
 CC eukaryotic cells of the cDNA of the following regions of the FMD genome:
 CC the P1 region encoding the capsid and the region encoding the 3C
 CC protease. The vaccine is effective, reliable and stable, and is effective
 CC at low doses. The vaccine is useful against foot and mouth disease/
 CC especially in cows, sheep, pigs or goats. The present sequence is an
 CC oligonucleotide which was used in an example from the invention.
 XX
 SQ Sequence 41 BP; 13 A; 7 C; 6 G; 15 T; 0 other;
 Query Match 70.5%; Score 14.8; DB 24; Length 41;
 Best Local Similarity 88.9%; Pred. No. 1.8e+03;
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 2 GATTCTCTAGCAATTCAAA 19
 ||||| || |||||
 DB 19 GATTTTATGCAATTCAAA 2
 RESULT 15
 ABL53041/C
 ID ABL53041 standard; DNA; 41 BP.
 AC ABL53041;
 DT 29-MAY-2002 (first entry)
 DE Oligonucleotide JCA 327.
 XX
 KW Virucide; vaccine; foot and mouth disease; P1 region; capsid;
 KM 3C protease; ds.
 OS Foot and mouth disease virus.
 XX
 PN WO200200251-A1.
 XX
 PD 03-JAN-2002.
 XX
 PE 27-JUN-2001; 2001WO-FR02042.
 XX
 PR 29-JUN-2000; 2000FR-0008437.
 XX
 PA (MERI-) Merial.
 XX
 PI King A, Burman A, Audonnet J, Lombard M;
 XX
 DR WPI; 2002-130837/17.
 XX
 PT Stable, potent effective vaccines against foot-and-mouth disease.
 PT comprises recombinantly produced empty virus capsids as antigens -
 XX
 PS Example 7; Page 30; 79pp; French.
 CC The present invention relates to a vaccine against foot and mouth disease
 CC (FMD) comprising (in addition to a veterinary vehicle or excipient) an
 CC antigen consisting of empty FMD virus capsids, obtained by expression in
 CC eukaryotic cells of the cDNA of the following regions of the FMD genome:
 CC the P1 region encoding the capsid and the region encoding the 3C
 CC protease. The vaccine is effective, reliable and stable, and is effective
 CC at low doses. The vaccine is useful against foot and mouth disease,
 CC especially in cows, sheep, pigs or goats. The present sequence is an
 CC oligonucleotide which was used in an example from the invention.
 XX

SQ Sequence 41 BP; 13 A; 6 C; 6 G; 16 T; 0 other;
 Query Match 70.5%; Score 14.8; DB 24; Length 41;
 Best Local Similarity 88.9%; Pred. No. 1.8e+03;
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 2 GATTCTCTAGCAATTCAAA 19
 ||||| || |||||
 DB 19 GATTTTATGCAATTCAAA 2
 Search completed: December 25, 2002, 12:55:32
 Job time : 1375 secs

GenCore version 5.1.3
Copyright (c) 1993 - 2002 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: December 25, 2002, 12:59:50 ; Search time 2684 Seconds
(without alignments)
97.588 Million cell updates/sec

Title: SCHMIDT875

Perfect score: 9

Sequence: 1 ttenngaa 9

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 2054640 seqs, 14551402878 residues

Total number of hits satisfying chosen parameters: 995600

Minimum DB seq length: 0

Maximum DB seq length: 100

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : GenBank:*

1: gb_da:*

2: gb_htg:*

3: gb_in:*

4: gb_om:*

5: gb_ov:*

6: gb_pat:*

7: gb_ph:*

8: gb_pl:*

9: gb_pr:*

10: gb_ro:*

11: gb_sts:*

12: gb_sy:*

13: gb_un:*

14: gb_vi:*

15: em_ba:*

16: em_fun:*

17: em_hum:*

18: em_in:*

19: em_mu:*

20: em_om:*

21: em_or:*

22: em_ov:*

23: em_pat:*

24: em_ph:*

25: em_pl:*

26: em_ro:*

27: em_sts:*

28: em_un:*

29: em_vi:*

30: em_htg_hum:*

31: em_htg_inv:*

32: em_htg_other:*

33: em_htg_mus:*

34: em_htg_pin:*

35: em_htg_rtd:*

36: em_htg_mam:*

37: em_htg_vrl:*

38: em_sy:*

39: em_htgo_hum:*

40: em_htgo_mus:*

41: em_htgo_other:*

Pred. No. is the number of results predicted by chance to have a

score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	66.7	9	6	AX041991	AX041991 Sequence
2	66.7	9	6	AX041991	AX041991 Sequence
3	66.7	9	6	AX058974	AX058974 Sequence
4	66.7	9	6	AX058974	AX058974 Sequence
5	66.7	9	6	BD012767	BD012767 Agent for
6	66.7	9	6	BD012767	BD012767 Agent for
7	66.7	10	6	AR043682	AR043682 Sequence
8	66.7	10	6	AR043682	AR043682 Sequence
9	66.7	10	6	AR043683	AR043683 Sequence
10	66.7	10	6	AR043683	AR043683 Sequence
11	66.7	10	6	AX301514	AX301514 Sequence
12	66.7	10	6	AX301514	AX301514 Sequence
13	66.7	10	6	AX301563	AX301563 Sequence
14	66.7	10	6	AX301563	AX301563 Sequence
15	66.7	11	6	A92561	A92561 Sequence 2
16	66.7	11	6	AR171056	AR171056 Sequence
17	66.7	11	6	AR171056	AR171056 Sequence
18	66.7	11	6	AR171059	AR171059 Sequence
19	66.7	11	6	AR171059	AR171059 Sequence
20	66.7	11	6	AX063653	AX063653 Sequence
21	66.7	11	6	AX063653	AX063653 Sequence
22	66.7	11	6	AX063656	AX063656 Sequence
23	66.7	11	6	AX063656	AX063656 Sequence
24	66.7	11	6	AX470574	AX470574 Sequence
25	66.7	11	6	AX470574	AX470574 Sequence
26	66.7	11	6	AX470746	AX470746 Sequence
27	66.7	11	6	AX470746	AX470746 Sequence
28	66.7	11	6	AX470746	AX470746 Sequence
29	66.7	11	6	AX470746	AX470746 Sequence
30	66.7	11	6	AX470746	AX470746 Sequence
31	66.7	11	6	AX470746	AX470746 Sequence
32	66.7	11	6	AX470746	AX470746 Sequence
33	66.7	11	6	AX470746	AX470746 Sequence
34	66.7	11	6	AX470746	AX470746 Sequence
35	66.7	11	6	AX470746	AX470746 Sequence
36	66.7	11	6	AX470746	AX470746 Sequence
37	66.7	11	6	AX470746	AX470746 Sequence
38	66.7	11	6	AX470746	AX470746 Sequence
39	66.7	11	6	AX470746	AX470746 Sequence
40	66.7	11	6	AX470746	AX470746 Sequence
41	66.7	11	6	AX470746	AX470746 Sequence
42	66.7	11	6	AX470746	AX470746 Sequence
43	66.7	11	6	AX470746	AX470746 Sequence
44	66.7	11	6	AX470746	AX470746 Sequence
45	66.7	11	6	AX470746	AX470746 Sequence

ALIGNMENTS

RESULT 1
LOCUS AX041991
DEFINITION Sequence 21 from Patent WO0065067
ACCESSION AX041991
VERSION AX041991.1 GI:11340794
KEYWORDS
SOURCE
ORGANISM human.
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniota; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
REFERENCE
AUTHORS Nelson, P.S., Hood, L. and Lin, B.
TITLE 1 (bases 1 to 9)
Prostate-specific polynucleotides, polypeptides and their methods
of use

DNA 9 bp linear PAT 23-NOV-2000

JOURNAL Patent: WO 0065067-A 21 02-NOV-2000;
 The University of Washington (US)
 FEATURES
 source 1..9
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 protein_bind 1..9
 /bound_moiety="Interleukin response element binding site"
 BASE COUNT 3 a 3 c 1 g 2 t
 ORIGIN

Query Match 66.7%; Score 6; DB 6; Length 9;
 Best Local Similarity 66.7%; Pred. No. 3.2e+09;
 Matches 6; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1 TTCNNNGAA 9
 ||| |||
 Db 1 TTCCCGAGAA 9

RESULT 2
 AX041991/c 9 bp DNA Linear PAT 23-NOV-2000
 LOCUS Sequence 21 from Patent WO0065067.
 DEFINITION AX041991
 ACCESSION AX041991
 VERSION AX041991.1 GI:11340754
 KEYWORDS
 SOURCE human.
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo.
 REFERENCE
 AUTHORS Nelson, P.S., Hood, L. and Lin, B.
 TITLE Prostate-specific polynucleotides, polypeptides and their methods
 of use
 JOURNAL Patent: WO 0065067-A 21 02-NOV-2000;
 The University of Washington (US)
 FEATURES
 source 1..9
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 protein_bind 1..9
 /bound_moiety="Interleukin response element binding site"
 BASE COUNT 3 a 3 c 1 g 2 t
 ORIGIN

Query Match 66.7%; Score 6; DB 6; Length 9;
 Best Local Similarity 66.7%; Pred. No. 3.2e+09;
 Matches 6; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1 TTCNNNGAA 9
 ||| |||
 Db 9 TTCTGGGAA 1

RESULT 3
 AX058974 9 bp DNA Linear PAT 17-JAN-2001
 LOCUS Sequence 13 from Patent WO0075326.
 DEFINITION AX058974
 ACCESSION AX058974
 VERSION AX058974.1 GI:12311244
 KEYWORDS
 SOURCE house mouse.
 ORGANISM Mus musculus
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 REFERENCE
 AUTHORS Auerhammer, C.J. and Shlomo, M.
 TITLE Suppressor of cytokine signaling (SOCS)-3 promoter and methods for
 its use
 JOURNAL Patent: WO 0075326-A 13 14-DEC-2000;
 CEDARS-SINAI MEDICAL CENTER (US)
 FEATURES
 Location/Qualifiers

source 1..9
 /organism="Mus musculus"
 /db_xref="taxon:10090"
 BASE COUNT 3 a 2 c 2 g 2 t
 ORIGIN

Query Match 66.7%; Score 6; DB 6; Length 9;
 Best Local Similarity 66.7%; Pred. No. 3.2e+09;
 Matches 6; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1 TTCNNNGAA 9
 ||| |||
 Db 1 TTCCCGAGAA 9

RESULT 4
 AX058974/c 9 bp DNA Linear PAT 17-JAN-2001
 LOCUS Sequence 13 from Patent WO0075326.
 DEFINITION AX058974
 ACCESSION AX058974
 VERSION AX058974.1 GI:12311244
 KEYWORDS
 SOURCE house mouse.
 ORGANISM Mus musculus
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 REFERENCE
 AUTHORS Auerhammer, C.J. and Shlomo, M.
 TITLE Suppressor of cytokine signaling (SOCS)-3 promoter and methods for
 its use
 JOURNAL Patent: WO 0075326-A 13 14-DEC-2000;
 CEDARS-SINAI MEDICAL CENTER (US)
 FEATURES
 source 1..9
 /organism="Mus musculus"
 /db_xref="taxon:10090"
 BASE COUNT 3 a 2 c 2 g 2 t
 ORIGIN

Query Match 66.7%; Score 6; DB 6; Length 9;
 Best Local Similarity 66.7%; Pred. No. 3.2e+09;
 Matches 6; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1 TTCNNNGAA 9
 ||| |||
 Db 9 TTCTGGGAA 1

RESULT 5
 BD012767 9 bp DNA Linear PAT 02-AUG-2002
 LOCUS Agent for enhancing expression of HML 24 antigen.
 DEFINITION BD012767
 ACCESSION BD012767
 VERSION BD012767.1 GI:22092956
 KEYWORDS
 SOURCE synthetic construct.
 ORGANISM artificial sequence.
 REFERENCE
 1 (bases 1 to 9)
 Kosaka, M., Ozaki, S. and Wakahara, Y.
 Agent for enhancing expression of HML 24 antigen
 Patent: WO 0113940-A 8 01-MAR-2001;
 CHUGAI PHARMACEUTICAL CO LTD, MASAOKI KOSAKA, SHUJI OZAKI, UJI
 WAKAHARA
 OS Artificial Sequence
 PN WO 0113940-A/8
 PD 01-MAR-2001
 PF 22-AUG-2000 WO 2000P0005617
 PR 23-AUG-1999 JP 99P 236007 16-FEB-2000 JP 00P 038689 PI
 MASAOKI KOSAKA, SHUJI OZAKI, YUJI WAKAHARA
 PC A61K39/21, A61K39/395, A61K45/00, A61P35/00, A61P19/00, G01N33/50,
 G01N33/15
 CC

FEATURES FH Key Location/Qualifiers.
source 1. .9
/organism="synthetic construct"
/db_xref="taxon:32630"

BASE COUNT 3 a 3 c 1 g 2 t
ORIGIN

Query Match 66.7%; Score 6; DB 6; Length 9;
Best Local Similarity 66.7%; Pred. No. 3.2e+09;
Matches 6; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1 TTCNNNGAA 9
Db 1 TTCGCCGAA 9

RESULT 6
BD012767/c 9 bp DNA linear PAT 02-AUG-2002
LOCUS BD012767 Agent for enhancing expression of HMI.24 antigen
DEFINITION BD012767
ACCESSION BD012767.1 GI:22092956
VERSION MO 0113940-A/8
KEYWORDS synthetic construct.
SOURCE synthetic construct.
ORGANISM artificial sequences.
REFERENCE 1 (bases 1 to 9)
AUTHORS Kosaka,M., Ozaki,S. and Wakahara,A.
TITLE Agent for enhancing expression of HMI.24 antigen
JOURNAL Patent: WO 0113940-A 8 01-MAR-2001;
CHUGAI PHARMACEUTICAL CO LTD; MASAKI KOSAKA, SHUJI OZAKI, UJI
WAKAHARA
COMMENT OS Artificial Sequence
PN MO 0113940-A/8
PD 01-MAR-2001
PE 22-AUG-2000 MO 2000JP005617
PR 23-AUG-1999 JP 99P 236007,16-FEB-2000 JP 00P 038689 PI
MASAKI KOSAKA, SHUJI OZAKI, YUJI WAKAHARA
PC A61K38/21, A61K39/395, A61K45/00, A61P35/00, A61P19/00, G01N33/50,
G01N33/15
CC

FEATURES FH Key Location/Qualifiers.
source 1. .9
/organism="synthetic construct"
/db_xref="taxon:32630"

BASE COUNT 3 a 3 c 1 g 2 t
ORIGIN

Query Match 66.7%; Score 6; DB 6; Length 9;
Best Local Similarity 66.7%; Pred. No. 3.2e+09;
Matches 6; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1 TTCNNNGAA 9
Db 9 TTCCTGGAA 1

RESULT 7
AR043682 10 bp DNA linear PAT 29-SEP-1999
LOCUS AR043682 Sequence 52 from patent US 5814517.
DEFINITION AR043682
ACCESSION AR043682
VERSION AR043682.1 GI:5964690
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE Unclassified.
AUTHORS Seidel,H.Martin. and Lamb,I.Peter.
TITLE DNA spacer regulatory elements responsive to cytokines and methods
JOURNAL Patent: US 5814517-A 53 29-SEP-1998;
FEATURES Location/Qualifiers
source 1. .10
/organism="unknown"

BASE COUNT 4 a 1 c 1 g 4 t
ORIGIN

Query Match 66.7%; Score 6; DB 6; Length 10;
Best Local Similarity 66.7%; Pred. No. 2.3e+06;
Matches 6; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1 TTCNNNGAA 9
Db 1 TTCNNNGAA 9

JOURNAL Patent: US 5814517-A 52 29-SEP-1998;
FEATURES Location/Qualifiers
source 1. .10
/organism="unknown"

BASE COUNT 2 a 4 c 1 g 3 t
ORIGIN

Query Match 66.7%; Score 6; DB 6; Length 10;
Best Local Similarity 66.7%; Pred. No. 2.3e+06;
Matches 6; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1 TTCNNNGAA 9
Db 2 TTCGCCGAA 10

RESULT 8
AR043682/c 10 bp DNA linear PAT 29-SEP-1999
LOCUS AR043682 Sequence 52 from patent US 5814517.
DEFINITION AR043682
ACCESSION AR043682
VERSION AR043682.1 GI:5964690
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE Unclassified.
AUTHORS Seidel,H.Martin. and Lamb,I.Peter.
TITLE DNA spacer regulatory elements responsive to cytokines and methods
JOURNAL Patent: US 5814517-A 52 29-SEP-1998;
FEATURES Location/Qualifiers
source 1. .10
/organism="unknown"

BASE COUNT 2 a 4 c 1 g 3 t
ORIGIN

Query Match 66.7%; Score 6; DB 6; Length 10;
Best Local Similarity 66.7%; Pred. No. 2.3e+06;
Matches 6; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1 TTCNNNGAA 9
Db 10 TTCGGGGA 2

RESULT 9
AR043683 10 bp DNA linear PAT 29-SEP-1999
LOCUS AR043683 Sequence 53 from patent US 5814517.
DEFINITION AR043683
ACCESSION AR043683
VERSION AR043683.1 GI:5964691
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE Unclassified.
AUTHORS Seidel,H.Martin. and Lamb,I.Peter.
TITLE DNA spacer regulatory elements responsive to cytokines and methods
JOURNAL Patent: US 5814517-A 53 29-SEP-1998;
FEATURES Location/Qualifiers
source 1. .10
/organism="unknown"

BASE COUNT 4 a 1 c 1 g 4 t
ORIGIN

Query Match 66.7%; Score 6; DB 6; Length 10;
Best Local Similarity 66.7%; Pred. No. 2.3e+06;
Matches 6; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1 TTCNNNGAA 9
Db 10 TTCGGGGA 2

Db 2 TTCCTAGAA 10

RESULT 10
LOCUS AR043683/c 10 bp DNA
DEFINITION Sequence 53 from patent US 5814517.
ACCESSION AR043683
VERSION AR043683.1 GI:5964691
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 10)
AUTHORS Seidel,H.Martin. and Lamb,I.Peter.
TITLE DNA spacer regulatory elements responsive to cytokines and methods for their use
JOURNAL Patent: US 5814517-A 53 29-SEP-1998;
FEATURES
source 1..10
BASE COUNT 4 a 1 c 1 g 4 t
ORIGIN

Query Match 66.7%; Score 6; DB 6; Length 10;
Best Local Similarity 66.7%; Pred.No. 2.3e+06;
Matches 6; Conservative 0; Mismatches 3; Indels 0;

OY 1 TTCNNNGAA 9
Db 10 TTCCTAGAA 2

RESULT 11
LOCUS AX301514 10 bp DNA
DEFINITION Sequence 228 from Patent WO0185941.
ACCESSION AX301514
VERSION AX301514.1 GI:17382597
KEYWORDS
SOURCE human.
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.
REFERENCE 1
AUTHORS Versteeg,R. and Caron,H.N.
TITLE Myc targets
JOURNAL Patent: WO 0185941-A 228 15-NOV-2001;
Academisch Ziekenhuis bij de Universiteit van Amsterdam (NL)
FEATURES
source 1..10
BASE COUNT 2 a 1 c 2 g 5 t
ORIGIN

Query Match 66.7%; Score 6; DB 6; Length 10;
Best Local Similarity 66.7%; Pred.No. 2.3e+06;
Matches 6; Conservative 0; Mismatches 3; Indels 0;

OY 1 TTCNNNGAA 9
Db 1 TTCCTGAA 9

RESULT 12
LOCUS AX301514/c 10 bp DNA
DEFINITION Sequence 228 from Patent WO0185941.
ACCESSION AX301514
VERSION AX301514.1 GI:17382597
KEYWORDS
SOURCE human.

ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.
REFERENCE 1
AUTHORS Versteeg,R. and Caron,H.N.
TITLE Myc targets
JOURNAL Patent: WO 0185941-A 228 15-NOV-2001;
Academisch Ziekenhuis bij de Universiteit van Amsterdam (NL)
FEATURES
source 1..10
BASE COUNT 2 a 1 c 2 g 5 t
ORIGIN

Query Match 66.7%; Score 6; DB 6; Length 10;
Best Local Similarity 66.7%; Pred.No. 2.3e+06;
Matches 6; Conservative 0; Mismatches 3; Indels 0;

OY 1 TTCNNNGAA 9
Db 9 TTCACAGAA 1

RESULT 13
LOCUS AX301563 10 bp DNA
DEFINITION Sequence 277 from Patent WO0185941.
ACCESSION AX301563
VERSION AX301563.1 GI:17382646
KEYWORDS
SOURCE human.
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.
REFERENCE 1
AUTHORS Versteeg,R. and Caron,H.N.
TITLE Myc targets
JOURNAL Patent: WO 0185941-A 277 15-NOV-2001;
Academisch Ziekenhuis bij de Universiteit van Amsterdam (NL)
FEATURES
source 1..10
BASE COUNT 2 a 1 c 2 g 5 t
ORIGIN

Query Match 66.7%; Score 6; DB 6; Length 10;
Best Local Similarity 66.7%; Pred.No. 2.3e+06;
Matches 6; Conservative 0; Mismatches 3; Indels 0;

OY 1 TTCNNNGAA 9
Db 1 TTCCTGAA 9

RESULT 14
LOCUS AX301563/c 10 bp DNA
DEFINITION Sequence 277 from Patent WO0185941.
ACCESSION AX301563
VERSION AX301563.1 GI:17382646
KEYWORDS
SOURCE human.
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.
REFERENCE 1
AUTHORS Versteeg,R. and Caron,H.N.
TITLE Myc targets
JOURNAL Patent: WO 0185941-A 277 15-NOV-2001;
Academisch Ziekenhuis bij de Universiteit van Amsterdam (NL)
FEATURES
Location/Qualifiers

```

source 1. .10
        /organism="Homo sapiens"
        /db_xref="taxon:9606"
BASE COUNT 2 a 1 c 2 g 5 t
ORIGIN
Query Match 66.7%; Score 6; DB 6; Length 10;
Best Local Similarity 66.7%; Pred. No. 2.3e+06;
Matches 6; Conservative 0; Mismatches 3; Indels 0; Gaps 0;


OY 1 TTCNNNGAA 9
   ||| |||
Db 9 TTCACAGAA 1

RESULT 15
A92561 11 bp DNA linear PAT 22-JAN-2000
LOCUS Sequence 2 from Patent WO9812320.
DEFINITION A92561
ACCESSION A92561
VERSION A92561.1 GI:6741220
KEYWORDS
SOURCE unidentified.
ORGANISM unidentified
REFERENCE unclassified
AUTHORS 1 (bases 1 to 11)
TITLE Stocklin, E. and Groner, B.
JOURNAL NUCLEIC ACID CONSTRUCT CODING FOR A PROTEIN COMPLEX FROM A STAT
PATENT: NO 8812320-A 2 26-MAR-1998.
FEATURES STOCKLIN ELISABETH (CH); GRONER BERND (CH)
          Location/Qualifiers
          1..11
          /db_xref="taxon:32644"
          /organism="unidentified"
BASE COUNT 3 a 2 c 2 g 4 t
ORIGIN
Query Match 66.7%; Score 6; DB 6; Length 11;
Best Local Similarity 66.7%; Pred. No. 2.3e+06;
Matches 6; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 1 TTCNNNGAA 9
   ||| |||
Db 3 TTCTTGAA 11

```

Search completed: December 25, 2002, 22:44:35
 Job time : 2686 secs



GenCore version 5.1.3
Copyright (c) 1993 - 2002 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: December 25, 2002, 11:24:49 ; Search time 3892 Seconds

(without alignments)
157.030 Million cell updates/sec

Title: US-09-744-875-1

Perfect score: 21

Sequence: 1 agattctagatcaatc 21

Scoring table: IDENTITY_NTC

Gapop 10.0 , Gapext 1.0

Searched: 2054640 segs, 14551402878 residues

Total number of hits satisfying chosen parameters: 995600

Minimum DB seq length: 0

Maximum DB seq length: 100

Post-processing: Minimum Match 0%

Listing first 45 summaries

Database : GenBank:*

1: gb.ba:*

2: gb.htg:*

3: gb.in:*

4: gb.com:*

5: gb.ov:*

6: gb.pat:*

7: gb.ph:*

8: gb.pl:*

9: gb.pr:*

10: gb.ro:*

11: gb.sts:*

12: gb.sy:*

13: gb.un:*

14: gb.vl:*

15: em.ba:*

16: em.fun:*

17: em.hum:*

18: em.in:*

19: em.mu:*

20: em.om:*

21: em.or:*

22: em.ov:*

23: em.pat:*

24: em.ph:*

25: em.pl:*

26: em.ro:*

27: em.sts:*

28: em.un:*

29: em.vl:*

30: em.htg.hum:*

31: em.htg.inv:*

32: em.htg.other:*

33: em.htg.mus:*

34: em.htg.pln:*

35: em.htg.tod:*

36: em.htg.mam:*

37: em.htg.vtl:*

38: em.sy:*

39: em.htgo.hum:*

40: em.htgo.mus:*

41: em.htgo.other:*

Pred. No. is the number of results predicted by chance to have a

score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	18	85.7	20	6	A89799
2	18	85.7	20	6	A90886
3	18	85.7	20	6	AX455533
4	18	85.7	21	6	I23456
5	18	85.7	100	6	AR174601
6	18	85.7	100	6	AR174602
7	18	85.7	100	6	AX047032
8	18	85.7	100	6	AX047033
9	18	85.7	100	6	AX280202
10	18	85.7	100	6	AX280203
11	18	85.7	100	6	AX365191
12	18	85.7	100	6	AX365192
13	18	85.7	100	6	AX343814
14	18	85.7	100	6	AX343815
15	18	85.7	100	6	AX343816
16	18	85.7	100	6	AX343817
17	18	85.7	100	6	AX343818
18	18	85.7	100	6	AX343819
19	18	85.7	100	6	AX343820
20	18	85.7	100	6	AX343821
21	18	85.7	100	6	AX343822
22	18	85.7	100	6	AX343823
23	18	85.7	100	6	AX343824
24	18	85.7	100	6	AX343825
25	18	85.7	100	6	AX343826
26	18	85.7	100	6	AX343827
27	18	85.7	100	6	AX343828
28	18	85.7	100	6	AX343829
29	18	85.7	100	6	AX343830
30	18	85.7	100	6	AX343831
31	18	85.7	100	6	AX343832
32	18	85.7	100	6	AX343833
33	18	85.7	100	6	AX343834
34	18	85.7	100	6	AX343835
35	18	85.7	100	6	AX343836
36	18	85.7	100	6	AX343837
37	18	85.7	100	6	AX343838
38	18	85.7	100	6	AX343839
39	18	85.7	100	6	AX343840
40	18	85.7	100	6	AX343841
41	18	85.7	100	6	AX343842
42	18	85.7	100	6	AX343843
43	18	85.7	100	6	AX343844
44	18	85.7	100	6	AX343845
45	18	85.7	100	6	AX343846

ALIGNMENTS

RESULT 1

LOCUS A89799

DEFINITION Sequence 21 from Patent WO9832462.

ACCESSION A89799

VERSION A89799.1 GI:6738313

KEYWORDS

SOURCE

ORGANISM

unidentified.

unidentified.

unclassified.

1 (bases 1 to 20)

REFERENCE

AUTHORS Lipford, G.B. and Heeg, K.

TITLE PHARMACEUTICAL COMPOSITIONS COMPRISING A POLYNUCLEOTIDE AND

OPTIONALLY AN ANTIGEN ESPECIALLY FOR VACCINATION

JOURNAL Patent: WO 9832462-A 21 30-JUL-1998;

FEATURES
source
LIPFORD GRAYSON B (DE); HEEG KLAUS (DE)
location/Qualifiers
1. 20
/organism="unidentified"
/db_xref="taxon:32644"

BASE COUNT
7 a 3 c 3 g 7 t

Query Match
Best Local Similarity 100.0%; Score 18; DB 6; Length 20;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGATTCTAGGAATTCAA 18
|||||

RESULT 2
A90886 A90886 20 bp DNA linear PAT 22-JAN-2000
LOCUS
DEFINITION Sequence 21 from Patent EP0855184.
ACCESSION A90886
VERSION A90886.1 GI:6739328
KEYWORDS
SOURCE unidentified.
ORGANISM unidentified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Heeg, K.P. and Lipford, G.B.
TITLE Pharmaceutical composition comprising a polynucleotide and an
JOURNAL antigen especially for vaccination
HEEG KLAUS PROF DR (DE); LIPFORD GRAYSON B DR (DE)
location/Qualifiers
1. 20
/organism="unidentified"
/db_xref="taxon:32644"

BASE COUNT
7 a 3 c 3 g 7 t

Query Match
Best Local Similarity 100.0%; Score 18; DB 6; Length 20;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGATTCTAGGAATTCAA 18
|||||

RESULT 3
AX455553 AX455553 20 bp DNA linear PAT 06-JUL-2002
LOCUS
DEFINITION Sequence 30 from Patent WO0222809.
ACCESSION AX455553
VERSION AX455553.1 GI:21714621
KEYWORDS
SOURCE synthetic construct.
ORGANISM synthetic construct.
REFERENCE 1
AUTHORS Bauer, S., Lipford, G. and Wagner, H.
TITLE Process for high throughput screening of cpg-based
JOURNAL immuno-agonist/antagonist.
Patent: WO 0222809-A 30 21-MAR-2002;
Coley Pharmaceutical GmbH (DE)
location/Qualifiers
1. 20
/organism="synthetic construct"
/db_xref="taxon:32630"
/note="Synthetic oligonucleotide"

BASE COUNT
7 a 3 c 3 g 7 t

QY 1 AGATTCTAGGAATTCAA 18
|||||

RESULT 4
I23456 I23456 21 bp DNA linear PAT 07-OCT-1996
LOCUS
DEFINITION Sequence 8 from patent US 5534409.
ACCESSION I23456
VERSION I23456.1 GI:1603326
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 21)
AUTHORS Groner, B., Gouilleux, F. and Wakao, H.
TITLE Cytokine regulated transcription factor
JOURNAL Patent: US 5534409-A 8 09-JUL-1996;
location/Qualifiers
1. 21
/organism="unknown"

BASE COUNT
7 a 4 c 3 g 7 t

Query Match
Best Local Similarity 100.0%; Score 18; DB 6; Length 21;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGATTCTAGGAATTCAA 18
|||||

RESULT 5
ARI74601 ARI74601 100 bp DNA linear PAT 17-DEC-2001
LOCUS
DEFINITION Sequence 59 from patent US 6307024.
ACCESSION ARI74601
VERSION ARI74601.1 GI:17914921
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 100)
AUTHORS Novak, J.E., Presnell, S.R., Sprecher, C.A., Foster, D.C., Holly, R.D.,
Gross, J.A., Johnston, J.V., Nelson, A.J., Dillon, S.R. and
Hammond, A.R.
TITLE Cytokine zaldhali ligand
JOURNAL Patent: US 6307024-A 59 23-OCT-2001;
location/Qualifiers
1. 100
/organism="unknown"

BASE COUNT
7 a 3 c 3 g 7 t

QY 1 AGATTCTAGGAATTCAA 18
|||||

Query Match
Best Local Similarity 100.0%; Score 18; DB 6; Length 20;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGATTCTAGGAATTCAA 18
|||||

RESULT 6
ARI74602 ARI74602 100 bp DNA linear PAT 17-DEC-2001
LOCUS
DEFINITION Sequence 60 from patent US 6307024.

BASE COUNT
7 a 4 c 3 g 7 t

QY 1 AGATTCTAGGAATTCAA 18
|||||

RESULT 7
ARI74603 ARI74603 100 bp DNA linear PAT 17-DEC-2001
LOCUS
DEFINITION Sequence 59 from patent US 6307024.
ACCESSION ARI74603
VERSION ARI74603.1 GI:17914921
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 100)
AUTHORS Novak, J.E., Presnell, S.R., Sprecher, C.A., Foster, D.C., Holly, R.D.,
Gross, J.A., Johnston, J.V., Nelson, A.J., Dillon, S.R. and
Hammond, A.R.
TITLE Cytokine zaldhali ligand
JOURNAL Patent: US 6307024-A 59 23-OCT-2001;
location/Qualifiers
1. 100
/organism="unknown"

BASE COUNT
7 a 4 c 3 g 7 t

Query Match
Best Local Similarity 100.0%; Score 18; DB 6; Length 21;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 AGATTCTAGGAATTCAA 18
|||||

RESULT 8
ARI74604 ARI74604 100 bp DNA linear PAT 17-DEC-2001
LOCUS
DEFINITION Sequence 59 from patent US 6307024.
ACCESSION ARI74604
VERSION ARI74604.1 GI:17914921
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 100)
AUTHORS Novak, J.E., Presnell, S.R., Sprecher, C.A., Foster, D.C., Holly, R.D.,
Gross, J.A., Johnston, J.V., Nelson, A.J., Dillon, S.R. and
Hammond, A.R.
TITLE Cytokine zaldhali ligand
JOURNAL Patent: US 6307024-A 59 23-OCT-2001;
location/Qualifiers
1. 100
/organism="unknown"

BASE COUNT
7 a 4 c 3 g 7 t

QY 1 AGATTCTAGGAATTCAA 18
|||||

RESULT 9
ARI74605 ARI74605 100 bp DNA linear PAT 17-DEC-2001
LOCUS
DEFINITION Sequence 59 from patent US 6307024.

BASE COUNT
7 a 4 c 3 g 7 t

QY 1 AGATTCTAGGAATTCAA 18
|||||

RESULT 10
ARI74606 ARI74606 100 bp DNA linear PAT 17-DEC-2001
LOCUS
DEFINITION Sequence 60 from patent US 6307024.

BASE COUNT
7 a 4 c 3 g 7 t

QY 1 AGATTCTAGGAATTCAA 18
|||||

ACCESSION AR174602
 VERSION AR174602.1 GI:17914922
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unknown.
 REFERENCE 1 (bases 1 to 100)
 Novak,J.E., Presnell,S.R., Sprecher,C.A., Foster,D.C., Holly,R.D.,
 Gross,J.A., Johnston,J.V., Nelson,A.J., Dillon,S.R. and
 Hammond,A.K.
 TITLE Soluble zai1phall cytokine receptors
 JOURNAL Patent: US 630024-A 60
 FEATURES
 source Location/Qualifiers
 1..100
 /organism="Unknown"
 BASE COUNT 26 a 17 c 32 g 25 t
 ORIGIN
 Query Match 85.7%; Score 18; DB 6; Length 100;
 Best Local Similarity 100.0%; Pred. No. 3.7e+03;
 Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 AGATTCTAGCAATTCAA 18
 ||||||||||||||||
 DB 38 AGATTCTAGCAATTCAA 21

RESULT 7
 AX047032 100 bp DNA linear PAT 15-DEC-2000
 LOCUS
 DEFINITION Sequence 37 from Patent WO0068381.
 ACCESSION AX047032
 VERSION AX047032.1 GI:11876456
 KEYWORDS
 SOURCE synthetic construct.
 ORGANISM synthetic construct.
 REFERENCE 1 (bases 1 to 100)
 Presnell,S.R., Foster,D.C., Hammond,A.K. and Lok,S.
 TITLE Cytokine receptor mouse zcytor10
 JOURNAL Patent: WO 0068381-A 37 16-NOV-2000;
 Zymogenetics, Inc. (US)
 FEATURES
 source Location/Qualifiers
 1..100
 /organism="synthetic construct"
 /db_xref="taxon:32630"
 /note="Oligonucleotide primer ZC12749"
 BASE COUNT 24 a 33 c 17 g 26 t
 ORIGIN
 Query Match 85.7%; Score 18; DB 6; Length 100;
 Best Local Similarity 100.0%; Pred. No. 3.7e+03;
 Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 AATTCTAGCAATTCAA 18
 ||||||||||||||||
 DB 67 AGATTCTAGCAATTCAA 84

RESULT 8
 AX047033 100 bp DNA linear PAT 15-DEC-2000
 LOCUS
 DEFINITION Sequence 38 from Patent WO0068381.
 ACCESSION AX047033
 VERSION AX047033.1 GI:11876457
 KEYWORDS
 SOURCE synthetic construct.
 ORGANISM synthetic construct.
 REFERENCE 1 (bases 1 to 100)
 Presnell,S.R., Foster,D.C., Hammond,A.K. and Lok,S.
 TITLE Cytokine receptor mouse zcytor10
 JOURNAL Patent: WO 0068381-A 38 16-NOV-2000;

Zymogenetics, Inc. (US)
 Location/Qualifiers
 1..100
 /organism="synthetic construct"
 /db_xref="taxon:32630"
 /note="Oligonucleotide primer ZC12748"
 BASE COUNT 26 a 17 c 33 g 24 t
 ORIGIN
 Query Match 85.7%; Score 18; DB 6; Length 100;
 Best Local Similarity 100.0%; Pred. No. 3.7e+03;
 Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 AGATTCTAGCAATTCAA 18
 ||||||||||||||||
 DB 38 AGATTCTAGCAATTCAA 21

RESULT 9
 AX280202 100 bp DNA linear PAT 02-NOV-2001
 LOCUS
 DEFINITION Sequence 48 from Patent WO0177171.
 ACCESSION AX280202
 VERSION AX280202.1 GI:16607595
 KEYWORDS
 SOURCE synthetic construct.
 ORGANISM synthetic construct.
 REFERENCE 1
 Sprecher,C.A., Novak,J.E., West,J.W., Presnell,S.R., Holly,R.D. and
 Nelson,A.J.
 TITLE Soluble zai1phall cytokine receptors
 JOURNAL Patent: WO 0177171-A 48 18-OCT-2001;
 Zymogenetics, Inc. (US)
 FEATURES
 source Location/Qualifiers
 1..100
 /organism="synthetic construct"
 /db_xref="taxon:32630"
 /note="Oligonucleotide primer ZC12749"
 BASE COUNT 24 a 33 c 17 g 26 t
 ORIGIN
 Query Match 85.7%; Score 18; DB 6; Length 100;
 Best Local Similarity 100.0%; Pred. No. 3.7e+03;
 Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 AGATTCTAGCAATTCAA 18
 ||||||||||||||||
 DB 67 AGATTCTAGCAATTCAA 84

RESULT 10
 AX280203 100 bp DNA linear PAT 02-NOV-2001
 LOCUS
 DEFINITION Sequence 49 from Patent WO0177171.
 ACCESSION AX280203
 VERSION AX280203.1 GI:16607596
 KEYWORDS
 SOURCE synthetic construct.
 ORGANISM synthetic construct.
 REFERENCE 1
 Sprecher,C.A., Novak,J.E., West,J.W., Presnell,S.R., Holly,R.D. and
 Nelson,A.J.
 TITLE Soluble zai1phall cytokine receptors
 JOURNAL Patent: WO 0177171-A 49 18-OCT-2001;
 Zymogenetics, Inc. (US)
 FEATURES
 source Location/Qualifiers
 1..100
 /organism="synthetic construct"
 /db_xref="taxon:32630"
 /note="Oligonucleotide primer ZC12748"
 BASE COUNT 26 a 17 c 33 g 24 t

ORIGIN

Query Match 85.7%; Score 18; DB 6; Length 100;
Best Local Similarity 100.0%; Pred. No. 3.7e+03;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 AGATTTCAGAAATTCAA 18
Db 38 AGATTTCAGAAATTCAA 21

RESULT 11

AX365191 100 bp DNA linear PAT 15-FEB-2002
LOCUS AX365191
DEFINITION Sequence 43 from Patent WO200721.
ACCESSION AX365191
VERSION AX365191.1 GI:18696947
KEYWORDS
SOURCE synthetic construct.
ORGANISM synthetic construct.
REFERENCE 1
AUTHORS Sprecher, C.A., Presnell, S.R., Gao, Z., Whitmore, T.E., Kuiper, J.L.
TITLE Cytokine receptor zcytor17
JOURNAL Patent: WO 0200721-A 43 03-JAN-2002;
FEATURES
source Location/Qualifiers
1.100
/organism="synthetic construct"
/db_xref="taxon:32630"
/note="Oligonucleotide primer ZC12749"

BASE COUNT 24 a 38 c 47 g 26 t
ORIGIN

Query Match 85.7%; Score 18; DB 6; Length 100;
Best Local Similarity 100.0%; Pred. No. 3.7e+03;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 AGATTTCAGAAATTCAA 18
Db 67 AGATTTCAGAAATTCAA 84

RESULT 12

AX365192/c 100 bp DNA linear PAT 15-FEB-2002
LOCUS AX365192
DEFINITION Sequence 44 from Patent WO200721.
ACCESSION AX365192
VERSION AX365192.1 GI:18696948
KEYWORDS
SOURCE synthetic construct.
ORGANISM synthetic construct.
REFERENCE 1
AUTHORS Sprecher, C.A., Presnell, S.R., Gao, Z., Whitmore, T.E., Kuiper, J.L.
TITLE Cytokine receptor zcytor17
JOURNAL Patent: WO 0200721-A 44 03-JAN-2002;
FEATURES
source Location/Qualifiers
1.100
/organism="synthetic construct"
/db_xref="taxon:32630"
/note="Oligonucleotide primer ZC12748"

BASE COUNT 26 a 17 c 33 g 24 t
ORIGIN

Query Match 85.7%; Score 18; DB 6; Length 100;
Best Local Similarity 100.0%; Pred. No. 3.7e+03;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 AGATTTCAGAAATTCAA 18

Db 38 AGATTTCAGAAATTCAA 21

RESULT 13

AX343814/c 41 bp DNA linear PAT 01-FEB-2002
LOCUS AX343814
DEFINITION Sequence 21 from Patent WO200251
ACCESSION AX343814
VERSION AX343814.1 GI:18491887
KEYWORDS
SOURCE synthetic construct.
ORGANISM synthetic construct.
REFERENCE 1
AUTHORS King, A., Burman, A., Audonnet, J.C., and Dombard, M.
TITLE Vaccine against foot-and-mouth disease
JOURNAL Patent: WO 0200251-A 21 03-JAN-2002;
FEATURES
source Location/Qualifiers
1.41
/organism="synthetic construct"
/db_xref="taxon:32630"
/note="Oligonucleotide"

BASE COUNT 13 a 7 c 6 g 15 t
ORIGIN

Query Match 70.5%; Score 14.8; DB 6; Length 41;
Best Local Similarity 88.9%; Pred. No. 1.1e+05;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 2 GATTTCAGAAATTCAA 19
Db 19 GATTTCAGAAATTCAA 2

RESULT 14

AX343816/c 41 bp DNA linear PAT 01-FEB-2002
LOCUS AX343816
DEFINITION Sequence 23 from Patent WO200251.
ACCESSION AX343816
VERSION AX343816.1 GI:18491889
KEYWORDS
SOURCE synthetic construct.
ORGANISM synthetic construct.
REFERENCE 1
AUTHORS King, A., Burman, A., Audonnet, J.C., and Lombard, M.
TITLE Vaccine against foot-and-mouth disease
JOURNAL Patent: WO 0200251-A 23 03-JAN-2002;
FEATURES
source Location/Qualifiers
1.41
/organism="synthetic construct"
/db_xref="taxon:32630"
/note="Oligonucleotide"

BASE COUNT 13 a 6 c 6 g 16 t
ORIGIN

Query Match 70.5%; Score 14.8; DB 6; Length 41;
Best Local Similarity 88.9%; Pred. No. 1.1e+05;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 2 GATTTCAGAAATTCAA 19
Db 19 GATTTCAGAAATTCAA 2

RESULT 15
AX343812/c 44 bp DNA linear PAT 01-FEB-2002
LOCUS AX343812
DEFINITION Sequence 19 from Patent WO200251.
ACCESSION AX343812

The first part of the paper discusses the importance of maintaining accurate records of all transactions. It is essential for the company to have a clear and concise record of all financial activities, including sales, purchases, and expenses. This will allow the company to track its performance over time and identify areas for improvement.

The second part of the paper discusses the importance of maintaining accurate records of all transactions. It is essential for the company to have a clear and concise record of all financial activities, including sales, purchases, and expenses. This will allow the company to track its performance over time and identify areas for improvement.

The third part of the paper discusses the importance of maintaining accurate records of all transactions. It is essential for the company to have a clear and concise record of all financial activities, including sales, purchases, and expenses. This will allow the company to track its performance over time and identify areas for improvement.

The fourth part of the paper discusses the importance of maintaining accurate records of all transactions. It is essential for the company to have a clear and concise record of all financial activities, including sales, purchases, and expenses. This will allow the company to track its performance over time and identify areas for improvement.

The fifth part of the paper discusses the importance of maintaining accurate records of all transactions. It is essential for the company to have a clear and concise record of all financial activities, including sales, purchases, and expenses. This will allow the company to track its performance over time and identify areas for improvement.

The sixth part of the paper discusses the importance of maintaining accurate records of all transactions. It is essential for the company to have a clear and concise record of all financial activities, including sales, purchases, and expenses. This will allow the company to track its performance over time and identify areas for improvement.

The seventh part of the paper discusses the importance of maintaining accurate records of all transactions. It is essential for the company to have a clear and concise record of all financial activities, including sales, purchases, and expenses. This will allow the company to track its performance over time and identify areas for improvement.

The eighth part of the paper discusses the importance of maintaining accurate records of all transactions. It is essential for the company to have a clear and concise record of all financial activities, including sales, purchases, and expenses. This will allow the company to track its performance over time and identify areas for improvement.

The ninth part of the paper discusses the importance of maintaining accurate records of all transactions. It is essential for the company to have a clear and concise record of all financial activities, including sales, purchases, and expenses. This will allow the company to track its performance over time and identify areas for improvement.

The tenth part of the paper discusses the importance of maintaining accurate records of all transactions. It is essential for the company to have a clear and concise record of all financial activities, including sales, purchases, and expenses. This will allow the company to track its performance over time and identify areas for improvement.

GenCore version 5.1.3
Copyright (c) 1993 - 2002 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: December 25, 2002, 11:40:44 ; Search time 52 Seconds
(without alignments)
53.079 Million cell updates/sec

Title: SCHMIDT875

Sequence: 1 ttcnngaa 9

Scoring table: IDENTITY_NUC
Gapop 10.0, Gapext 1.0

Searched: 441362 seqs, 153338381 residues

Total number of hits satisfying chosen parameters: 687286

Minimum DB seq length: 0
Maximum DB seq length: 100

Post-processing: Minimum Match 0%
Maximum Match 100%

Listing first 45 summaries

Database: Issued Patents, NA:

1: /cgn2_6/ptodata/1/ina/5A.COMB.seq:*
2: /cgn2_6/ptodata/1/ina/5B.COMB.seq:*
3: /cgn2_6/ptodata/1/ina/6A.COMB.seq:*
4: /cgn2_6/ptodata/1/ina/6B.COMB.seq:*
5: /cgn2_6/ptodata/1/ina/PCBUS.COMB.seq:*
6: /cgn2_6/ptodata/1/ina/backfileseq1.seq:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	66.7	9	1	US-08-411-020-1	Sequence 1, Appl
2	66.7	9	1	US-08-411-020-1	Sequence 10, Appl
3	66.7	9	1	US-08-411-020-10	Sequence 11, Appl
4	66.7	9	1	US-08-411-020-11	Sequence 12, Appl
5	66.7	9	1	US-08-411-020-12	Sequence 13, Appl
6	66.7	9	1	US-08-411-020-13	Sequence 14, Appl
7	66.7	9	1	US-08-411-020-13	Sequence 15, Appl
8	66.7	9	1	US-08-369-796-25	Sequence 25, Appl
9	66.7	9	1	US-08-369-796-25	Sequence 26, Appl
10	66.7	9	1	US-08-369-796-26	Sequence 27, Appl
11	66.7	9	1	US-08-369-796-26	Sequence 28, Appl
12	66.7	9	1	US-08-369-796-26	Sequence 29, Appl
13	66.7	9	1	US-08-369-796-27	Sequence 30, Appl
14	66.7	9	1	US-08-369-796-27	Sequence 31, Appl
15	66.7	9	1	US-08-369-796-31	Sequence 32, Appl
16	66.7	9	1	US-08-369-796-31	Sequence 33, Appl
17	66.7	9	1	US-08-369-796-31	Sequence 34, Appl
18	66.7	9	1	US-08-369-796-34	Sequence 35, Appl
19	66.7	9	1	US-08-369-796-34	Sequence 36, Appl
20	66.7	9	1	US-08-369-796-35	Sequence 37, Appl
21	66.7	9	1	US-08-369-796-35	Sequence 38, Appl
22	66.7	9	1	US-08-369-796-36	Sequence 39, Appl
23	66.7	9	1	US-08-369-796-36	Sequence 40, Appl
24	66.7	9	1	US-08-369-796-38	Sequence 41, Appl
25	66.7	9	1	US-08-369-796-38	Sequence 42, Appl
26	66.7	9	1	US-08-369-796-38	Sequence 43, Appl
27	66.7	9	1	US-08-410-779B-6	Sequence 44, Appl

C 28	66.7	9	1	US-08-410-779B-6	Sequence 6, Appl
C 29	66.7	9	1	US-08-410-779B-23	Sequence 23, Appl
C 30	66.7	9	1	US-08-410-779B-23	Sequence 24, Appl
C 31	66.7	9	1	US-08-410-779B-26	Sequence 25, Appl
C 32	66.7	9	1	US-08-410-779B-26	Sequence 26, Appl
C 33	66.7	9	1	US-08-410-779B-28	Sequence 27, Appl
C 34	66.7	9	1	US-08-410-779B-28	Sequence 28, Appl
C 35	66.7	9	1	US-08-410-779B-31	Sequence 29, Appl
C 36	66.7	9	1	US-08-410-779B-31	Sequence 30, Appl
C 37	66.7	9	1	US-08-410-779B-33	Sequence 31, Appl
C 38	66.7	9	1	US-08-410-779B-33	Sequence 32, Appl
C 39	66.7	9	1	US-08-410-779B-35	Sequence 33, Appl
C 40	66.7	9	1	US-08-410-779B-35	Sequence 34, Appl
C 41	66.7	9	1	US-08-410-779B-51	Sequence 35, Appl
C 42	66.7	9	1	US-08-410-779B-51	Sequence 36, Appl
C 43	66.7	9	2	US-08-852-091-25	Sequence 37, Appl
C 44	66.7	9	2	US-08-852-091-25	Sequence 38, Appl
C 45	66.7	9	2	US-08-852-091-26	Sequence 39, Appl

ALIGNMENTS



RESULT 1
US-08-411-020-1
Sequence 1, Application US/08411020
Patent No. 5712094
GENERAL INFORMATION:
APPLICANT: SEIDEL, H. MARZI
APPLICANT: LAMB, I. PETER
TITLE OF INVENTION: CHAN, SHIN-SHAY TIEN
TITLE OF INVENTION: METHODS AND ASSOCIATED REAGENTS FOR
TITLE OF INVENTION: DETECTING MODULATORS OF CYTOKINE ACTION
NUMBER OF SEQUENCES: 59
CORRESPONDENCE ADDRESS:
ADDRESSEE: Ligand Pharmaceuticals Incorporated
STREET: 9393 Towne Centre Drive
CITY: San Diego
STATE: California
COUNTRY: US
ZIP: 92121
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/411.020
FILING DATE: 27-MAR-1995
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Jurgensen, Thomas F.
REGISTRATION NUMBER: 34,195
REFERENCE/DOCKET NUMBER: 016-0030. US
TELECOMMUNICATION INFORMATION:
TELEPHONE: (619) 535-3906
TELEFAX: (619) 535-7675
INFORMATION FOR SEQ ID NO: 1:
SEQUENCE CHARACTERISTICS:
LENGTH: 9 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: other nucleic acid
DESCRIPTION: /desc = "OTHER NUCLEIC ACID,
SYNTHETIC DNA"
US-08-411-020-1

Query Match 66.7%; Score 6; DB 1; Length 9;
Best Local Similarity 100.0%; Pred. No. 3.2e+07;
Matches 9; Conservative 0; Mismatches 0; Indels 0;
Gaps 0;
QY 1 TTCNNNGAA 9

Db 1 TTCNNNGAA 9

RESULT 2

US-08-411-020-1/c
Sequence 1, Application US/08411020
Patent No. 5712094

GENERAL INFORMATION:

APPLICANT: SEIDEL, H. MARTI
APPLICANT: LAMB, I. PETER
APPLICANT: CHAN, SHIN-SHAY TIAN
TITLE OF INVENTION: METHODS AND ASSOCIATED REAGENTS FOR
TITLE OF INVENTION: DETECTING MODULATORS OF CYTOKINE ACTION
NUMBER OF SEQUENCES: 59
CORRESPONDENCE ADDRESS:
ADDRESSEE: Ligand Pharmaceuticals Incorporated
STREET: 9393 Towne Centre Drive
CITY: San Diego
STATE: California
COUNTRY: US
ZIP: 92121

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/411,020
FILING DATE: 27-MAR-1995
CLASSIFICATION: 435

ATTORNEY/AGENT INFORMATION:

NAME: Jurgensen, Thomas E.
REGISTRATION NUMBER: 34,195
REFERENCE/DOCKET NUMBER: 016-0030.US
TELECOMMUNICATION INFORMATION:
TELEPHONE: (619) 550-7675
TELEFAX: (619) 535-3906
INFORMATION FOR SEQ ID NO: 1:
SEQUENCE CHARACTERISTICS:
LENGTH: 9 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear

MOLECULE TYPE: other nucleic acid
DESCRIPTION: /desc = "OTHER NUCLEIC ACID,
SYNTHETIC DNA"

US-08-411-020-1

Query Match

Best Local Similarity 66.7%; Score 6; DB 1; Length 9;
Best Local Similarity 100.0%; Pred. No. 3.2e+07;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TTCNNNGAA 9
Db 9 TTCNNNGAA 1

RESULT 3

US-08-411-020-10
Sequence 10, Application US/08411020
Patent No. 5712094

GENERAL INFORMATION:

APPLICANT: SEIDEL, H. MARTI
APPLICANT: LAMB, I. PETER
APPLICANT: CHAN, SHIN-SHAY TIAN
TITLE OF INVENTION: METHODS AND ASSOCIATED REAGENTS FOR
TITLE OF INVENTION: DETECTING MODULATORS OF CYTOKINE ACTION
NUMBER OF SEQUENCES: 59
CORRESPONDENCE ADDRESS:
ADDRESSEE: Ligand Pharmaceuticals Incorporated
STREET: 9393 Towne Centre Drive
CITY: San Diego

STATE: California
COUNTRY: US
ZIP: 92121

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/411,020
FILING DATE: 27-MAR-1995
CLASSIFICATION: 435

ATTORNEY/AGENT INFORMATION:

NAME: Jurgensen, Thomas E.
REGISTRATION NUMBER: 34,195
REFERENCE/DOCKET NUMBER: 016-0030.US
TELECOMMUNICATION INFORMATION:
TELEPHONE: (619) 550-7675
TELEFAX: (619) 535-3906
INFORMATION FOR SEQ ID NO: 10:
SEQUENCE CHARACTERISTICS:
LENGTH: 9 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear

MOLECULE TYPE: other nucleic acid
DESCRIPTION: /desc = "OTHER NUCLEIC ACID,
SYNTHETIC DNA"

US-08-411-020-10

Query Match

Best Local Similarity 66.7%; Score 6; DB 1; Length 9;
Best Local Similarity 100.0%; Pred. No. 3.2e+07;
Matches 6; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1 TTCNNNGAA 9
Db 1 TTCNNNGAA 9

RESULT 4

US-08-411-020-10/c
Sequence 10, Application US/08411020
Patent No. 5712094

GENERAL INFORMATION:

APPLICANT: SEIDEL, H. MARTI
APPLICANT: LAMB, I. PETER
APPLICANT: CHAN, SHIN-SHAY TIAN
TITLE OF INVENTION: METHODS AND ASSOCIATED REAGENTS FOR
TITLE OF INVENTION: DETECTING MODULATORS OF CYTOKINE ACTION
NUMBER OF SEQUENCES: 59
CORRESPONDENCE ADDRESS:
ADDRESSEE: Ligand Pharmaceuticals Incorporated
STREET: 9393 Towne Centre Drive
CITY: San Diego
STATE: California
COUNTRY: US
ZIP: 92121

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/411,020
FILING DATE: 27-MAR-1995
CLASSIFICATION: 435

ATTORNEY/AGENT INFORMATION:

NAME: Jurgensen, Thomas E.
REGISTRATION NUMBER: 34,195
REFERENCE/DOCKET NUMBER: 016-0030.US
TELECOMMUNICATION INFORMATION:
TELEPHONE: (619) 550-7675
TELEFAX: (619) 535-3906

```

US-08-411-020-11/c
: Sequence 11, Application US/08411020
: Patent No. 5712094
:
GENERAL INFORMATION:
: APPLICANT: SEIDEL, H. MARTI
: APPLICANT: LAMB, I. PETER
: APPLICANT: CHAN, SHIN-SHAY TIAN
: TITLE OF INVENTION: METHODS AND ASSOCIATED REAGENTS FOR
: TITLE OF INVENTION: DETECTING MODULATORS OF CYTOKINE ACTION
: NUMBER OF SEQUENCES: 59
: CORRESPONDENCE ADDRESS:
: ADDRESSEE: Ligand Pharmaceuticals Incorporated
: STREET: 9393 Towne Centre Drive
: CITY: San Diego
: STATE: California
: COUNTRY: US
: ZIP: 92121
:
COMPUTER READABLE FORM:
: MEDIUM TYPE: Floppy disk
: COMPUTER: IBM PC compatible
: OPERATING SYSTEM: PC-DOS/MS-DOS
: SOFTWARE: Patent Release #1.0, Version #1.30
:
CURRENT APPLICATION DATA:
: APPLICATION NUMBER: US/08/411,020
: FILING DATE: 27-MAR-1995
: CLASSIFICATION: 435
: ATTORNEY/AGENT INFORMATION:
: NAME: Jurgensen, Thomas E.
: REGISTRATION NUMBER: 34,195
: REFERENCE/DOCKET NUMBER: 016-0030.US
: TELECOMMUNICATION INFORMATION:
: TELEPHONE: (619) 550-7675
: TELEFAX: (619) 535-3906
:
INFORMATION FOR SEQ ID NO: 11:
: SEQUENCE CHARACTERISTICS:
: LENGTH: 9 base pairs
: TYPE: nucleic acid
: STRANDEDNESS: single
: TOPOLOGY: linear
: MOLECULE TYPE: other nucleic acid
: DESCRIPTION: /desc = "OTHER NUCLEIC ACID,
: DESCRIPTION: SYNTHETIC DNA"
:
US-08-411-020-11
:
Query Match 66.7%; Score 6; DB 1; Length 9;
Best local Similarity 66.7%; Pred. No. 3.2e+07;
Matches 6; Conservative 0; Mismatches 3; Indels 0; Gaps 0
:
QY 1 TTCNNGAA 9
: ||| |||
DB 9 TTCGGGCAA 1
:
RESULT 7
US-08-411-020-12
: Sequence 12, Application US/08411020
: Patent No. 5712094
:
GENERAL INFORMATION:
: APPLICANT: SEIDEL, H. MARTI
: APPLICANT: LAMB, I. PETER
: APPLICANT: CHAN, SHIN-SHAY TIAN
: TITLE OF INVENTION: METHODS AND ASSOCIATED REAGENTS FOR
: TITLE OF INVENTION: DETECTING MODULATORS OF CYTOKINE ACTION
: NUMBER OF SEQUENCES: 59
: CORRESPONDENCE ADDRESS:
: ADDRESSEE: Ligand Pharmaceuticals Incorporated
: STREET: 9393 Towne Centre Drive
: CITY: San Diego
: STATE: California
: COUNTRY: US
: ZIP: 92121

```

COMPUTER READABLE FORM:

```

; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/411,020
; FILING DATE: 27-MAR-1995
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Jurgensen, Thomas E.
; REGISTRATION NUMBER: 34,195
; REFERENCE/DOCKET NUMBER: 016-0030.US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (619) 550-7675
; TELEFAX: (619) 535-3906
; INFORMATION FOR SEQ ID NO: 12:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 9 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; DESCRIPTION: /desc = "OTHER NUCLEIC ACID,"
; DESCRIPTION: SYNTHETIC DNA"
US-08-411-020-12

```

Query Match

```

Best Local Similarity 66.7%; Score 6; DB 1; Length 9;
Matches 6; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

```

```

QY 1 TTCNNNGAA 9
    ||| |||
Db 1 TTCAGAA 9

```

RESULT 8

```

US-08-411-020-12/c
; Sequence 12, Application US/08411020
; Patent No. 5712094
; GENERAL INFORMATION:
; APPLICANT: SEIDEL, H. MARTI
; APPLICANT: LAMB, I. PETER
; APPLICANT: CHAN, SHIN-SHAY TIAN
; TITLE OF INVENTION: METHODS AND ASSOCIATED REAGENTS FOR
; TITLE OF INVENTION: DETECTING MODULATORS OF CYTOKINE ACTION
; NUMBER OF SEQUENCES: 59
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Ligand Pharmaceuticals Incorporated
; STREET: 9393 Towne Centre Drive
; CITY: San Diego
; STATE: California
; COUNTRY: US
; ZIP: 92121
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/411,020
; FILING DATE: 27-MAR-1995
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Jurgensen, Thomas E.
; REGISTRATION NUMBER: 34,195
; REFERENCE/DOCKET NUMBER: 016-0030.US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (619) 550-7675
; TELEFAX: (619) 535-3906
; INFORMATION FOR SEQ ID NO: 12:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 9 base pairs

```

```

; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; DESCRIPTION: /desc = "OTHER NUCLEIC ACID,"
; DESCRIPTION: SYNTHETIC DNA"
US-08-411-020-12

```

Query Match

```

Best Local Similarity 66.7%; Score 6; DB 1; Length 9;
Matches 6; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

```

```

QY 1 TTCNNNGAA 9
    ||| |||
Db 9 TTCAGAA 1

```

RESULT 9

```

US-08-411-020-13
; Sequence 13, Application US/08411020
; Patent No. 5712094
; GENERAL INFORMATION:
; APPLICANT: SEIDEL, H. MARTI
; APPLICANT: LAMB, I. PETER
; APPLICANT: CHAN, SHIN-SHAY TIAN
; TITLE OF INVENTION: METHODS AND ASSOCIATED REAGENTS FOR
; TITLE OF INVENTION: DETECTING MODULATORS OF CYTOKINE ACTION
; NUMBER OF SEQUENCES: 59
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Ligand Pharmaceuticals Incorporated
; STREET: 9393 Towne Centre Drive
; CITY: San Diego
; STATE: California
; COUNTRY: US
; ZIP: 92121
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/411,020
; FILING DATE: 27-MAR-1995
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Jurgensen, Thomas E.
; REGISTRATION NUMBER: 34,195
; REFERENCE/DOCKET NUMBER: 016-0030.US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (619) 550-7675
; TELEFAX: (619) 535-3906
; INFORMATION FOR SEQ ID NO: 13:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 9 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; DESCRIPTION: /desc = "OTHER NUCLEIC ACID,"
; DESCRIPTION: SYNTHETIC DNA"
US-08-411-020-13

```

Query Match

```

Best Local Similarity 66.7%; Score 6; DB 1; Length 9;
Matches 6; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

```

```

QY 1 TTCNNNGAA 9
    ||| |||
Db 1 TTCAGAA 9

```

RESULT 10

```

US-08-411-020-13/c

```



```

: Sequence 13, Application US/08411020
: Patent No. 5712094
: GENERAL INFORMATION:
: APPLICANT: SEIDEL, H. MARTI
: APPLICANT: LAMB, I. PETER
: APPLICANT: CHAN, SHIN-SHAY TIEN
: TITLE OF INVENTION: METHODS AND ASSOCIATED REAGENTS FOR
: TITLE OF INVENTION: DETECTING MODULATORS OF CYTOKINE ACTION
: NUMBER OF SEQUENCES: 59
: CORRESPONDENCE ADDRESS:
: ADDRESSEE: Ligand Pharmaceuticals Incorporated
: STREET: 9393 Towne Centre Drive
: City: San Diego
: STATE: California
: COUNTRY: US
: ZIP: 92121
: COMPUTER READABLE FORM:
: MEDIUM TYPE: Floppy disk
: COMPUTER: IBM PC compatible
: OPERATING SYSTEM: PC-DOS/MS-DOS
: SOFTWARE: Patentin Release #1.0, Version #1.30
: CURRENT APPLICATION DATA:
: APPLICATION NUMBER: US/08/411,020
: FILING DATE: 27-MAR-1995
: CLASSIFICATION: 435
: ATTORNEY/AGENT INFORMATION:
: NAME: Jurgensen, Thomas E.
: REGISTRATION NUMBER: 34,195
: REFERENCE/DOCKET NUMBER: 016-0030.US
: TELECOMMUNICATION INFORMATION:
: TELEPHONE: (619) 550-7675
: TELEFAX: (619) 535-3906
: INFORMATION FOR SEQ ID NO: 13:
: SEQUENCE CHARACTERISTICS:
: LENGTH: 9 base pairs
: TYPE: nucleic acid
: STRANDEDNESS: single
: TOPOLOGY: linear
: MOLECULE TYPE: other nucleic acid
: DESCRIPTION: /desc = "OTHER NUCLEIC ACID,
: DESCRIPTION: SYNTHETIC DNA"
: US-08-411-020-13
:
: Query Match 66.7%; Score 6; DB 1; Length 9;
: Best Local Similarity 66.7%; Pred. No. 3.2e+07;
: Matches 6; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
:
: QY 1 TTCNNNGAA 9
: DB 9 TTCTGAGAA 1
:
: RESULT 11
: US-08-369-796-25
: Sequence 25, Application US/08369796
: Patent No. 5716622
: GENERAL INFORMATION:
: APPLICANT: James E. Darnell, Jr.
: APPLICANT: Zilong Wen
: APPLICANT: Curt M. Horvath
: APPLICANT: Zhong Zhong
: TITLE OF INVENTION: FUNCTIONALLY ACTIVE REGIONS OF SIGNAL
: TITLE OF INVENTION: TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION (STAT) PROTEINS
: NUMBER OF SEQUENCES: 39
: CORRESPONDENCE ADDRESS:
: ADDRESSEE: Klauber & Jackson
: STREET: 411 Hackensack Avenue
: City: Hackensack
: STATE: New Jersey
: COUNTRY: USA
: ZIP: 07601
: COMPUTER READABLE FORM:
: MEDIUM TYPE: Floppy disk

```

11/12/95

```

: COMPUTER: IBM PC compatible
: OPERATING SYSTEM: PC-DOS/MS-DOS
: SOFTWARE: Patentin Release #1.0, Version #1.25
: CURRENT APPLICATION DATA:
: APPLICATION NUMBER: US/08/369,796
: FILING DATE: 06-JAN-1995
: CLASSIFICATION: 435
: ATTORNEY/AGENT INFORMATION:
: NAME: Jackson Esq., David A.
: REGISTRATION NUMBER: 26,742
: REFERENCE/DOCKET NUMBER: 600-1-116
: TELECOMMUNICATION INFORMATION:
: TELEPHONE: 201 487-5800
: TELEFAX: 201 343-1684
: TELEEX: 133521
: INFORMATION FOR SEQ ID NO: 25:
: SEQUENCE CHARACTERISTICS:
: LENGTH: 9 base pairs
: TYPE: nucleic acid
: STRANDEDNESS: double
: TOPOLOGY: linear
: MOLECULE TYPE: DNA synthetic probe
: HYPOHETICAL: NO
: ANTI-SENSE: NO
: US-08-369-796-25
:
: Query Match 66.7%; Score 6; DB 1; Length 9;
: Best Local Similarity 66.7%; Pred. No. 3.2e+07;
: Matches 6; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
:
: QY 1 TTCNNNGAA 9
: DB 1 TTCCCGGAA 9
:
: RESULT 12
: US-08-369-796-25/c
: Sequence 25, Application US/08369796
: Patent No. 5716622
: GENERAL INFORMATION:
: APPLICANT: James E. Darnell, Jr.
: APPLICANT: Zilong Wen
: APPLICANT: Curt M. Horvath
: APPLICANT: Zhong Zhong
: TITLE OF INVENTION: FUNCTIONALLY ACTIVE REGIONS OF SIGNAL
: TITLE OF INVENTION: TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION (STAT) PROTEINS
: NUMBER OF SEQUENCES: 39
: CORRESPONDENCE ADDRESS:
: ADDRESSEE: Klauber & Jackson
: STREET: 411 Hackensack Avenue
: City: Hackensack
: STATE: New Jersey
: COUNTRY: USA
: ZIP: 07601
: COMPUTER READABLE FORM:
: MEDIUM TYPE: Floppy disk
: COMPUTER: IBM PC compatible
: OPERATING SYSTEM: PC-DOS/MS-DOS
: SOFTWARE: Patentin Release #1.0, Version #1.25
: CURRENT APPLICATION DATA:
: APPLICATION NUMBER: US/08/369,796
: FILING DATE: 06-JAN-1995
: CLASSIFICATION: 435
: ATTORNEY/AGENT INFORMATION:
: NAME: Jackson Esq., David A.
: REGISTRATION NUMBER: 26,742
: REFERENCE/DOCKET NUMBER: 600-1-116
: TELECOMMUNICATION INFORMATION:
: TELEPHONE: 201 487-5800
: TELEFAX: 201 343-1684
: TELEEX: 133521
: INFORMATION FOR SEQ ID NO: 25:
: SEQUENCE CHARACTERISTICS:

```

LENGTH: 9 base pairs
TYPE: nucleic acid
STRANDEDNESS: double
TOPOLOGY: linear
MOLECULE TYPE: DNA synthetic probe
HYPOTHETICAL: NO
ANTI-SENSE: NO
US-08-369-796-25

Query Match 66.7%; Score 6; DB 1; Length 9;
Best Local Similarity 66.7%; Pred. No. 3.2e+07;
Matches 6; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1 TTCNNNGAA 9
||| |||
Db 9 TTCGGGGA 1

RESULT 13

US-08-369-796-26
Sequence 26, Application US/08369796
Patent No. 5716622
GENERAL INFORMATION:
APPLICANT: James E. Darnell, Jr.
APPLICANT: Zilong Wen
APPLICANT: Curt M. Horvath
APPLICANT: Zhong Zhong
TITLE OF INVENTION: FUNCTIONALLY ACTIVE REGIONS OF SIGNAL
TITLE OF INVENTION: TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION (STAT) PROTEINS
NUMBER OF SEQUENCES: 39
CORRESPONDENCE ADDRESS:
ADDRESSEE: Klauber & Jackson
STREET: 411 Hackensack Avenue
CITY: Hackensack
STATE: New Jersey
COUNTRY: USA
ZIP: 07601
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/369,796
FILING DATE: 06-JAN-1995
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Jackson Esq., David A.
REGISTRATION NUMBER: 26,742
REFERENCE/DOCKET NUMBER: 600-1-116
TELECOMMUNICATION INFORMATION:
TELEPHONE: 201 487-5800
TELEFAX: 201 343-1684
TELEX: 133521
INFORMATION FOR SEQ ID NO: 26:
SEQUENCE CHARACTERISTICS:
LENGTH: 9 base pairs
TYPE: nucleic acid
STRANDEDNESS: double
TOPOLOGY: linear
MOLECULE TYPE: DNA synthetic probe
HYPOTHETICAL: NO
ANTI-SENSE: NO
US-08-369-796-26

Query Match 66.7%; Score 6; DB 1; Length 9;
Best Local Similarity 66.7%; Pred. No. 3.2e+07;
Matches 6; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1 TTCNNNGAA 9
||| |||
Db 1 TTCGGGGA 9

RESULT 14

US-08-369-796-26/C
Sequence 26, Application US/08369796
Patent No. 5716622
GENERAL INFORMATION:
APPLICANT: James E. Darnell, Jr.
APPLICANT: Zilong Wen
APPLICANT: Curt M. Horvath
APPLICANT: Zhong Zhong
TITLE OF INVENTION: FUNCTIONALLY ACTIVE REGIONS OF SIGNAL
TITLE OF INVENTION: TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION (STAT) PROTEINS
NUMBER OF SEQUENCES: 39
CORRESPONDENCE ADDRESS:
ADDRESSEE: Klauber & Jackson
STREET: 411 Hackensack Avenue
CITY: Hackensack
STATE: New Jersey
COUNTRY: USA
ZIP: 07601
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/369,796
FILING DATE: 06-JAN-1995
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Jackson Esq., David A.
REGISTRATION NUMBER: 26,742
REFERENCE/DOCKET NUMBER: 600-1-116
TELECOMMUNICATION INFORMATION:
TELEPHONE: 201 487-5800
TELEFAX: 201 343-1684
TELEX: 133521
INFORMATION FOR SEQ ID NO: 26:
SEQUENCE CHARACTERISTICS:
LENGTH: 9 base pairs
TYPE: nucleic acid
STRANDEDNESS: double
TOPOLOGY: linear
MOLECULE TYPE: DNA synthetic probe
HYPOTHETICAL: NO
ANTI-SENSE: NO
US-08-369-796-26

Query Match 66.7%; Score 6; DB 1; Length 9;
Best Local Similarity 66.7%; Pred. No. 3.2e+07;
Matches 6; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1 TTCNNNGAA 9
||| |||
Db 9 TTCGGGGA 1

RESULT 15

US-08-369-796-27
Sequence 27, Application US/08369796
Patent No. 5716622
GENERAL INFORMATION:
APPLICANT: James E. Darnell, Jr.
APPLICANT: Zilong Wen
APPLICANT: Curt M. Horvath
APPLICANT: Zhong Zhong
TITLE OF INVENTION: FUNCTIONALLY ACTIVE REGIONS OF SIGNAL
TITLE OF INVENTION: TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION (STAT) PROTEINS
NUMBER OF SEQUENCES: 39
CORRESPONDENCE ADDRESS:
ADDRESSEE: Klauber & Jackson
STREET: 411 Hackensack Avenue
CITY: Hackensack

```

; STATE: New Jersey
; COUNTRY: USA
; ZIP: 07601
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/369,796
; FILING DATE: 06-JAN-1995
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Jackson Esq., David A.
; REGISTRATION NUMBER: 26,742
; REFERENCE/DOCKET NUMBER: 600-1-116
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 201 487-5800
; TELEFAX: 201 343-1684
; TELEEX: 133521
; INFORMATION FOR SEQ ID NO: 27:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 9 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: linear
; MOLECULE TYPE: DNA synthetic probe
; HYPOTHEICAL: NO
; ANTI-SENSE: NO
; US-08-369-796-27

```

```

Query Match          66.7%; Score 6; DB 1; Length 9;
Best Local Similarity 66.7%; Pred. No. 3.2e+07;
Matches 6; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1 TTCNNNGAA 9
   ||| |||
Db 1 TTCCGGGAA 9

```

Search completed: December 25, 2002, 20:21:58
 Job time : 53 secs

GenCore version 5.1.3
Copyright (c) 1993 - 2002 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: December 25, 2002, 11:24:48 ; Search time 227 Seconds
(without alignments)
28.371 Million cell updates/sec

Title: US-09-744-875-1

Sequence: 1 agattctaggaatcaatc 21

Scoring table: IDENTITY NUC
Gapop 10.0 , Gapext 1.0

Searched: 441362 seqs, 153338381 residues

Total number of hits satisfying chosen parameters: 687286

Minimum DB seq length: 0
Maximum DB seq length: 100

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Issued Patents -NA: *
1: /cgn2_6/ptodata/1/ina/5A.COMB.seq: *
2: /cgn2_6/ptodata/1/ina/5B.COMB.seq: *
3: /cgn2_6/ptodata/1/ina/5A.COMB.seq: *
4: /cgn2_6/ptodata/1/ina/5B.COMB.seq: *
5: /cgn2_6/ptodata/1/ina/PTUS.COMB.seq: *
6: /cgn2_6/ptodata/1/ina/backfile1.seq: *

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length DB	ID	Description
1	18	85.7	21	1	US-08-366-276-8
2	18	85.7	100	4	US-09-522-217-59
3	18	85.7	100	4	US-09-522-217-60
4	14.6	69.5	58	4	US-09-140-804-46
5	14.6	69.5	58	4	US-09-173-043-22
6	14.6	69.5	58	4	US-09-209-525-42
7	14.2	67.6	20	4	US-09-662-402A-35
8	13.8	65.7	30	1	US-08-201-697-12
9	13.8	65.7	30	1	US-08-463-090B-24
10	13.6	64.8	34	1	US-08-332-420-54
11	13.6	64.8	37	1	US-07-941-363-1
12	13.6	64.8	38	4	US-09-143-634-28
13	13.6	64.8	40	1	US-08-308-196A-4
14	13.6	64.8	40	1	US-09-289-803-3
15	13.6	64.8	40	5	PCT-US91-06452-4
16	13.6	64.8	41	4	US-09-289-803-2
17	13.6	64.8	42	4	US-09-289-803-1
18	13.6	64.8	68	6	5221737-7
19	13.4	63.8	30	3	US-09-030-613-30
20	13.4	63.8	30	4	US-09-451-905-30
21	13.4	63.8	40	4	US-09-313-221A-77
22	13.2	62.9	25	3	US-08-840-316-5
23	13.2	62.9	25	4	US-08-809-523-5
24	13.2	62.9	25	4	US-08-471-971-5
25	13.2	62.9	25	4	US-09-402-776-5
26	13.2	62.9	25	5	PCT-US93-08849A-5
27	13.2	62.9	25	5	PCT-US93-08849-5

C 28	13.2	62.9	31	3	US-09-182-816-30	Sequence 30, Appl
C 29	13.2	62.9	31	3	US-09-471-528-30	Sequence 30, Appl
C 30	13.2	62.9	31	4	US-09-634-530-30	Sequence 30, Appl
C 31	13.2	62.9	33	1	US-07-955-041-6	Sequence 6, Appl1
C 32	13.2	62.9	33	1	US-08-227-455-6	Sequence 6, Appl1
C 33	13.2	62.9	33	1	US-08-472-482-6	Sequence 6, Appl1
C 34	13.2	62.9	33	1	US-08-487-056-6	Sequence 6, Appl1
C 35	13.2	62.9	33	4	US-08-169-715-47	Sequence 47, Appl
C 36	13.2	62.9	63	4	US-09-140-804-38	Sequence 38, Appl
C 37	13.2	62.9	72	1	US-08-413-118-122	Sequence 122, App
C 38	13.2	62.9	72	3	US-08-473-446-122	Sequence 122, App
C 39	13	61.9	21	1	US-08-242-680-14	Sequence 14, Appl
C 40	13	61.9	21	2	US-08-653-382A-14	Sequence 14, Appl
C 41	13	61.9	26	2	US-08-215-089-4	Sequence 4, Appl1
C 42	13	61.9	26	5	PCT-US95-03384-4	Sequence 4, Appl1
C 43	13	61.9	27	1	US-08-480-604A-15	Sequence 15, Appl
C 44	13	61.9	27	2	US-08-405-496A-15	Sequence 15, Appl
C 45	13	61.9	27	4	US-08-915-136-15	Sequence 15, Appl

ALIGNMENTS

RESULT 1
US-08-366-276-8
Sequence 8, Application US/08366276
Patent No. 5534409
GENERAL INFORMATION:
APPLICANT: Groner, Bernd
APPLICANT: Gouilleux, Fabrice
APPLICANT: Wakao, Hiroshi
TITLE OF INVENTION: Cytokine Regulated Transcription Factor
NUMBER OF SEQUENCES: 12
CORRESPONDENCE ADDRESS:
ADDRESSEE: CIBA-GEIGY Corporation
STREET: 7 Skyline Drive
CITY: Hawthorne
STATE: New York
COUNTRY: USA
ZIP: 10532
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentia Release #1.0, Version #1.30B
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/366,276
FILING DATE:
CLASSIFICATION: 435
PRIORITY APPLICATION DATA:
APPLICATION NUMBER: GB 9409396.0
FILING DATE: 11-MAY-1994
ATTORNEY/AGENT INFORMATION:
NAME: Elmer, James Scott
REGISTRATION NUMBER: 36,129
REFERENCE/DOCKET NUMBER: 4-19992/A
TELECOMMUNICATION INFORMATION:
TELEPHONE: (919) 541-8614
TELEFAX: (919) 541-8689
INFORMATION FOR SEQ ID NO: 8:
SEQUENCE CHARACTERISTICS:
LENGTH: 21 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: other nucleic acid
DESCRIPTION: /desc = "MGF binding sequence from
? DESCRIPTION: Bovine b-casein"
? HYPOTHETICAL: NO
US-08-366-276-8
Query Match 85.7%; Score 18; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 7.8;

FEATURE:
OTHER INFORMATION: synthetic oligonucleotide
US-09-173-043-22

Query Match 69.5%; Score 14.6; DB 4; Length 58;
Best Local Similarity 81.0%; Pred. No. 2.8e+02;
Matches 17; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 1 AGATTCTAGCAATTCGAATC 21
DB 14 AGAATACCTAGCAATTCCTACTC 34

RESULT 6
US-09-209-525-42
Sequence 42, Application US/09209525
Patent No. 6303770
GENERAL INFORMATION:
APPLICANT: LOK, S1
APPLICANT: Conklin, Darrell C.
TITLE OF INVENTION: Mammalian Alpha Helical Protein-1
FILE REFERENCE: 97-71
CURRENT APPLICATION NUMBER: US/09/209,525
CURRENT FILING DATE: 1998-12-10
NUMBER OF SEQ ID NOS: 56
SOFTWARE: FASTSEQ for Windows Version 3.0
SEQ ID NO 42
LENGTH: 58
TYPE: DNA
ORGANISM: Homo sapiens
US-09-209-525-42

Query Match 69.5%; Score 14.6; DB 4; Length 58;
Best Local Similarity 81.0%; Pred. No. 2.8e+02;
Matches 17; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 1 AGATTCTAGCAATTCGAATC 21
DB 14 AGAATACCTAGCAATTCCTACTC 34

RESULT 7
US-09-662-402A-35/C
Sequence 35, Application US/09662402A
Patent No. 6420117
GENERAL INFORMATION:
APPLICANT: Wessler, Susan R
APPLICANT: Casa, Alexandra M
TITLE OF INVENTION: MINATURE INVERTED REPEAT TRANSPOSABLE ELEMENTS AND
FILE REFERENCE: 235.00230101
CURRENT APPLICATION NUMBER: US/09/662,402A
CURRENT FILING DATE: 2000-09-14
PRIOR APPLICATION NUMBER: 60/153,812
PRIOR FILING DATE: 1999-09-14
NUMBER OF SEQ ID NOS: 40
SOFTWARE: PatentIn Ver. 2.1
SEQ ID NO 35
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence:
US-09-662-402A-35

Query Match 67.6%; Score 14.2; DB 4; Length 20;
Best Local Similarity 84.2%; Pred. No. 4e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 3 ATTCTAGCAATTCGAATC 21
DB 14 AGAATACCTAGCAATTCCTACTC 34

DB 19 ATTCTAGCAATTCGAATC 1

RESULT 8
US-08-201-697-12/C
Sequence 12, Application US/08201697
Patent No. 5705623
GENERAL INFORMATION:

APPLICANT: Wiggins, Roger C.
APPLICANT: Thomas, Peedikayil E.
TITLE OF INVENTION: Mammalian Glomerular Epithelial Protein
FILE REFERENCE: 1
NUMBER OF SEQUENCES: 17
CORRESPONDENCE ADDRESS:

ADDRESS: Campbell and Flores
STREET: 4370 La Jolla Village Drive, Suite 700
CITY: San Diego
STATE: California
COUNTRY: USA
ZIP: 92122

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/201,697
FILING DATE: 25-FEB-1994
CLASSIFICATION: 530
ATTORNEY/AGENT INFORMATION:

NAME: Campbell, Cathryn A.
REGISTRATION NUMBER: P-0M 9783
REFERENCE/DOCKET NUMBER: 31,815
TELECOMMUNICATION INFORMATION:
TELEPHONE: (619) 535-9001
TELEFAX: (619) 535-8949
INFORMATION FOR SEQ ID NO.: 12:

SEQUENCE CHARACTERISTICS:
LENGTH: 30 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-201-697-12

Query Match 65.7%; Score 13.8; DB 1; Length 30;
Best Local Similarity 88.2%; Pred. No. 6.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 3 ATTCTAGCAATTCGAATC 19
DB 17 AGTCTAGCAATTCGAATC 1

RESULT 9
US-08-463-090B-24/C
Sequence 24, Application US/08463090B
Patent No. 5601015
GENERAL INFORMATION:

APPLICANT: Cottarel, Guillaume
APPLICANT: Damagnez, Veronique
APPLICANT: Drealetta, Guilio
TITLE OF INVENTION: Cell-Cycle Regulatory Proteins from
NUMBER OF SEQUENCES: 25
CORRESPONDENCE ADDRESS:

ADDRESS: Foley, Hoag & Eliot, LLP
STREET: One Post Office Square
CITY: Boston
STATE: MA
COUNTRY: USA
ZIP: 02109
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk

```

; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: ASCII (text)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/463,090B
; FILING DATE: 05-JUN-1995
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Vincent, Matthew P.
; REGISTRATION NUMBER: 36,709
; REFERENCE/DOCKET NUMBER: MIV032.01
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (617) 832-1299
; TELEFAX: (617) 832-7000
; INFORMATION FOR SEQ ID NO: 24:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 30 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: oligonucleotide
; US-08-463-090B-24

```

```

Query Match      65.7%; Score 13.8; DB 1; Length 30;
Best Local Similarity 88.2%; Pred. No. 6.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```

```

QY 3 ATTCTAGCAATTCAA 19
DB 20 ATTACTAGCAATTCAA 4

```

```

RESULT 10
US-08-332-420-54/c
; Sequence 54, Application US/08332420
; Patent No. 5744300
; GENERAL INFORMATION:
; APPLICANT: Maarten H.K. Linskens, et al.
; TITLE OF INVENTION: METHODS AND REAGENTS FOR THE
; TITLE OF INVENTION: IDENTIFICATION AND REGULATION
; NUMBER OF SEQUENCES: 70
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: USA
; ZIP: 90017
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: IBM P.C. DOS (Version 5.0)
; SOFTWARE: Wordperfect (Version 5.1)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/332,420
; FILING DATE: October 31, 1994
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/235,180
; FILING DATE: April 29, 1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Wardburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 210/041
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TEFEX: 67-3510
; INFORMATION FOR SEQ ID NO: 54:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 34
; TYPE: nucleic acid

```

```

; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-332-420-54

```

```

Query Match      64.8%; Score 13.6; DB 1; Length 34;
Best Local Similarity 80.0%; Pred. No. 7.8e+02;
Matches 16; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

```

```

QY 1 AGATTCTAGCAATTCAA 20
DB 32 AGAGTCGAGCAATTCAA 13

```

```

RESULT 11
US-07-941-363-1
; Sequence 1, Application US/07941363
; Patent No. 5348886
; GENERAL INFORMATION:
; APPLICANT: Lee, Stephen C.
; APPLICANT: Luckow, Verne A.
; APPLICANT: Leusch, Mark S.
; APPLICANT: Olin, Peter O.
; TITLE OF INVENTION: Method of Producing Recombinant
; TITLE OF INVENTION: Eukaryotic Viruses in Bacteria
; NUMBER OF SEQUENCES: 9
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Dennis A. Bennett, Monsanto Co., A3SG
; STREET: 800 N. Lindbergh Blvd.
; CITY: St. Louis
; STATE: Missouri
; COUNTRY: USA
; ZIP: 63167
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/941,363
; FILING DATE: 19920904
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Bennett, Dennis A.
; REGISTRATION NUMBER: 34,547
; REFERENCE/DOCKET NUMBER: 07-21(872)A
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (314)694-5402
; TELEFAX: (314)694-9009
; INFORMATION FOR SEQ ID NO: 1:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 37 base pairs
; TYPE: NUCLEIC ACID
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; US-07-941-363-1

```

```

Query Match      64.8%; Score 13.6; DB 1; Length 37;
Best Local Similarity 80.0%; Pred. No. 7.8e+02;
Matches 16; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

```

```

QY 1 AGATTCTAGCAATTCAA 20
DB 1 AGATCTGAGCAATTCAT 20

```

```

RESULT 12
US-09-143-634-28/c
; Sequence 28, Application US/09143634
; Patent No. 6214602
; GENERAL INFORMATION:
; APPLICANT: Zdanovsky, Alexey G.
; TITLE OF INVENTION: EXPRESSION OF CLOSTRIDIAL TOXINS AND PROTEINS

```


FILE REFERENCE: PRNG-03193
CURRENT APPLICATION NUMBER: US/09/143,634
CURRENT FILING DATE: 1998-08-28
NUMBER OF SEQ ID NOS: 28
SOFTWARE: PatentIn Ver. 2.0
SEQ ID NO 28
LENGTH: 38
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-09-143-634-28

Query Match 64.8%; Score 13.6; DB 4; Length 38;
Best Local Similarity 80.0%; Pred. No. 7.9e+02;
Matches 16; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

OY 2 GATTCTGGAATTCAAATC 21
DB 21 GATATTTAAGAAATTCAGATC 2

RESULT 13
US-08-308-196A-4
Sequence 4, Application US/08308196A
Patent No. 5612198
GENERAL INFORMATION:
APPLICANT: Brietley, Russell A.
APPLICANT: Davis, Geneva R.
APPLICANT: Holtz, Gregory C.
APPLICANT: Gleeson, Martin A.
APPLICANT: Howard, Bradley D.
TITLE OF INVENTION: Production of Insulin-Like Growth
NUMBER OF SEQUENCES: 17
CORRESPONDENCE ADDRESSES:
ADDRESS: Brown, Martin, Haller & McClain
STREET: 1660 Union Street
CITY: San Diego
STATE: California
COUNTRY: USA
ZIP: 92101-2926
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
OPERATING SYSTEM: IBM PC compatible
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/308,196A
FILING DATE: 09-SEPT-1994
PRIORITY APPLICATION DATA:
APPLICATION NUMBER: US 07/983,523
FILING DATE: 03-MAR-1993
PRIORITY APPLICATION DATA:
APPLICATION NUMBER: US 07/578,728
FILING DATE: 04-SEP-1990
ATTORNEY/AGENT INFORMATION:
NAME: Seidman, Stephanie L.
REGISTRATION NUMBER: 33,779
REFERENCE/DOCKET NUMBER: 51875
TELECOMMUNICATION INFORMATION:
TELEPHONE: (619)238-0999
TELEFAX: (619)238-0062
INFORMATION FOR SEQ ID NO: 4:
SEQUENCE CHARACTERISTICS:
LENGTH: 40 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: unknown
MOLECULE TYPE: DNA (genomic DNA)
US-08-308-196A-4

Query Match 64.8%; Score 13.6; DB 1; Length 40;

Best Local Similarity 80.0%; Pred. No. 7.9e+02;
Matches 16; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
OY 1 AGATTCTGGAATTCAAAT 20
DB 5 AGCTTGATTAAGAAATTCAAAT 24

RESULT 14
US-09-289-803-3
Sequence 3, Application US/09289803
Patent No. 6162605
GENERAL INFORMATION:
APPLICANT: Fort, Thomas L.
APPLICANT: McMillan, Ray A.
APPLICANT: Hellyer, Tobin
APPLICANT: You, Qimin
TITLE OF INVENTION: Amplification and Detection of Shiga-Like Toxin I
FILE REFERENCE: SLT-I Application
CURRENT APPLICATION NUMBER: US/09/289,803
CURRENT FILING DATE: 1999-04-12
NUMBER OF SEQ ID NOS: 10
SOFTWARE: PatentIn Ver. 2.0
SEQ ID NO 3
LENGTH: 40
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: Primer for SDA
US-09-289-803-3

Query Match 64.8%; Score 13.6; DB 4; Length 40;
Best Local Similarity 80.0%; Pred. No. 7.9e+02;
Matches 16; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

OY 1 AGATTCTGGAATTCAAAT 20
DB 13 AGACTTCTCGGATTCACAT 32

RESULT 15
PCT-US91-06452-4
Sequence 4, Application PC/TUS9106452
GENERAL INFORMATION:
APPLICANT: Brietley, Russell A.
APPLICANT: Davis, Geneva R.
APPLICANT: Holtz, Gregory C.
APPLICANT: Gleeson, Martin A.
APPLICANT: Bradley, D. H.
TITLE OF INVENTION: Production of Insulin-Like Growth
NUMBER OF SEQUENCES: 12
CORRESPONDENCE ADDRESSES:
ADDRESS: Fitch, Even, Tabin & Flannery
STREET: 135 South LaSalle Street, Suite 900
CITY: Chicago
STATE: Illinois
COUNTRY: USA
ZIP: 60603
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
OPERATING SYSTEM: IBM PC compatible
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US91/06452
FILING DATE: 19910409
CLASSIFICATION: 435
PRIORITY APPLICATION DATA:
APPLICATION NUMBER: US 07/578,728
FILING DATE: 04-SEP-1990

```

: ATTORNEY/AGENT INFORMATION:
: NAME: Seidman, Stephanie L.
: REGISTRATION NUMBER: 33,779
: REFERENCE/DOCKET NUMBER: 51874
: TELECOMMUNICATION INFORMATION:
: TELEPHONE: (619)552-1311
: TELEFAX: (619)552-0095
: INFORMATION FOR SRD ID NO: 4:
: SEQUENCE CHARACTERISTICS:
: LENGTH: 40 base pairs
: TYPE: NUCLEIC ACID
: STRANDEDNESS: single
: TOPOLOGY: unknown
: MOLECULE TYPE: DNA (genomic)
PCT-US91-06452-4

```

```

Query Match      64.8%; Score 13.6; DB 5; Length 40;
Best Local Similarity 80.0%; Fred. No. 7.9e+02;
Matches 16; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

```

```

QY      1 AGATTCTAGGAAATCAAT 20
        ||||| |||||
DB      5 AGCTGATAGAAATCAAT 24

```

Search completed: December 25, 2002, 11:36:14
Job time : 229 secs

GenCore version 5.1.3
Copyright (c) 1993 - 2002 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: December 25, 2002, 11:24:49 ; Search time 262 Seconds
(without alignments)
77.359 Million cell updates/sec

Title: SCHMIDT875
Perfect score: 9
Sequence: 1 ttcnmgaa 9

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 2185239 seqs, 112599159 residues
Total number of hits satisfying chosen parameters: 2390332

Minimum DB seq length: 0
Maximum DB seq length: 100

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : N_Geneseq_101002:*

- 1: /SID2/gcgdata/geneseq/geneseqn-emb1/NA1980.DAT:*
- 2: /SID2/gcgdata/geneseq/geneseqn-emb1/NA1981.DAT:*
- 3: /SID2/gcgdata/geneseq/geneseqn-emb1/NA1982.DAT:*
- 4: /SID2/gcgdata/geneseq/geneseqn-emb1/NA1983.DAT:*
- 5: /SID2/gcgdata/geneseq/geneseqn-emb1/NA1984.DAT:*
- 6: /SID2/gcgdata/geneseq/geneseqn-emb1/NA1985.DAT:*
- 7: /SID2/gcgdata/geneseq/geneseqn-emb1/NA1986.DAT:*
- 8: /SID2/gcgdata/geneseq/geneseqn-emb1/NA1987.DAT:*
- 9: /SID2/gcgdata/geneseq/geneseqn-emb1/NA1988.DAT:*
- 10: /SID2/gcgdata/geneseq/geneseqn-emb1/NA1989.DAT:*
- 11: /SID2/gcgdata/geneseq/geneseqn-emb1/NA1990.DAT:*
- 12: /SID2/gcgdata/geneseq/geneseqn-emb1/NA1991.DAT:*
- 13: /SID2/gcgdata/geneseq/geneseqn-emb1/NA1992.DAT:*
- 14: /SID2/gcgdata/geneseq/geneseqn-emb1/NA1993.DAT:*
- 15: /SID2/gcgdata/geneseq/geneseqn-emb1/NA1994.DAT:*
- 16: /SID2/gcgdata/geneseq/geneseqn-emb1/NA1995.DAT:*
- 17: /SID2/gcgdata/geneseq/geneseqn-emb1/NA1996.DAT:*
- 18: /SID2/gcgdata/geneseq/geneseqn-emb1/NA1997.DAT:*
- 19: /SID2/gcgdata/geneseq/geneseqn-emb1/NA1998.DAT:*
- 20: /SID2/gcgdata/geneseq/geneseqn-emb1/NA1999.DAT:*
- 21: /SID2/gcgdata/geneseq/geneseqn-emb1/NA2000.DAT:*
- 22: /SID2/gcgdata/geneseq/geneseqn-emb1/NA2001A.DAT:*
- 23: /SID2/gcgdata/geneseq/geneseqn-emb1/NA2001B.DAT:*
- 24: /SID2/gcgdata/geneseq/geneseqn-emb1/NA2002.DAT:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	66.7	9	16	AA114120	Cytokine responsiv
2	66.7	9	16	AA114120	Cytokine responsiv
3	66.7	9	16	AA114165	Cytokine responsiv
4	66.7	9	16	AA114165	Cytokine responsiv
5	66.7	9	16	AA114149	Cytokine responsiv
6	66.7	9	16	AA114149	Cytokine responsiv
7	66.7	9	16	AA114145	Cytokine responsiv
8	66.7	9	16	AA114145	Cytokine responsiv
9	66.7	9	16	AA114147	Cytokine responsiv

C	10	6	66.7	9	16	AA114147	Cytokine responsiv
C	11	6	66.7	9	16	AA114140	Cytokine responsiv
C	12	6	66.7	9	16	AA114140	Cytokine responsiv
C	13	6	66.7	9	16	AA114142	Cytokine responsiv
C	14	6	66.7	9	16	AA114142	Cytokine responsiv
C	15	6	66.7	9	16	AA114137	Cytokine responsiv
C	16	6	66.7	9	16	AA114137	Cytokine responsiv
C	17	6	66.7	9	17	AA114181	Cytokine activated
C	18	6	66.7	9	17	AA114181	Cytokine activated
C	19	6	66.7	9	17	AA114180	Cytokine activated
C	20	6	66.7	9	17	AA114180	Cytokine activated
C	21	6	66.7	9	17	AA114182	Cytokine activated
C	22	6	66.7	9	17	AA114182	Cytokine activated
C	23	6	66.7	9	17	AA114183	Cytokine activated
C	24	6	66.7	9	17	AA114183	Cytokine activated
C	25	6	66.7	9	19	AA114182	Regulatory element
C	26	6	66.7	9	19	AA114182	Regulatory element
C	27	6	66.7	9	19	AA114182	Regulatory element
C	28	6	66.7	9	19	AA114182	Regulatory element
C	29	6	66.7	9	19	AA114182	Regulatory element
C	30	6	66.7	9	19	AA114182	Regulatory element
C	31	6	66.7	9	19	AA114182	Regulatory element
C	32	6	66.7	9	19	AA114182	Regulatory element
C	33	6	66.7	9	19	AA114182	Regulatory element
C	34	6	66.7	9	19	AA114182	Regulatory element
C	35	6	66.7	9	19	AA114182	Regulatory element
C	36	6	66.7	9	19	AA114182	Regulatory element
C	37	6	66.7	9	19	AA114182	Regulatory element
C	38	6	66.7	9	19	AA114182	Regulatory element
C	39	6	66.7	9	19	AA114182	Regulatory element
C	40	6	66.7	9	19	AA114182	Regulatory element
C	41	6	66.7	9	19	AA114182	Regulatory element
C	42	6	66.7	9	19	AA114182	Regulatory element
C	43	6	66.7	9	21	AA114182	Regulatory element
C	44	6	66.7	9	21	AA114182	Regulatory element
C	45	6	66.7	9	21	AA114182	Regulatory element

ALIGNMENTS

RESULT 1
AA114120
AA114120 standard; DNA: 9 BP.

AC AA114120;
30-MAY-1996 (first entry)

DE Cytokine responsive DNA spacer regulatory element.

DE Regulatory element; transcriptional regulatory protein;
KW signalling molecule; DNA spacer; agonist; antagonist; anaemia;
KW gene transcription; inflammation; cytopenia; cancer; ss.

DS Synthetic.
NN NO9528482-A2.
XX 26-OCT-1995.
XX 16-APR-1995; 95NO-0504477.
XX 27-MAR-1995; 95US-0410780.
XX 14-APR-1994; 94US-0228935.
PA (LIGA-) LIGAND PHARM INC.
PI Lamb IP, Seidel HW;
XX WPI: 1995-373797/48.
DR DNA spacer regulatory elements responsive to cytokine(s) - for

PT detecting the presence of transcriptional regulatory protein in a sample

PS Disclosure: Page 18; 135pp; English.

CC The present oligonucleotide comprises a regulatory element
CC TT(Nx)A, where x is 4-7, and the regulatory element binds an
CC activated transcriptional regulatory protein in response to a
CC signalling mol., i.e. a cytokine. This cytokine responsive DNA
CC spacer regulatory element can be used to detect the presence of
CC a transcriptional regulatory protein in a sample, and in assays
CC for (ant)agonists of gene transcription. The identified cpds.
CC may be used to treat cytokine-induced disease states, or to
CC ameliorate disease states caused by cytokine deficiency, e.g.
CC inflammation, anaemia, cytopenia and (pre)cancerous conditions.

SO Sequence 9 BP; 2 A; 1 C; 1 G; 2 T; 3 other;

Query Match 66.7%; Score 6; DB 16; Length 9;

Best Local Similarity 100.0%; Pred. No. 2.4e+08;

Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 TTCNNNGAA 9

DB 1 TTCNNNGAA 9

RESULT 2

ID AAT14120/c

AC AAT14120;

DT 30-MAY-1996 (first entry)

DE Cytokine responsive DNA spacer regulatory element.

KW Regulatory element; transcriptional regulatory protein;

KW signalling molecule; DNA spacer; agonist; antagonist; anaemia;

KW gene transcription; inflammation; cytopenia; cancer; ss.

OS Synthetic.

PN WO9528482-A2.

PD 26-OCT-1995.

PE 10-APR-1995; 95WO-US04477.

PR 27-MAR-1995; 95US-0410780.

PR 14-APR-1994; 94US-0228935.

PA (LIGA-) LIGAND PHARM INC.

PI Lamb IP, Seidel HM;

PT DNA spacer regulatory elements responsive to cytokine(s) - for

PT detecting the presence of transcriptional regulatory protein in a

PT sample

PS Disclosure: Page 18; 135pp; English.

CC The present oligonucleotide comprises a regulatory element
CC TT(Nx)A, where x is 4-7, and the regulatory element binds an
CC activated transcriptional regulatory protein in response to a
CC signalling mol., i.e. a cytokine. This cytokine responsive DNA
CC spacer regulatory element can be used to detect the presence of
CC a transcriptional regulatory protein in a sample, and in assays
CC for (ant)agonists of gene transcription. The identified cpds.
CC may be used to treat cytokine-induced disease states, or to
CC ameliorate disease states caused by cytokine deficiency, e.g.

CC inflammation, anaemia, cytopenia and (pre)cancerous conditions.

SO Sequence 9 BP; 2 A; 1 C; 1 G; 2 T; 3 other;

Query Match 66.7%; Score 6; DB 16; Length 9;

Best Local Similarity 100.0%; Pred. No. 2.4e+08;

Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 TTCNNNGAA 9

DB 9 TTCNNNGAA 1

RESULT 3

ID AAT14165

AC AAT14165;

DT 29-MAY-1996 (first entry)

DE Cytokine responsive DNA spacer regulatory element.

KW Regulatory element; transcriptional regulatory protein;

KW signalling molecule; DNA spacer; agonist; antagonist; anaemia;

KW gene transcription; inflammation; cytopenia; cancer; ss.

OS Synthetic.

PN WO9528482-A2.

PD 26-OCT-1995.

PE 10-APR-1995; 95WO-US04477.

PR 27-MAR-1995; 95US-0410780.

PR 14-APR-1994; 94US-0228935.

PA (LIGA-) LIGAND PHARM INC.

PI Lamb IP, Seidel HM;

PT DNA spacer regulatory elements responsive to cytokine(s) - for

PT detecting the presence of transcriptional regulatory protein in a

PT sample

PS Claim 7; Page 125; 135pp; English.

CC The present oligonucleotide comprises a regulatory element

CC TT(Nx)A, where x is 4-7, and the regulatory element binds an

CC activated transcriptional regulatory protein in response to a

CC signalling mol., i.e. a cytokine. This cytokine responsive DNA

CC spacer regulatory element can be used to detect the presence of

CC a transcriptional regulatory protein in a sample, and in assays

CC for (ant)agonists of gene transcription. The identified cpds.

CC may be used to treat cytokine-induced disease states, or to

CC ameliorate disease states caused by cytokine deficiency, e.g.

CC inflammation, anaemia, cytopenia and (pre)cancerous conditions.

SO Sequence 9 BP; 4 A; 1 C; 1 G; 3 T; 0 other;

Query Match 66.7%; Score 6; DB 16; Length 9;

Best Local Similarity 66.7%; Pred. No. 2.4e+08;

Matches 6; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 1 TTCNNNGAA 9

DB 1 TTCNNNGAA 9

RESULT 4

AA114165/C
ID AA114165 standard; DNA; 9 BP.
XX
AC AA114165;
XX
DE 29-MAY-1996 (first entry)
XX
DE Cytokine responsive DNA spacer regulatory element.
XX
KW Regulatory element; transcriptional regulatory protein;
KW signalling molecule; DNA spacer; agonist; antagonist; anaemia;
KW gene transcription; inflammation; cytopenia; cancer; ss.
XX
OS Synthetic.
XX
PN WO9528482-A2.
XX
PD 26-OCT-1995.
XX
PF 10-APR-1995; 95WO-US04477.
XX
PR 27-MAR-1995; 95US-0410780.
PR 14-APR-1994; 94US-0228935.
XX
PA (LIGA-) LIGAND PHARM INC.
XX
PI Lamb IP, Seidel HM;
XX
DR WPI; 1995-373797/48.
XX
PT DNA spacer regulatory elements responsive to cytokine(s) - for
PT detecting the presence of transcriptional regulatory protein in a
PT sample
XX
PS Claim 7; Page 125; 135pp; English.
XX
CC The present oligonucleotide comprises a regulatory element
CC TT(X)AA, where x is 4-7, and the regulatory element binds an
CC activated transcriptional regulatory protein in response to a
CC signalling mol., i.e. a cytokine. This cytokine responsive DNA
CC spacer regulatory element can be used to detect the presence of
CC a transcriptional regulatory protein in a sample, and in assays
CC for (ant)agonists of gene transcription. The identified cpds.
CC may be used to treat cytokine-induced disease states, or to
CC ameliorate disease states caused by cytokine deficiency, e.g.
CC inflammation, anaemia, cytopenia and (pre)cancerous conditions.
XX
SQ Sequence 9 BP; 4 A; 1 G; 3 T; 0 other;
XX
Query Match 66.7%; Score 6; DB 16; Length 9;
Best Local Similarity 66.7%; Pred. No. 2.4e+08;
Matches 6; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
XX
QY 1 TTCNNNGAA 9
 ||| |||
DB 9 TTCCTAGAA 1

XX
PN WO9528482-A2.
XX
PD 26-OCT-1995.
XX
PF 10-APR-1995; 95WO-US04477.
XX
PR 27-MAR-1995; 95US-0410780.
PR 14-APR-1994; 94US-0228935.
XX
PA (LIGA-) LIGAND PHARM INC.
XX
PI Lamb IP, Seidel HM;
XX
DR WPI; 1995-373797/48.
XX
PT DNA spacer regulatory elements responsive to cytokine(s) - for
PT detecting the presence of transcriptional regulatory protein in a
PT sample
XX
PS Claim 7; Page 125; 135pp; English.
XX
CC The present oligonucleotide comprises a regulatory element
CC TT(X)AA, where x is 4-7, and the regulatory element binds an
CC activated transcriptional regulatory protein in response to a
CC signalling mol., i.e. a cytokine. This cytokine responsive DNA
CC spacer regulatory element can be used to detect the presence of
CC a transcriptional regulatory protein in a sample, and in assays
CC for (ant)agonists of gene transcription. The identified cpds.
CC may be used to treat cytokine-induced disease states, or to
CC ameliorate disease states caused by cytokine deficiency, e.g.
CC inflammation, anaemia, cytopenia and (pre)cancerous conditions.
XX
SQ Sequence 9 BP; 3 A; 2 G; 1 T; 0 other;
XX
Query Match 66.7%; Score 6; DB 16; Length 9;
Best Local Similarity 66.7%; Pred. No. 2.4e+08;
Matches 6; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
XX
QY 1 TTCNNNGAA 9
 ||| |||
DB 1 TTCCTAGAA 9

RESULT 6
AA114149/C
ID AA114149 standard; DNA; 9 BP.
XX
AC AA114149;
XX
DE 29-MAY-1996 (first entry)
XX
DE Cytokine responsive DNA spacer regulatory element.
XX
KW Regulatory element; transcriptional regulatory protein;
KW signalling molecule; DNA spacer; agonist; antagonist; anaemia;
KW gene transcription; inflammation; cytopenia; cancer; ss.
XX
OS Synthetic.
XX
PN WO9528482-A2.
XX
PD 26-OCT-1995.
XX
PF 10-APR-1995; 95WO-US04477.
XX
PR 27-MAR-1995; 95US-0410780.
PR 14-APR-1994; 94US-0228935.
XX
PA (LIGA-) LIGAND PHARM INC.
XX
PI Lamb IP, Seidel HM;
XX

DR WPI: 1995-373797/48.
 XX DNA spacer regulatory elements responsive to cytokine(s) - for
 PT detecting the presence of transcriptional regulatory protein in a
 PT sample
 PS Claim 7; Page 125; 135pp; English.
 XX
 CC The present oligonucleotide comprises a regulatory element
 CC TT(Nx)AA, where x is 4-7, and the regulatory element binds an
 CC activated transcriptional regulatory protein in response to a
 CC signalling mol., i.e. a cytokine. This cytokine responsive DNA
 CC spacer regulatory element can be used to detect the presence of
 CC a transcriptional regulatory protein in a sample, and in assays
 CC for (ant)agonists of gene transcription. The identified cpds.
 CC may be used to treat cytokine-induced disease states, or to
 CC ameliorate disease states caused by cytokine deficiency, e.g.
 CC inflammation, anaemia, cytopenia and (pre)cancerous conditions.
 CC
 SQ Sequence 9 BP; 3 A; 2 C; 1 G; 3 T; 0 other;
 XX
 Query Match 66.7%; Score 6; DB 16; Length 9;
 Best Local Similarity 66.7%; Pred. No. 2.4e+08;
 Matches 6; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 OY 1 TTCNNNGAA 9
 DB 9 TTCGTGAGAA 1
 XX
 RESULT 7
 ID AAT14145 standard- DNA; 9 BP.
 XX
 AC AAT14145;
 XX
 DT 28-MAY-1996 (first entry)
 XX
 DE Cytokine responsive DNA spacer regulatory element.
 XX
 KW Regulatory element; transcriptional regulatory protein;
 KW signalling molecule; DNA spacer; agonist; antagonist; anaemia;
 KW gene transcription; inflammation; cytopenia; cancer; ss.
 XX
 OS Synthetic.
 XX
 PN WO9528482-A2.
 XX
 PD 26-OCT-1995.
 XX
 PF 10-APR-1995; 95WO-US04477.
 XX
 PR 27-MAR-1995; 95US-0410780.
 PR 14-APR-1994; 94US-0228935.
 XX
 PA (LIGA-) LIGAND PHARM INC.
 XX
 PI Lamb IP, Seidel HM;
 XX
 DR WPI: 1995-373797/48.
 XX
 PT DNA spacer regulatory elements responsive to cytokine(s) - for
 PT detecting the presence of transcriptional regulatory protein in a
 PT sample
 PS Claim 7; Page 125; 135pp; English.
 XX
 CC The present oligonucleotide comprises a regulatory element
 CC TT(Nx)AA, where x is 4-7, and the regulatory element binds an
 CC activated transcriptional regulatory protein in response to a
 CC signalling mol., i.e. a cytokine. This cytokine responsive DNA
 CC spacer regulatory element can be used to detect the presence of
 CC a transcriptional regulatory protein in a sample, and in assays

CC for (ant)agonists of gene transcription. The identified cpds.
 CC may be used to treat cytokine-induced disease states, or to
 CC ameliorate disease states caused by cytokine deficiency, e.g.
 CC inflammation, anaemia, cytopenia and (pre)cancerous conditions.
 CC
 SQ Sequence 9 BP; 3 A; 3 C; 1 G; 2 T; 0 other;
 XX
 Query Match 66.7%; Score 6; DB 16; Length 9;
 Best Local Similarity 66.7%; Pred. No. 2.4e+08;
 Matches 6; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 OY 1 TTCNNNGAA 9
 DB 1 TTCGCCAGAA 9
 XX
 RESULT 8
 ID AAT14145/C
 XX
 AC AAT14145;
 XX
 DT 29-MAY-1996 (first entry)
 XX
 DE Cytokine responsive DNA spacer regulatory element.
 XX
 KW Regulatory element; transcriptional regulatory protein;
 KW signalling molecule; DNA spacer; agonist; antagonist; anaemia;
 KW gene transcription; inflammation; cytopenia; cancer; ss.
 XX
 OS Synthetic.
 XX
 PN WO9528482-A2.
 XX
 PD 26-OCT-1995.
 XX
 PF 10-APR-1995; 95WO-US04477.
 XX
 PR 27-MAR-1995; 95US-0410780.
 PR 14-APR-1994; 94US-0228935.
 XX
 PA (LIGA-) LIGAND PHARM INC.
 XX
 PI Lamb IP, Seidel HM;
 XX
 DR WPI: 1995-373797/48.
 XX
 PT DNA spacer regulatory elements responsive to cytokine(s) - for
 PT detecting the presence of transcriptional regulatory protein in a
 PT sample
 PS Claim 7; Page 125; 135pp; English.
 XX
 CC The present oligonucleotide comprises a regulatory element
 CC TT(Nx)AA, where x is 4-7, and the regulatory element binds an
 CC activated transcriptional regulatory protein in response to a
 CC signalling mol., i.e. a cytokine. This cytokine responsive DNA
 CC spacer regulatory element can be used to detect the presence of
 CC a transcriptional regulatory protein in a sample, and in assays
 CC for (ant)agonists of gene transcription. The identified cpds.
 CC may be used to treat cytokine-induced disease states, or to
 CC ameliorate disease states caused by cytokine deficiency, e.g.
 CC inflammation, anaemia, cytopenia and (pre)cancerous conditions.
 CC
 SQ Sequence 9 BP; 3 A; 3 C; 1 G; 2 T; 0 other;
 XX
 Query Match 66.7%; Score 6; DB 16; Length 9;
 Best Local Similarity 66.7%; Pred. No. 2.4e+08;
 Matches 6; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 OY 1 TTCNNNGAA 9
 DB 9 TTCGTGAGAA 1

RESULT 9
ID AAT14147 standard; DNA: 9 BP.
XX AAT14147;
AC AAT14147;
DT 29-MAY-1996 (first entry)
DE Cytokine responsive DNA spacer regulatory element.
XX
XX Regulatory element: transcriptional regulatory protein:
KW signalling molecule; DNA spacer; agonist; antagonist; anaemia;
KM gene transcription; inflammation; cytopenia; cancer; ss.
XX
XX Synthetic.
OS
PN MO9528482-A2.
XX
XX 26-OCT-1995.
PD
XX
PE 10-APR-1995; 95MO-US04477.
XX
PR 27-MAR-1995; 95US-0410780.
PP 14-APR-1994; 94US-0228935.
XX
XX (LIGA-) LIGAND PHARM INC.
PM
PI Lamb IP, Seidel HM;
XX
XX PRI: 1995-373792/48.
DR
XX
PT DNA spacer regulatory elements responsive to cytokine(s) - for
PT detecting the presence of transcriptional regulatory protein in a
PT sample
XX
XX
PS Claim 7; Page 125; 135pp; English.

XX
XX The present oligonucleotide comprises a regulatory element
CC TT(XN)A_x, where x is 4-7, and the regulatory element binds an
CC activated transcriptional regulatory protein in response to a
CC signalling mol., i.e. a cytokine. This cytokine responsive DNA
CC spacer regulatory element can be used to detect the presence of
CC a transcriptional regulatory protein in a sample, and in assays
CC for (antagonists of gene transcription. The identified cpds.
CC may be used to treat cytokine-induced disease states, or to
CC ameliorate disease states caused by cytokine deficiency, e.g.
CC inflammation, anaemia, cytopenia and (pre)cancerous conditions.
CC
CC
SQ Sequence 9 BP; 2 A; 1 G; 1 G; 5 T; 0 other;

Query Match 66.7%; Score 6; DB 16; Length 9;
Best local Similarity 66.7%; Pred. No. 2.4e+08;
Matches 6; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1 TTCNNNGAA 9
||| |||
Db 1 TTCCTTGAA 9

RESULT 10
AAT14147/C
ID AAT14147 standard; DNA: 9 BP.
AC AAT14147;
XX
XX 29-MAY-1996 (first entry)
DE Cytokine responsive DNA spacer regulatory element.
XX
XX
XX Regulatory element: transcriptional regulatory protein;
KW signalling molecule; DNA spacer; agonist; antagonist; anaemia;
KM
XX

XX	gene transcription; inflammation; cytopenia; cancer; ss.
XX	Synthetic.
XX	MO9528482-A2.
XX	26-OCT-1995.
XX	10-APR-1995; 95MO-US04477.
XX	27-MAR-1995; 95US-0410780.
XX	14-APR-1994; 94US-0228935.
XX	(LIGA-) LIGAND PHARM INC.
XX	Lamb IP, Seidel HM;
XX	WPI; 1995-373797/48.
XX	DNA spacer regulatory elements responsive to cytokine(s) - for
XX	detecting the presence of transcriptional regulatory protein in a
XX	sample
XX	Claim 7; Page 125; 135pp; English.
XX	The present oligonucleotide comprises a regulatory element
XX	TT(MX)AA, where x is 4-7, and the regulatory element binds an
XX	activated transcriptional regulatory protein in response to a
XX	signalling mol., i.e. a cytokine. This cytokine responsive DNA
XX	spacer regulatory element can be used to detect the presence of
XX	a transcriptional regulatory protein in a sample, and in assays
XX	for (ant)agonists of gene transcription. The identified cpds.
XX	may be used to treat cytokine-induced disease states, or to
XX	ameliorate disease states caused by cytokine deficiency, e.g.
XX	inflammation, anaemia, cytopenia and (pre)cancerous conditions.
XX	
XX	Sequence 9 BP; 2 A; 1 C; 1 G; 5 T; 0 other;
XX	
XX	Query Match 66.7%; Score 6; DB 16; Length 9;
XX	Best Local Similarity 66.7%; Pred. No. 2.4e+08;
XX	Matches 6; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
XX	1 TTCNNNGAA 9
XX	
XX	9 TTCAAAGAA 1
XX	
XX	RESULT 11
XX	AAT14140
XX	ID AAT14140 standard; DNA: 9 BP.
XX	AAT14140;
XX	29-MAY-1996 (first entry)
XX	Cytokine responsive DNA spacer regulatory element.
XX	Regulatory element; transcriptional regulatory protein;
XX	signalling molecule; DNA spacer; agonist; antagonist; anaemia;
XX	gene transcription; inflammation; cytopenia; cancer; ss.
XX	Synthetic.
XX	MO9528482-A2.
XX	26-OCT-1995.
XX	10-APR-1995; 95MO-US04477.
XX	27-MAR-1995; 95US-0410780.
XX	14-APR-1994; 94US-0228935.
XX	(LIGA-) LIGAND PHARM INC.
XX	Lamb IP, Seidel HM;
XX	WPI; 1995-373797/48.
XX	DNA spacer regulatory elements responsive to cytokine(s) - for
XX	detecting the presence of transcriptional regulatory protein in a
XX	sample
XX	Claim 7; Page 125; 135pp; English.
XX	The present oligonucleotide comprises a regulatory element
XX	TT(MX)AA, where x is 4-7, and the regulatory element binds an
XX	activated transcriptional regulatory protein in response to a
XX	signalling mol., i.e. a cytokine. This cytokine responsive DNA
XX	spacer regulatory element can be used to detect the presence of
XX	a transcriptional regulatory protein in a sample, and in assays
XX	for (ant)agonists of gene transcription. The identified cpds.
XX	may be used to treat cytokine-induced disease states, or to
XX	ameliorate disease states caused by cytokine deficiency, e.g.
XX	inflammation, anaemia, cytopenia and (pre)cancerous conditions.
XX	
XX	Sequence 9 BP; 2 A; 1 C; 1 G; 5 T; 0 other;
XX	
XX	Query Match 66.7%; Score 6; DB 16; Length 9;
XX	Best Local Similarity 66.7%; Pred. No. 2.4e+08;
XX	Matches 6; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
XX	1 TTCNNNGAA 9
XX	
XX	9 TTCAAAGAA 1
XX	
XX	RESULT 11
XX	AAT14140
XX	ID AAT14140 standard; DNA: 9 BP.
XX	AAT14140;
XX	29-MAY-1996 (first entry)
XX	Cytokine responsive DNA spacer regulatory element.
XX	Regulatory element; transcriptional regulatory protein;
XX	signalling molecule; DNA spacer; agonist; antagonist; anaemia;
XX	gene transcription; inflammation; cytopenia; cancer; ss.
XX	Synthetic.
XX	MO9528482-A2.
XX	26-OCT-1995.
XX	10-APR-1995; 95MO-US04477.
XX	27-MAR-1995; 95US-0410780.
XX	14-APR-1994; 94US-0228935.
XX	(LIGA-) LIGAND PHARM INC.
XX	Lamb IP, Seidel HM;
XX	WPI; 1995-373797/48.
XX	DNA spacer regulatory elements responsive to cytokine(s) - for
XX	detecting the presence of transcriptional regulatory protein in a
XX	sample
XX	Claim 7; Page 125; 135pp; English.
XX	The present oligonucleotide comprises a regulatory element
XX	TT(MX)AA, where x is 4-7, and the regulatory element binds an
XX	activated transcriptional regulatory protein in response to a
XX	signalling mol., i.e. a cytokine. This cytokine responsive DNA
XX	spacer regulatory element can be used to detect the presence of
XX	a transcriptional regulatory protein in a sample, and in assays
XX	for (ant)agonists of gene transcription. The identified cpds.
XX	may be used to treat cytokine-induced disease states, or to
XX	ameliorate disease states caused by cytokine deficiency, e.g.
XX	inflammation, anaemia, cytopenia and (pre)cancerous conditions.
XX	
XX	Sequence 9 BP; 2 A; 1 C; 1 G; 5 T; 0 other;
XX	
XX	Query Match 66.7%; Score 6; DB 16; Length 9;
XX	Best Local Similarity 66.7%; Pred. No. 2.4e+08;
XX	Matches 6; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
XX	1 TTCNNNGAA 9
XX	
XX	9 TTCAAAGAA 1
XX	
XX	RESULT 11
XX	AAT14140
XX	ID AAT14140 standard; DNA: 9 BP.
XX	AAT14140;
XX	29-MAY-1996 (first entry)
XX	Cytokine responsive DNA spacer regulatory element.
XX	Regulatory element; transcriptional regulatory protein;
XX	signalling molecule; DNA spacer; agonist; antagonist; anaemia;
XX	gene transcription; inflammation; cytopenia; cancer; ss.
XX	Synthetic.
XX	MO9528482-A2.
XX	26-OCT-1995.
XX	10-APR-1995; 95MO-US04477.
XX	27-MAR-1995; 95US-0410780.
XX	14-APR-1994; 94US-0228935.
XX	(LIGA-) LIGAND PHARM INC.
XX	Lamb IP, Seidel HM;
XX	WPI; 1995-373797/48.
XX	DNA spacer regulatory elements responsive to cytokine(s) - for
XX	detecting the presence of transcriptional regulatory protein in a
XX	sample
XX	Claim 7; Page 125; 135pp; English.
XX	The present oligonucleotide comprises a regulatory element
XX	TT(MX)AA, where x is 4-7, and the regulatory element binds an
XX	activated transcriptional regulatory protein in response to a

[illegible]

CC	signalling mol., i.e. a cytokine. This cytokine responsive DNA spacer regulatory element can be used to detect the presence of a transcriptional regulatory protein in a sample, and in assays for (ant)agonists of gene transcription. The identified opds. CC may be used to treat cytokine-induced disease states, or to ameliorate disease states caused by cytokine deficiency, e.g. inflammation, anaemia, cytopenia and (pre)cancerous conditions.	XX
CC	Sequence 9 BP; 2 A; 3 C; 2 G; 2 T; 0 other;	XX
QY	1 TTCNNNGAA 9 	QY
DB	9 TTCGGGGA 1	DB
RESULT 13		
ID	AAAT4142 standard; DNA; 9 BP.	AC
AC	AAAT4142;	AC
PT	29-MAY-1996 (first entry)	PT
DE	Cytokine responsive DNA spacer regulatory element.	DE
XX	Regulatory element; transcriptional regulatory protein;	XX
XX	signalling molecule; DNA spacer; agonist; antagonist; anaemia;	XX
KW	gene transcription; inflammation; cytopenia; cancer; ss.	KW
XX	Synthetic.	OS
XX	WO9528482-A2.	XX
XX	26-OCT-1995.	XX
XX	10-APR-1995; 95WO-US04477.	XX
XX	27-MAR-1995; 95US-0410780.	XX
PR	14-APR-1994; 94US-0228935.	PR
XX	(LIGA-) LIGAND PHARM INC.	XX
FA	Lamb IP, Seidel BM;	FA
PI	WPI; 1995-373797/48.	PI
DR	DNA spacer regulatory elements responsive to cytokine(s) - for detecting the presence of transcriptional regulatory protein in a sample	DR
PT	claim 7, Page 125; 135pp; English.	PT
PS	The present oligonucleotide comprises a regulatory element TT(Kx)AA, where x is 4-7, and the regulatory element binds an activated transcriptional regulatory protein in response to a signalling mol., i.e. a cytokine. This cytokine responsive DNA spacer regulatory element can be used to detect the presence of a transcriptional regulatory protein in a sample, and in assays for (ant)agonists of gene transcription. The identified opds. CC may be used to treat cytokine-induced disease states, or to ameliorate disease states caused by cytokine deficiency, e.g. inflammation, anaemia, cytopenia and (pre)cancerous conditions.	PS
XX	Sequence 9 BP; 2 A; 2 C; 2 G; 3 T; 0 other;	XX
QY	66.7%; Score 6; DB 16; Length 9;	QY
DB	Best Local Similarity 66.7%; Pred. No. 2.4e+08;	DB
Matches	6; Conservative 0; Mismatches 3; Indels 0; Caps 0;	Matches

OY 1 TTCNNNGAA 9
 ||| |||
 DB 1 TTCCTCGAA 9

RESULT 14

AA14142/c
 ID AA14142 standard; DNA; 9 BP;

AA14142;

DT 29-MAY-1996 (first entry)

DE cytokine responsive DNA spacer regulatory element.

KW Regulatory element; transcriptional regulatory protein;

KW signalling molecule; DNA spacer; agonist; antagonist; anaemia;

XX gene transcription; inflammation; cytopenia; cancer; ss.

OS Synthetic.

PN WO9528482-A2.

PD 26-OCT-1995.

PF 10-APR-1995; 95WO-US04477.

PR 27-MAR-1995; 95US-0410780.

PR 14-APR-1994; 94US-0228935.

PA (LIGA-) LIGAND PHARM INC.

PI Lamb IP, Seidel HM;

DR WPI; 1995-373797/48.

PS Claim 7; Page 125; 135pp; English.

XX The present oligonucleotide comprises a regulatory element
 CC TR(Nx)AA, where x is 4-7, and the regulatory element binds an
 CC activated transcriptional regulatory protein in response to a
 CC signalling mol., i.e. a cytokine. This cytokine responsive DNA
 CC spacer regulatory element can be used to detect the presence of
 CC a transcriptional regulatory protein in a sample, and in assays
 CC for (ant)agonists of gene transcription. The identified cpds.
 CC may be used to treat cytokine-induced disease states, or to
 CC ameliorate disease states caused by cytokine deficiency, e.g.
 CC inflammation, anaemia, cytopenia and (pre)cancerous conditions.

SQ Sequence 9 BP; 2 A; 2 C; 2 G; 3 T; 0 other:

Query Match 66.7%; Score 6; DB 16; Length 9;

Best Local Similarity 66.7%; Pred. No. 2.4e+08;

Matches 6; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 1 TTCNNNGAA 9
 ||| |||
 DB 9 TTCACGAA 1

RESULT 15

AA14137
 ID AA14137 standard; DNA; 9 BP.

AA14137;

DT 29-MAY-1996 (first entry)

DE Cytokine responsive DNA spacer regulatory element.

XX Regulatory element; transcriptional regulatory protein;
 KW signalling molecule; DNA spacer; agonist; antagonist; anaemia;
 KW gene transcription; inflammation; cytopenia; cancer; ss.

OS Synthetic.

PN WO9528482-A2.

PD 26-OCT-1995.

PF 10-APR-1995; 95WO-US04477.

PR 27-MAR-1995; 95US-0410780.

PR 14-APR-1994; 94US-0228935.

PA (LIGA-) LIGAND PHARM INC.

PI Lamb IP, Seidel HM;

DR WPI; 1995-373797/48.

PS Claim 7; Page 124; 135pp; English.

XX The present oligonucleotide comprises a regulatory element
 CC TR(Nx)AA, where x is 4-7, and the regulatory element binds an
 CC activated transcriptional regulatory protein in response to a
 CC signalling mol., i.e. a cytokine. This cytokine responsive DNA
 CC spacer regulatory element can be used to detect the presence of
 CC a transcriptional regulatory protein in a sample, and in assays
 CC for (ant)agonists of gene transcription. The identified cpds.
 CC may be used to treat cytokine-induced disease states, or to
 CC ameliorate disease states caused by cytokine deficiency, e.g.
 CC inflammation, anaemia, cytopenia and (pre)cancerous conditions.

SQ Sequence 9 BP; 2 A; 4 C; 1 G; 2 T; 0 other:

Query Match 66.7%; Score 6; DB 16; Length 9;

Best Local Similarity 66.7%; Pred. No. 2.4e+08;

Matches 6; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 1 TTCNNNGAA 9
 ||| |||
 DB 1 TTCACGAA 9

Search completed: December 25, 2002, 18:15:59
 Job time : 263 secs

Db 67 AGATTTC TAGGAATTCA 84

```
RESULT 2
US-09-923-246-60/c
; Sequence 60, Application US/09923246
; Patent No. US20020128446A1
; GENERAL INFORMATION:
; APPLICANT: No. US20020128446A1ak, Julia E.
; APPLICANT: Presnell, Scott R.
; APPLICANT: Sprecher, Cindy A.
; APPLICANT: Foster, Donald C.
; APPLICANT: Holly, Richard D.
; APPLICANT: Gross, Jane A.
; APPLICANT: Johnston, Janet V.
; APPLICANT: Nelson, Andrew J.
; APPLICANT: Dillon, Stacey R.
; APPLICANT: Hammond, Angela K.
; TITLE OF INVENTION: NOVEL CYTOKINE ZALPHA11 LIGAND
; FILE REFERENCE: 99-16
; CURRENT APPLICATION NUMBER: US/09/923,246
; PRIOR FILING DATE: 2001-08-03
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US/09/522,217
; PRIOR FILING DATE: EARLIER FILING DATE: 2000-03-09
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/123,904
; PRIOR FILING DATE: EARLIER FILING DATE: 1999-03-11
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/142,013
; PRIOR FILING DATE: EARLIER FILING DATE: 1999-07-01
; NUMBER OF SEQ ID NOS: 115
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 60
; LENGTH: 100
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Oligonucleotide ZC12748
US-09-923-246-60

Query Match      85.7%; Score 18; DB 10; Length 100;
Best Local Similarity 100.0%; Pred. No. 15;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 AGATTCTAGCAATTCAA 18
Db      38 AGATTCTAGCAATTCAA 21

RESULT 3
US-09-825-561A-48
; Sequence 48, Application US/09825561A
; Patent No. US20020137677A1
; GENERAL INFORMATION:
; APPLICANT: Sprecher, Cindy A.
; APPLICANT: No. US20020137677A1ak, Julia E.
; APPLICANT: West, James W.
; APPLICANT: Presnell, Scott R.
; APPLICANT: Holly, Richard D.
; APPLICANT: Nelson, Andrew J.
; TITLE OF INVENTION: SOLUBLE ZALPHA11 CYTOKINE RECEPTORS
; FILE REFERENCE: 00-22
; CURRENT APPLICATION NUMBER: US/09/825,561A
; CURRENT FILING DATE: 2000-04-05
; PRIOR APPLICATION NUMBER: US 60/194,731
; PRIOR FILING DATE: 2000-04-05
; PRIOR APPLICATION NUMBER: US 60/222,121
; PRIOR FILING DATE: 2000-07-28
; NUMBER OF SEQ ID NOS: 86
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 48
; LENGTH: 100
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Oligonucleotide primer ZC12749

US-09-825-561A-48
Query Match      85.7%; Score 18; DB 10; Length 100;
Best Local Similarity 100.0%; Pred. No. 15;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 AGATTCTAGCAATTCAA 18
Db      38 AGATTCTAGCAATTCAA 21

RESULT 4
US-09-825-561A-49/c
; Sequence 49, Application US/09825561A
; Patent No. US20020137677A1
; GENERAL INFORMATION:
; APPLICANT: Sprecher, Cindy A.
; APPLICANT: No. US20020137677A1ak, Julia E.
; APPLICANT: West, James W.
; APPLICANT: Presnell, Scott R.
; APPLICANT: Holly, Richard D.
; APPLICANT: Nelson, Andrew J.
; TITLE OF INVENTION: SOLUBLE ZALPHA11 CYTOKINE RECEPTORS
; FILE REFERENCE: 00-22
; CURRENT APPLICATION NUMBER: US/09/825,561A
; CURRENT FILING DATE: 2000-04-05
; PRIOR APPLICATION NUMBER: US 60/194,731
; PRIOR FILING DATE: 2000-04-05
; PRIOR APPLICATION NUMBER: US 60/222,121
; PRIOR FILING DATE: 2000-07-28
; NUMBER OF SEQ ID NOS: 86
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 49
; LENGTH: 100
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Oligonucleotide primer ZC12748
US-09-825-561A-49

Query Match      85.7%; Score 18; DB 10; Length 100;
Best Local Similarity 100.0%; Pred. No. 15;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 AGATTCTAGCAATTCAA 18
Db      38 AGATTCTAGCAATTCAA 21

RESULT 5
US-09-932-679-42
; Sequence 42, Application US/09932679
; Patent No. US20020058801A1
; GENERAL INFORMATION:
; APPLICANT: Lok, Si
; APPLICANT: Konklin, Darrell C.
; APPLICANT: No. US20020058801A1ak, Julia E.
; TITLE OF INVENTION: Mammalian Alpha Helical Protein-1
; FILE REFERENCE: 97-71D1
; CURRENT APPLICATION NUMBER: US/09/932,679
; CURRENT FILING DATE: 2001-08-15
; PRIOR APPLICATION NUMBER: 09/209,525
; PRIOR FILING DATE: 1998-12-10
; PRIOR APPLICATION NUMBER: 60/067,779
; PRIOR FILING DATE: 1997-12-10
; NUMBER OF SEQ ID NOS: 56
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 42
; LENGTH: 58
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: Oligonucleotide primer ZC12749
US-09-932-679-42
```

Query Match 69.5%; Score 14.6; DB 10; Length 58;
Best Local Similarity 81.0%; Pred. No. 5.1e+02;
Matches 17; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
QY 1 AGATTCTAGCAATTCGAATC 21
||| | ||||| |||
Db 14 AGAATCTAGCAATTCCTACTC 34

RESULT 6
US-09-969-373-1158/C
; Sequence 1158, Application US/09969373
; Patent No. US20020133852A1
; GENERAL INFORMATION:
; APPLICANT: Effertz, Roger J.
; APPLICANT: Haugue, Brian M.
; TITLE OF INVENTION: Soybean SSRs and Methods of Genotyping
; FILE REFERENCE: 38-10(52679)A
; CURRENT APPLICATION NUMBER: US/09/969,373
; CURRENT FILING DATE: 2001-10-02
; PRIOR APPLICATION NUMBER: US 09/754,853
; PRIOR FILING DATE: 2001-01-05
; PRIOR APPLICATION NUMBER: US 09/760,427
; PRIOR FILING DATE: 2001-01-13
; PRIOR APPLICATION NUMBER: US 09/855,768
; PRIOR FILING DATE: 2001-05-15
; NUMBER OF SEQ ID NOS: 4593
; SEQ ID NO 1158
; LENGTH: 99
; TYPE: DNA
; ORGANISM: Glycine max
US-09-969-373-1158

Query Match 67.6%; Score 14.2; DB 10; Length 99;
Best Local Similarity 84.2%; Pred. No. 8.1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 3 ATTCTAGCAATTCGAATC 21
||| | ||||| |||||
Db 60 ATTATATGCAATTCGAATC 42

RESULT 7
US-09-881-012-130
; Sequence 130, Application US/09881012
; Publication No. US20020192655A1
; GENERAL INFORMATION:
; APPLICANT: Gims, Edward I.
; APPLICANT: Egeland, Janice A.
; APPLICANT: Paul, Steven M.
; APPLICANT: The Government of the United States of America
; APPLICANT: as represented by the Secretary of the
; APPLICANT: Department of Health and Human Services
; TITLE OF INVENTION: Susceptibility and Resistance Genes for
; TITLE OF INVENTION: Bipolar Affective Disorder
; FILE REFERENCE: 015280-24810US
; CURRENT APPLICATION NUMBER: US/09/881,012
; CURRENT FILING DATE: 2001-06-13
; PRIOR APPLICATION NUMBER: US/09/175,158
; PRIOR FILING DATE: 1998-10-19
; PRIOR APPLICATION NUMBER: US 60/062,924
; PRIOR FILING DATE: 1997-10-20
; NUMBER OF SEQ ID NOS: 240
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 130
; LENGTH: 22
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: D4S1564 reverse primer
US-09-881-012-130

Query Match 61.9%; Score 13; DB 9; Length 22;

Best Local Similarity 100.0%; Pred. No. 2.5e+03;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 AGATTCTAGCAA 13
||| | ||||| |||
Db 2 AGATTCTAGCAA 14

RESULT 8
US-09-927-933A-14/C
; Sequence 14, Application US/09927933A
; Patent No. US20020107869A1
; GENERAL INFORMATION:
; APPLICANT: LEROY, Pierre
; TITLE OF INVENTION: NOVEL IMPLANT AND NOVEL VECTOR FOR THE TREATMENT OF
; FILE REFERENCE: 032751-012
; CURRENT APPLICATION NUMBER: US/09/927,933A
; CURRENT FILING DATE: 2001-08-13
; PRIOR APPLICATION NUMBER: 08/809,110
; PRIOR FILING DATE: EARLIER FILING DATE: 1999-12-06
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: FR 94 10911
; PRIOR FILING DATE: EARLIER FILING DATE: 1994-09-13
; SOFTWARE: patentlin Ver. 2.0
; NUMBER OF SEQ ID NOS: 20
; SEQ ID NO 14
; LENGTH: 30
; TYPE: DNA
; ORGANISM: human CD4 CDNA
US-09-927-933A-14

Query Match 61.9%; Score 13; DB 10; Length 30;
Best Local Similarity 76.2%; Pred. No. 2.6e+03;
Matches 16; Conservative 0; Mismatches 5; Indels 0; Gaps 0;
QY 1 AGATTCTAGCAATTCGAATC 21
||| | ||||| |||||
Db 25 AGCTTCCAGAGCCCAATC 5

RESULT 9
US-09-927-933A-15
; Sequence 15, Application US/09927933A
; Patent No. US20020107869A1
; GENERAL INFORMATION:
; APPLICANT: LEROY, Pierre
; TITLE OF INVENTION: NOVEL IMPLANT AND NOVEL VECTOR FOR THE TREATMENT OF
; FILE REFERENCE: 032751-012
; CURRENT APPLICATION NUMBER: US/09/927,933A
; CURRENT FILING DATE: 2001-08-13
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: 08/809,110
; PRIOR FILING DATE: EARLIER FILING DATE: 1999-12-06
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: FR 94 10911
; PRIOR FILING DATE: EARLIER FILING DATE: 1994-09-13
; NUMBER OF SEQ ID NOS: 20
; SOFTWARE: patentlin Ver. 2.0
; SEQ ID NO 15
; LENGTH: 30
; TYPE: DNA
; ORGANISM: cDNA of heavy chain of antibody 2F5
US-09-927-933A-15

Query Match 61.9%; Score 13; DB 10; Length 30;
Best Local Similarity 76.2%; Pred. No. 2.6e+03;
Matches 16; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

QY 1 AGATTCTAGCAATTCGAATC 21
||| | ||||| |||||
Db 6 AGCTTCCAGAGCCCAATC 26

RESULT 10

US-09-832-659-10/c
; Sequence 10, Application US/09832659
; Patent No. US20020155547A1
; GENERAL INFORMATION:
; APPLICANT: BIOGEN, INC.
; TITLE OF INVENTION: Interferon-Beta Fusion Proteins and Uses
; FILE REFERENCE: A064PCTSEQ
; CURRENT APPLICATION NUMBER: US/09/832,659
; CURRENT FILING DATE: 2001-04-11
; PRIOR FILING DATE: 1999-02-16
; PRIOR APPLICATION NUMBER: 60/120,237
; PRIOR FILING DATE: 1998-10-16
; NUMBER OF SEQ ID NOS: 44
; SOFTWARE: Patentln Ver. 2.0
; SEQ ID NO 10
; LENGTH: 50
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-832-659-10

Query Match 61.9%; Score 13; DB 9; Length 50;
Best Local Similarity 76.2%; Pred. No. 2.7e+03;
Matches 16; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

QY 1 AGATTCTAGGAAATTCAAATC 21
Db 26 AGTTTCTAGGAAATTCAGCTC 6

RESULT 11
US-09-832-659-30/c
; Sequence 30, Application US/09832659
; Patent No. US20020155547A1
; GENERAL INFORMATION:
; APPLICANT: BIOGEN, INC.
; TITLE OF INVENTION: Interferon-Beta Fusion Proteins and Uses
; FILE REFERENCE: A064PCTSEQ
; CURRENT APPLICATION NUMBER: US/09/832,659
; CURRENT FILING DATE: 2001-04-11
; PRIOR FILING DATE: 1999-02-16
; PRIOR APPLICATION NUMBER: 60/120,237
; PRIOR FILING DATE: 1998-10-16
; NUMBER OF SEQ ID NOS: 44
; SOFTWARE: Patentln Ver. 2.0
; SEQ ID NO 30
; LENGTH: 50
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-832-659-30

Query Match 61.9%; Score 13; DB 9; Length 50;
Best Local Similarity 76.2%; Pred. No. 2.7e+03;
Matches 16; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

QY 1 AGATTCTAGGAAATTCAAATC 21
Db 26 AGTTTCTAGGAAATTCAGCTC 6

RESULT 12
US-09-792-420-11
; Sequence 11, Application US/09792420
; Patent No. US20020055138A1
; GENERAL INFORMATION:
; APPLICANT: Chien, Yueh-tyng
; APPLICANT: Mobber, C. Richard
; APPLICANT: Healy, Judith
; TITLE OF INVENTION: STAPHYLOCOCCAL GTPase obg NUCLEOTIDE SEQUENCE ENCODING STAPHYLOCO
; FILE REFERENCE: DN 1711 US

; CURRENT APPLICATION NUMBER: US/09/792,420
; CURRENT FILING DATE: 2001-02-23
; PRIOR APPLICATION NUMBER: US 60/184,742
; PRIOR FILING DATE: 2000-02-24
; NUMBER OF SEQ ID NOS: 11
; SOFTWARE: Patentln version 3.0
; SEQ ID NO 11
; LENGTH: 30
; TYPE: DNA
; ORGANISM: Staphylococcus aureus
US-09-792-420-11

Query Match 61.0%; Score 12.8; DB 10; Length 30;
Best Local Similarity 87.5%; Pred. No. 3.2e+03;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 5 TTCTAGGAAATTCAAAT 20
Db 13 TTCACGAAATTCAAAT 28

RESULT 13
US-09-863-179-2/c
; Sequence 2, Application US/09863179
; Patent No. US20020091094A1
; GENERAL INFORMATION:
; APPLICANT: DURING, MATTHEW
; APPLICANT: KAPLITZ, MICHAEL
; TITLE OF INVENTION: GLUTAMIC ACID DECARBOXYLASE (GAD) BASED DELIVERY SYSTEM
; FILE REFERENCE: 102182-12
; CURRENT APPLICATION NUMBER: US/09/863,179
; CURRENT FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: 60/206,281
; PRIOR FILING DATE: 2000-05-23
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: Patentln version 3.0
; SEQ ID NO 2
; LENGTH: 33
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-863-179-2

Query Match 61.0%; Score 12.8; DB 10; Length 33;
Best Local Similarity 87.5%; Pred. No. 3.2e+03;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 AGATTCTAGGAAATTC 16
Db 22 AGATTATATAGAAATTC 7

RESULT 14
US-09-878-574-3000/c
; Sequence 3000, Application US/09878574
; Patent No. US20020110548A1
; GENERAL INFORMATION:
; APPLICANT: Byrum, Joseph R.
; APPLICANT: La Rosa, Thomas J.
; APPLICANT: Thompson, Michael D.
; TITLE OF INVENTION: Nucleic Acid Molecules and Other Molecules Associated with
; FILE REFERENCE: 38-21(15401)B
; CURRENT APPLICATION NUMBER: US/09/878,574
; CURRENT FILING DATE: 2001-12-21
; PRIOR APPLICATION NUMBER: 09/333,535
; PRIOR FILING DATE: 1999-06-14
; NUMBER OF SEQ ID NOS: 15775
; SEQ ID NO 3000
; LENGTH: 98
; TYPE: DNA
; ORGANISM: Glycine max
; OTHER INFORMATION: Clone ID: LIB3028-017-Q1-B1-D5
US-09-878-574-3000

Query Match 61.0%; Score 12.8; DB 10; Length 98;
 Best Local Similarity 87.5%; Pred. No. 3.5e+03;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 5 TTCTAGGAATTCAAAT 20
 |||
 DB 64 TTATAGGAATTCAAAT 49

RESULT 15
 US-09-843-905A-10/c
 ; Sequence 10, Application US/09843905A
 ; Patent No. US20020168683A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Bird, Timothy A.
 ; APPLICANT: Cosman, David J.
 ; TITLE OF INVENTION: HUMAN PELLINO POLYPEPTIDES
 ; FILE REFERENCE: 2990-A
 ; CURRENT APPLICATION NUMBER: US/09/843,905A
 ; CURRENT FILING DATE: 2001-04-27
 ; PRIOR APPLICATION NUMBER: US 60/200,198
 ; PRIOR FILING DATE: 2000-04-28
 ; NUMBER OF SEQ ID NOS: 15
 ; SOFTWARE: Patent version 3.1
 ; SEQ ID NO 10
 ; LENGTH: 37
 ; TYPE: DNA
 ; ORGANISM: Artificial Sequence
 ; FEATURE:
 ; OTHER INFORMATION: oligonucleotide primer
 US-09-843-905A-10

Query Match 60.0%; Score 12.6; DB 9; Length 37;
 Best Local Similarity 78.9%; Pred. No. 4e+03;
 Matches 15; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
 QY 2 GATTCTAGGAATTCAAAT 20
 |||
 DB 24 GATAGTAGGAATTCATAT 6

Search completed: December 25, 2002, 11:40:36
 Job time : 243 secs

The first part of the paper discusses the importance of the study and the objectives of the research. It then proceeds to a literature review, followed by a description of the methodology used in the study. The results of the study are presented in the next section, followed by a discussion of the findings and their implications. The paper concludes with a summary of the main points and a list of references.

The study was conducted in a laboratory setting, and the results were compared with those of previous studies. The findings of the study are consistent with those of previous studies, and they provide new insights into the topic. The implications of the study are discussed in detail, and the authors conclude that the study has contributed to the understanding of the topic.

The authors would like to thank the following people for their assistance in the study: [Name], [Name], and [Name]. The study was supported by the [Funding Source], and the authors would like to thank them for their support.

GenCore version 5.1.3
Copyright (c) 1993 - 2002 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: December 25, 2002, 11:24:49 ; Search time 2979 Seconds

(without alignments)
114.168 Million cell updates/sec

Title: US-09-744-875-1

Perfect score: 21
Sequence: 1 agattctaggaatcaatc 21

Scoring table: IDENTITY_NDC
Gapop 10.0 / Gapext 1.0

Searched: 16154066 segs, 809774376 residues

Total number of hits satisfying chosen parameters: 357874

Minimum DB seq length: 0

Maximum DB seq length: 100

Post-processing: Minimum Match 0%

Listing first 45 summaries

Database :

EST:*
1: em_estba:*
2: em_estchum:*
3: em_estlin:*
4: em_estmu:*
5: em_estrov:*
6: em_estrpl:*
7: em_estro:*
8: em_hlc:*
9: gb_estl:*
10: gb_estl2:*
11: gb_hlc:*
12: gb_est3:*
13: gb_est4:*
14: gb_est5:*
15: em_estfun:*
16: em_estom:*
17: gb_gss:*
18: em_gss_hum:*
19: em_gss_inv:*
20: em_gss_pln:*
21: em_gss_vrt:*
22: em_gss_fun:*
23: em_gss_man:*
24: em_gss_mus:*
25: em_gss_other:*
26: em_gss_pro:*
27: em_gss_rtd:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	16.2	77.1	82	9	A1218421
2	15.2	72.4	84	17	A2782789
3	14.6	69.5	73	9	AA749115
4	14.4	68.6	63	10	AM695026
5	14.4	68.6	97	17	A2437380
6	14.2	67.6	48	17	BH851999

Result No.	Score	Query Match	Length	DB ID	Description
7	14.2	67.6	60	12	BG153679
8	13.8	65.7	83	9	A1966296
9	13.8	65.7	47	13	B0777154
10	13.8	65.7	49	9	AA422541
11	13.8	65.7	69	17	A2810918
12	13.8	65.7	69	17	A2956832
13	13.8	65.7	76	12	BG153467
14	13.8	65.7	82	12	BG151684
15	13.8	65.7	88	12	BG151856
16	13.8	65.7	91	17	AF087391
17	13.8	65.7	91	17	BH758017
18	13.6	64.8	48	17	BH615007
19	13.6	64.8	50	12	BF789276
20	13.6	64.8	63	12	BF463652
21	13.6	64.8	71	12	BG668331
22	13.6	64.8	86	9	AA863156
23	13.6	64.8	92	14	D75616
24	13.6	64.8	94	17	BH218165
25	13.6	64.8	96	13	BM181183
26	13.6	64.8	96	17	CNS000HH
27	13.4	63.8	88	14	N73593
28	13.4	63.8	100	9	AA420566
29	13.2	62.9	52	10	AM697073
30	13.2	62.9	61	17	BH218412
31	13.2	62.9	72	14	BQ754476
32	13.2	62.9	76	9	AU011284
33	13.2	62.9	78	17	A2774680
34	13.2	62.9	78	17	BH854811
35	13.2	62.9	78	17	BH854812
36	13.2	62.9	79	9	A1916764
37	13.2	62.9	89	10	AM712808
38	13.2	62.9	90	17	BH218396
39	13.2	62.9	92	9	AU259036
40	13.2	62.9	92	10	BE575638
41	13.2	62.9	93	9	AA877878
42	13.2	62.9	94	10	AM518620
43	13.2	62.9	96	17	BH251012
44	13.2	62.9	97	13	B1942693
45	13.2	62.9	100	17	BH170159

ALIGNMENTS

RESULT 1
A1218421
LOCUS 82 bp mRNA linear EST 30-NOV-1998
DEFINITION qh24b10.x1 Soares_NFL-T_GHC_S1 Homo sapiens CDNA clone
IMAGE:1845595 3', mRNA sequence.

ACCESSION A1218421
VERSION A1218421.1 GI:3798236
KEYWORDS EST.

SOURCE human.

ORGANISM Homo sapiens

REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.

AUTHORS NCI-CCGAP http://www.ncbi.nlm.nih.gov/ncicgap.
TITLE National Cancer Institute, Cancer Genome Anatomy Project (CGAP).

JOURNAL Tumor Gene Index

COMMENT Unpublished (1997)

Contact: Robert Strausberg, Ph.D.

Email: cgapbs-remail.nih.gov

This clone is available royalty-free through LNL; contact the IMAGE Consortium (info@image.llnl.gov) for further information.

Insert Length: 925 Std Error: 0.00
Seq primer: -400p from Gibco

High quality sequence stop: 73.

FEATURES
Source Location/Qualifiers

1..82
/organism="Homo sapiens"
/db_xref="taxon:9606"
/clone="IMAGE:1845595"

```

/c/clone.lib="Scores_NFL_T_GBC_S1"
/lab_host="DH10B"
/organism="Mus musculus"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUCG2M0023P07"
/c/clone.lib="Mouse 10kb plasmid UUCG1M library"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/note="Vector: pMD42nv, Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a

```

```

BASE COUNT      37 a      11 c      13 g      21 t
ORIGIN
Query Match      77.1%; Score 16.2; DB 9; Length 82;
Best Local Similarity 85.7%; Pred. No. 2.9e+03;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

```

```

QY      1 AGATTCTAGCAATTCATC 21
      1 |||||
Db      46 AAATTCTAGCAATTAAGC 66

```

```

RESULT 2
A2782789      84 bp      DNA      linear      GSS 16-FEB-2001
LOCUS      A2782789
DEFINITION      2M0023P07R Mouse 10kb plasmid UUCG1M library Mus musculus genomic
clone UUCG2M0023P07 R, DNA sequence.
ACCESSION      A2782789
VERSION      A2782789.1 GI:1291863
KEYWORDS      GSS.
SOURCE      house mouse.
ORGANISM      Mus musculus
Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Scuriongnath; Muridae; Murinae; Mus.
1 (bases 1 to 84)
Dunn, D., Aoyagi, A., Barber, M., Beacorn, T., Duval, B., Hamill, C.,
Islam, H., Longacre, S., Mahmoud, M., Meenen, E., Pedersen, T., Reilly
and Wright, D., Weis, R.,
M., Rose, M., Rose, R., Stokes, R., Tinger, A., von Niederhausen, A.
and Wright, D., Weis, R.,
Mouse whole genome scaffolding with paired end reads from 10kb
plasmid inserts
Unpublished (2000)
Contact: Robert B. Weis
University of Utah
Rm 308 Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
84112 USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0023 row: P column: 07
Seq primer: CACACGGAACACCATGAC
Class: plasmid ends
High quality sequence stop: 84.
Location/Qualifiers
1. 84
/organism="Mus musculus"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUCG2M0023P07"
/c/clone.lib="Mouse 10kb plasmid UUCG1M library"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/note="Vector: pMD42nv, Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a

```

```

0.005 inch orifice at constant velocity. The sheared DNA
was blunt end-repaired with T4 DNA polymerase and T4
polynucleotide kinase. Adaptor oligonucleotides were
ligated to the blunt ends in high molar excess. The
adapted DNA was purified and size-selected for a 9.5 to
10.5 kb range using preparative agarose gel
electrophoresis. Vector DNA was prepared from a derivative
of pMD42 (g1473211419b1AF129072.1), a copy-number
inducible derivative of plasmid R1. The vector was ligated
with adaptors complementary to the insert adaptors and
purified. The sheared, adapted mouse DNA was annealed to
adapted vector DNA, and transformed into
chemically-competent E. coli XL10-Gold (Stratagene) cells
and selected for ampicillin resistance."
BASE COUNT      24 a      18 c      14 g      28 t
ORIGIN
Query Match      72.4%; Score 15.2; DB 17; Length 84;
Best Local Similarity 85.0%; Pred. No. 8.5e+03;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

```

```

QY      1 AGATTCTAGCAATTCATC 20
      1 |||||
Db      23 AATTCTAGCAATTCATC 42

```

```

RESULT 3
AA749115      73 bp      mRNA      linear      EST 27-JAN-1998
LOCUS      AA749115
DEFINITION      oa8b04.s1 NCI_CGAP_GCB1 Homo sapiens CDNA clone IMAGE:1309206 3',
mRNA sequence.
ACCESSION      AA749115
VERSION      AA749115.1 GI:2789073
KEYWORDS      EST.
SOURCE      human.
ORGANISM      Homo sapiens
Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
1 (bases 1 to 73)
NCI-CGAP http://www.ncbi.nlm.nih.gov/ncicgap.
National Cancer Institute, Cancer Genome Anatomy Project (CGAP),
Tumor Gene Index
Unpublished (1997)
Contact: Robert Strausberg, Ph.D.
Email: cgabs-remail.nih.gov
Tissue Procurement: Louis M. Staudt, M.D., Ph.D., David Allman,
Ph.D., Gerald Marti, M.D.
CDNA Library Preparation: M. Bento Soares, Ph.D., M. Fatima
Bonaldo, Ph.D.
CDNA Library Arrayed by: Greg Lennon, Ph.D.
DNA sequencing by: Washington University Genome Sequencing Center
Clone distribution: NCI-CGAP clone distribution information can be
found through the I.M.A.G.E. Consortium/LLNL at:
www.bio.lnl.gov/dbp/image/image.html
Insert Length: 805 Std Error: 0.00
Seq primer: -40ml3 fwd. RT from Amersham
High quality sequence stop: 65.
Location/Qualifiers
1. 73
/organism="Homo sapiens"
/db_xref="taxon:9606"
/clone="IMAGE:1309206"
/c/clone.lib="NCI_CGAP_GCB1"
/tissue_type="germinal center B cell"
/lab_host="DH10B"
/note="Vector: pT73D-Pac (Pharmacia) with a modified
polylinker. Site 1: Not I; Site 2: Eco RI; 1st strand cDNA
was prepared from human tonsillar cells enriched for
germinal center B cells by flow sorting (CD20+, IgD+),
provided by Dr. Louis M. Staudt (NCI). Dr. David Allman
(NCI) and Dr. Gerald Marti (CEBR). cDNA synthesis was
primed with a Not I - oligo(dT) primer
[5'-GTGACACATCGAAGTGGAGCGCGCCCTCATTTTCTTTTCTTTT-3'

```

FEATURES

source

```

1. 84
/organism="Mus musculus"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUCG2M0023P07"
/c/clone.lib="Mouse 10kb plasmid UUCG1M library"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/note="Vector: pMD42nv, Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a

```

FEATURES

source

```

1. 73
/organism="Homo sapiens"
/db_xref="taxon:9606"
/clone="IMAGE:1309206"
/c/clone.lib="NCI_CGAP_GCB1"
/tissue_type="germinal center B cell"
/lab_host="DH10B"
/note="Vector: pT73D-Pac (Pharmacia) with a modified
polylinker. Site 1: Not I; Site 2: Eco RI; 1st strand cDNA
was prepared from human tonsillar cells enriched for
germinal center B cells by flow sorting (CD20+, IgD+),
provided by Dr. Louis M. Staudt (NCI). Dr. David Allman
(NCI) and Dr. Gerald Marti (CEBR). cDNA synthesis was
primed with a Not I - oligo(dT) primer
[5'-GTGACACATCGAAGTGGAGCGCGCCCTCATTTTCTTTTCTTTT-3'

```

1 Double-stranded cDNA was ligated to Eco RI adaptors (Pharmacia), digested with Not I and cloned into the Not I and Eco RI sites of the modified pT73 vector. Library went through one round of normalization, and was constructed by Bento Soares and M. Fatima Bonaldo."

BASE COUNT 29 a 10 c 7 g 27 t

Query Match 69.5%; Score 14.6; DB 9; Length 73;
Best Local Similarity 81.0%; Pred. No. 1.6e+04;
Matches 17; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

OY 1 AGATTCTAGGAATTCAAATC 21
||||| ||||| |||||
Db 17 AGATTTCAGCAAAATTTAATC 37

RESULT 4
AM695026/c 63 bp mRNA linear EST 21-DEC-2000

LOCUS AM695026
DEFINITION NF082E06ST1F1050 Developing stem Medicago truncatula cDNA clone

ACCESSION AM695026
VERSION AM695026.2 GI:11957373
KEYWORDS EST.

ORGANISM barrel medic.
Medicago truncatula

Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; Rosidae; eurosids I; Fabales; Fabaceae; Papilionoideae; Trifoliae; Medicago.

REFERENCE 1 (bases 1 to 63)
He,X.-Z., Shadle,G., Scott,A.D., Harris,A.R., Gonzales,R.A., Bell,C.J., Flores,H.R., Imman,J.T., Weller,J.W., May,G.D. and Dixon,R.A.

Expressed Sequence Tags from the Samuel Roberts Noble Foundation
Medicago truncatula stem library
Unpublished (2000)
On Apr 14, 2000 this sequence version replaced gi.7569788.

JOURNAL CONTACT: Dixon RA
Plant Biology Division
The Samuel Roberts Noble Foundation
2510 Sam Noble Parkway, Ardmore, OK 73402, USA
Tel: 580 221 7302
Fax: 580 221 7380

Email: radix@noble.org
Insert Length: 685 Std Error: 0.00
Plate: 082 row: E column: 06
Seq primer: TCACACGAGAAACAGCTATGAC.

FEATURES
Location/Qualifiers
1..63
/organism="Medicago truncatula"
/db_xref="taxon:3880"
/clone="NF082E06ST"
/clone_lib="Developing stem"
/tissue_type="stem"
/dev_stage="Pooled developmental"
/note="Vector: Lambda Zap; Contains a mixture of intermodal stem segments"

BASE COUNT 31 a 16 c 5 g 11 t
ORIGIN

Query Match 68.6%; Score 14.4; DB 10; Length 63;
Best Local Similarity 93.8%; Pred. No. 2e+04;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 5 TTCTAGGAATTCAAAT 20
||||| ||||| |||||
Db 30 TTGTAGGAATTCAAAT 15

RESULT 5
A2437380

LOCUS A2437380 97 bp DNA linear GSS 03-OCT-2000
DEFINITION 1M0225B12R Mouse 10kb plasmid UUC1M library Mus musculus genomic clone UUC1M0225B12 R. DNA sequence.

ACCESSION A2437380
VERSION A2437380.1 GI:10561393
KEYWORDS GSS.

SOURCE house mouse.
Mus musculus

REFERENCE 1 (bases 1 to 97)
Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Federszen,T., Kelly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausen,A. and Wright,D., Weiss,R.

Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts
Unpublished (2000)
Contact: Robert B. Weiss
University of Utah Genome Center
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLG, UT 84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu

Insert Length: 10000 Std Error: 0.00
Plate: 0225 row: B column: 12
Seq primer: CACACGAGAAACAGCTATGAC
Class: plasmid ends

High quality sequence stop: 97.
Location/Qualifiers
1..97
/organism="Mus musculus"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUC1M0225B12"
/clone_lib="Mouse 10kb plasmid UUC1M library"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, Tl-resistant, F-"
/note="Vector: PMD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource
(http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptor DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of PMD42 (gi14732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptor mouse DNA was annealed to adaptor vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

BASE COUNT 33 a 13 c 19 g 32 t
ORIGIN

Query Match 68.6%; Score 14.4; DB 17; Length 97;
Best Local Similarity 93.8%; Pred. No. 2e+04;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 4 TTCTAGGAATTCAA 19
||||| ||||| |||||
Db 21 TTCTAGGAATTCACA 36

RESULT 6
BH851999

LOCUS BH651999 48 bp DNA linear GSS 13-JUN-2002
 DEFINITION SALK_074019.36.90.x Arabidopsis thaliana TDNA insertion lines
 Arabidopsis thaliana genomic clone SALK_074019.36.90.x. DNA
 sequence.
 ACCSSION BH651999
 VERSION BH651999.1 GI:21422870
 KEYWORDS GSS.
 SOURCE thale cress.
 ORGANISM Arabidopsis thaliana
 Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
 Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
 Rosidae; eurosids II; Brassicales; Brassicaceae; Arabidopsis.
 REFERENCE 1 (bases 1 to 48)
 Alonso, J.M., Leisner, J.J., Barajas, P., Chen, H., Cheuk, R., Gadgil, P.,
 C. Jeske, A., Karnes, M., Kim, C.J., Parker, H., Prednis, L., Shinn, P.,
 Zimmerman, J., and Ecker, J.R.
 A Sequence-Indexed Library of Insertion Mutations in the
 Arabidopsis Genome
 Unpublished (2001)
 CONTACT: Joseph R. Ecker
 The Salk Institute Genomic Analysis Laboratory (SIGAL)
 10010 N. Torrey Pines Road, La Jolla, CA 92037, USA
 Tel: 858 453 4100 x1752
 Fax: 858 558 6379
 Email: eckersalk.salk.edu
 This is single pass sequence recovered from the left border of
 TDNA. This sequence lies within 300 bases of the 5' end of
 At5g16310 and 300 bases of the 3' end of At5g16320.
 Class: TDNA tagged.
 Location/Qualifiers
 1..48
 /organism="Arabidopsis thaliana"
 /strain="Columbia 0"
 /db_xref="taxon:3702"
 /clone="SALK_074019.36.90.x"
 /note="PCR was performed on Arabidopsis thaliana lines
 each of which contains one or more TDNA insertion
 elements. The resultant fragment for each line was
 directly sequenced to determine the genomic sequence at
 the site of insertion. Details of the protocols used can
 be found at http://signal.salk.edu/tdna_protocols.html"
 BASE COUNT 12 a 4 c 12 g 20 t
 ORIGIN
 Query Match 67.6%; Score 14.2; DB 17; Length 48;
 Best Local Similarity 84.2%; Pred. No. 2.5e+04;
 Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 Oy 2 GATTCTAGCAATTCGAAT 20
 ||||| ||||| |||||
 Db 28 GATTGTAGCAATTCGAAT 46
 RESULT 7
 LOCUS BG153679 60 bp mRNA linear EST 05-FEB-2001
 DEFINITION nag58g08.x1 NCI_CGAP_Co26 Homo sapiens cDNA clone IMAGE:4225743 3',
 mRNA sequence.
 ACCSSION BG153679
 VERSION BG153679.1 GI:12665709
 KEYWORDS EST.
 SOURCE human.
 ORGANISM Homo sapiens
 Eukaryota; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
 REFERENCE 1 (bases 1 to 60)
 NCI-CGAP <http://www.ncbi.nlm.nih.gov/ncicgap>.
 National Cancer Institute, Cancer Genome Anatomy Project (CGAP),
 Tumor Gene Index
 Unpublished (1997)
 CONTACT: Robert Strausberg, Ph.D.

Email: cgapbs-remail.nih.gov
 CDNA Library Preparation: David B. Krizman, Ph.D.
 CDNA Library Arrayed by: The I.M.A.G.E. Consortium/LNL
 DNA Sequencing by: Washington University Genome Sequencing Center
 Clone distribution: NCI-CGAP clone distribution information can be
 found through the I.M.A.G.E. Consortium/LNL, send email to:
 info@image.lnl.gov
 Seq primer: -400P from Glbco.
 FEATURES
 source
 1..60
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /clone="IMAGE:4225743"
 /clone_lib="NCI_CGAP_Co26"
 /tissue_type="normal colonic mucosa"
 /lab_host="DH10B"
 /note="Organ: colon; Vector: pMMP1; mRNA made from normal
 colonic mucosa, cDNA made by oligo-dT priming.
 Directionally cloned into UDG sites. Size-selected on
 agarose gel, average insert size 300 bp. Primary library.
 CDNA Library Preparation: David B. Krizman, Ph.D.
 Reference: Krizman et al. (1996) Cancer Research
 56:5380-5383."
 BASE COUNT 17 a 17 c 9 g 17 t
 ORIGIN
 Query Match 67.6%; Score 14.2; DB 12; Length 60;
 Best Local Similarity 84.2%; Pred. No. 2.5e+04;
 Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 Oy 2 GATTCTAGCAATTCGAAT 20
 ||||| ||||| |||||
 Db 20 GAATTCGAGCAATTCGAAT 2
 RESULT 8
 LOCUS A1966296 83 bp mRNA linear EST 30-NOV-2001
 DEFINITION sc36h04.y1 Gm-c1014 Glycine max cDNA clone GENOME SYSTEMS CLONE ID:
 Gm-c1014-1232 5', mRNA sequence.
 ACCSSION A1966296
 VERSION A1966296.1 GI:5760933
 KEYWORDS EST.
 SOURCE soybean.
 ORGANISM Glycine max
 Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
 Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
 Rosidae; eurosids I; Fabales; Fabaceae; Papilionoideae; Phaseoleae;
 Glycine.
 REFERENCE 1 (bases 1 to 83)
 Shoemaker, R., Keim, P., Vodkin, L., Erpelting, J., Coryell, V., Khanna,
 A., Bolla, B., Matra, M., Hillier, L., Kucaba, T., Martin, J., Beck, C.,
 Wylie, T., Underwood, K., Steptoe, M., Rheising, B., Allen, M., Bowers,
 Y., Person, B., Swaller, T., Gibbons, M., Pape, D., Harvey, N., Schurk,
 R., Ritzer, E., Kohn, S., Shin, T., Jackson, Y., Cardenas, M., McCann,
 R., Waterston, R. and Willson, R.
 Public Soybean EST Project
 Unpublished (1999)
 CONTACT: Shoemaker R./Public Soybean EST Project
 Public Soybean EST Project
 Washington University School of Medicine
 4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108, USA
 Tel: 314 286 1800
 Fax: 314 286 1810
 Email: est@wustl.edu
 This clone is available through: ResGen, Invitrogen Corp. 2130
 South Memorial Parkway Huntsville, AL 35801 For further information
 call: (800)-533-4363 or contact via email: ccutresgen.com
 Seq primer: -400P from Glbco.
 FEATURES
 source
 1..83
 /organism="Glycine max"
 /db_xref="taxon:3847"

				/clone="GENOME SYSTEMS CLONE ID: Gm-c1014-1232"			
				/clone.lib="Gm-c1014"			
				/tissue_type="Leaves, 2-3 week old seedlings, greenhouse grown"			
				/lab_host="DH10B"			
				/note="Vector: pVT3pac (pVT73, Pharmacia); Site.1: EcoRI; Site.2: HindIII; This cDNA library was constructed from mRNA isolated from leaves of 2-3 week old greenhouse grown plants. Complementary DNA was synthesized from mRNA using a 3' anchored poly (dT) primer. EcoRI adapters were ligated to the blunt-ended cDNA fragments followed by digestion with EcoRI and HindIII. The cDNA fragments were directionally cloned into the EcoRI-HindIII restriction site of the pVT3-Pac vector. The ligated cDNA fragments were transformed into DH10 host cells (Gibco BRL). This library was constructed by Dr. Randy Shoemaker and Dr. John Erpelidg."			
BASE COUNT	32 a	9 c	8 g	34 t			
ORIGIN							
Query Match	67.6%	Score 14.2;	DB 9;	Length 83;			
Best Local Similarity	84.2%	Pred. No. 2.4e+04;					
Matches 16;	Conservative	0;	Mismatches 3;	Indels 0;	Gaps 0;		
OY	1	AGATTTCAGGAATTCAAA	19				
	I			I			
Db	12	AAATTTCAGGAATTCGAA	30				
RESULT 9							
LOCUS	BJ077154/c	47 bp	mRNA	linear	EST 11-DEC-2001		
DEFINITION	BJ077154 NIBB Mochii normalized Xenopus tailbud library Xenopus						
ACCESSION	laevis cDNA clone XL060a15 3', mRNA sequence.						
VERSION	BJ077154						
KEYWORDS	BJ077154.1 GI:17522070						
SOURCE	EST.						
ORGANISM	African clawed frog.						
	Xenopus laevis						
	Eukaryota; Metazoa; Chordata; Cranialia; Vertebrata; Euteleostomi;						
	Amphibia; Batrachia; Anura; Mesobatrachia; Pipidoidea; Pipidae;						
	Xenopodinae; Xenopus.						
	1 (bases 1 to 47)						
REFERENCE	Kitayama,A., Terasaka,C., Mochii,M., Ueno,N., Shin-i,T. and Kohara						
AUTHORS	Y.,						
TITLE	Expressed genes in X. laevis embryo						
JOURNAL	Unpublished (2001)						
COMMENT	Contact: Tadasu Shin-i						
	Center For Genetic Resource Information						
	National Institute of Genetics						
	111 Yata, Mishima, Shizuoka 411-8540, Japan						
	Tel: 81-559-81-6856						
	Fax: 81-559-81-6855						
	Email: tshini@genes.nig.ac.jp.						
FEATURES	Location/Qualifiers						
SOURCE	1. 47						
	/organism="Xenopus laevis"						
	/db_xref="taxon:8355"						
	/clone="XL060a15"						
	/clone.lib="NIBB Mochii normalized Xenopus tailbud						
	library"						
	/tissue_type="whole embryo"						
	/dev_stage="stage 25"						
	/note="Vector: pBSRN3, Site.1: NotI; Site.2: EcoRI, cDNAs						
	were oligo-dT primed and directionally cloned. Staging						
	according to Nieukoop and Faber. Library is substracted						
	and was constructed by N. Garrett and A.M. Zorn,						
	(Wellcome/CRC Institute)."						
BASE COUNT	9 a	3 c	9 g	22 t	4 others		
QUERY MATCH							
Best Local Similarity	65.7%	Score 13.8;	DB 13;	Length 47;			
	88.2%	Pred. No. 3.9e+04;					

Matches	15;	Conservative	0;	Mismatches	2;	Indels	0;	Gaps	0;
QY	3	ATTCTAGCAATTCAAA	19						
Db	19	AGTTCTAGCAATTCAAA	3						
RESULT 10									
AA422541									
LOCUS									
DEFINITION		AA422541		49 bp	mRNA	linear	EST 16-OCT-1997		
ACCESSION		AA422541							
VERSION		AA422541.1							
KEYWORDS		EST.							
SOURCE		house mouse.							
ORGANISM		Mus musculus							
REFERENCE		Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.							
AUTHORS		1 (bases 1 to 49)							
		Marra, M., Hillier, L., Allen, M., Bowles, M., Dietrich, N., Dubuque, T., Geisel, S., Kucaba, T., Lacy, M., Le, M., Martin, J., Morris, M., Schellenberg, K., Steptoe, M., Tan, F., Underwood, R., Moore, B., Thaising, B., Wylie, T., Lennon, G., Soares, B., Wilson, R. and Waterston, R.							
TITLE		The WashU-HMI Mouse EST Project							
COMMENT		Unpublished (1996) Contact: Marra M/Mouse EST Project WashU-HMI Mouse EST Project Washington University School of Medicine 4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108 Tel: 314 286 1800 Fax: 314 286 1810 Email: mouseest@wustl.edu This clone is available royalty-free through LNL; contact the IMAGE Consortium (info@image.lnl.gov) for further information. MGI:495300 Seq primer: -40m13 fwd, ET from Amersham.							
FEATURES									
source		Location/Qualifiers							
		1..49							
		/organism="Mus musculus"							
		/strain="C57BL/6J x DBA/2J F1"							
		/db_xref="taxon:10090"							
		/clone="IMAGE:835684"							
		/clone_idb="Knowles Soltner mouse unfertilized egg"							
		/tissue_type="unfertilized egg"							
		/lab_host="DH10B"							
		/note="Organ: unfertilized egg; Vector: pBluescribe (modified); Site.1: MluI; Site.2: SalI; Cloned unidirectionally from mRNA prepared from 5000 unfertilized eggs. Primer: SalI(dT): 5'-GGTGCACGCGACCGTTTCTTTTCTTTT-3'. cDNAs were cloned into the MluI/SalI sites of a modified pBluescribe vector using commercial linkers (NEB). Average insert size: 1.0 kb."							
BASE COUNT		22 a		3 c		10 g		14 t	
ORIGIN									
Query Match		65.7%		Score 13.8;		DB 9;		Length 49;	
Best Local Similarity		88.2%		Pred. No. 3.8e-04;					
Matches		15;		Conservative		0;		Mismatches	
		2;		Indels		0;		Gaps	
QY		3		ATTCTAGCAATTCAAA		19			
Db		29		AGTTCTAGCAATTCAAA		45			
RESULT 11									
AA2810918/c									
LOCUS									
DEFINITION		AA2810918		69 bp	DNA	linear	GSS 20-FEB-2001		
ACCESSION		AA2810918							
		clone UUGC2M0076K14 R, DNA sequence.							

VERSION AZ810918.1 GI:12978657
 KEYWORDS GSS.
 SOURCE house mouse.
 ORGANISM Mus musculus
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 REFERENCE 1 (bases 1 to 69)
 Dunn, D., Aoyagi, A., Barber, M., Beacorn, T., Duval, B., Hamil, C., Islam, H., Longacre, S., Mahmoud, M., Meenen, E., Pedersen, T., Reilly, M., Rose, M., Rose, R., Stokes, R., Tingey, A., von Niederhausern, A., and Wright, D., Weiss, R.
 Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts
 TITLE Unpublished (2000)
 JOURNAL Contact: Robert B. Weiss
 COMMENT University of Utah Genome Center
 Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA
 Tel: 801 585 5606
 Fax: 801 585 7177
 Email: ddunn@genetics.utah.edu
 Insert Length: 10000 Std Error: 0.00
 Plate: 0076 row: K column: 14
 Seq primer: CACACAGAAACAGCTATGACC
 Class: plasmid ends
 High quality sequence stop: 69.
 Location/Qualifiers
 1. 69
 /organism="Mus musculus"
 /strain="C57BL/6J"
 /db_xref="taxon:10090"
 /clone="UUCG2M0076K14"
 /clone_1lb="Mouse 10kb plasmid UUCG1M library"
 /sex="Male"
 /lab_host="E. coli strain XL10-Gold, T1-resistant, F-"
 /note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptor DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of PWD42 (g114732114[9b]AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptor mouse DNA was annealed to adaptor vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

BASE COUNT 21 a 16 c 10 g 22 t
 ORIGIN
 Query Match 65.7%; Score 13.8; DB 17; Length 69;
 Best Local Similarity 88.2%; Pred. No. 3.8e+04;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 4 TTCTAGAGATTCGAAT 20
 ||| ||||| |||||
 Db 27 TTTCAGGAAATTAAT 11

RESULT 12
 AZ956832/c 69 bp DNA linear GSS 27-Apr-2001
 LOCUS 2M0223C05R Mouse 10kb plasmid UUCG2M library Mus musculus genomic
 DEFINITION clone UUCG2M0223C05 R, DNA sequence.
 ACCESSION AZ956832

VERSION AZ956832.1 GI:13828059
 KEYWORDS GSS.
 SOURCE house mouse.
 ORGANISM Mus musculus
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 REFERENCE 1 (bases 1 to 69)
 Dunn, D., Aoyagi, A., Barber, M., Beacorn, T., Duval, B., Hamil, C., Islam, H., Longacre, S., Mahmoud, M., Meenen, E., Pedersen, T., Reilly, M., Rose, M., Rose, R., Stokes, R., Tingey, A., von Niederhausern, A., and Wright, D., Weiss, R.
 Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts
 TITLE Unpublished (2000)
 JOURNAL Contact: Robert B. Weiss
 COMMENT University of Utah Genome Center
 Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA
 Tel: 801 585 5606
 Fax: 801 585 7177
 Email: ddunn@genetics.utah.edu
 Insert Length: 10000 Std Error: 0.00
 Plate: 0223 row: C column: 05
 Seq primer: CACACAGAAACAGCTATGACC
 Class: plasmid ends
 High quality sequence stop: 69.
 Location/Qualifiers
 1. 69
 /organism="Mus musculus"
 /strain="C57BL/6J"
 /db_xref="taxon:10090"
 /clone="UUCG2M0223C05"
 /clone_1lb="Mouse 10kb plasmid UUCG2M library"
 /sex="Female"
 /lab_host="E. coli strain XL10-Gold, T1-resistant, F-"
 /note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (female) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptor DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of PWD42 (g114732114[9b]AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptor mouse DNA was annealed to adaptor vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

BASE COUNT 18 a 19 c 11 g 21 t
 ORIGIN
 Query Match 65.7%; Score 13.8; DB 17; Length 69;
 Best Local Similarity 88.2%; Pred. No. 3.8e+04;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1 AGATTCTAGGATTCGA 17
 ||| ||||| ||||| |||||
 Db 18 AGATTCTAGGATTCGA 2

RESULT 13
 BG153467/c 76 bp mRNA linear EST 05-FEB-2001
 LOCUS ng42a01.x1 NCI_GAP_Co29 Homo sapiens cDNA clone IMAGE:4204320 3',
 DEFINITION mRNA sequence.
 ACCESSION BG153467

```

VERSION      BG153467.1  GI:12665497
KEYWORDS     EST
SOURCE       human.
ORGANISM     Homo sapiens
REFERENCE    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
AUTHORS      Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
TITLE        1 (bases 1 to 76)
NCI-CCAP http://www.ncbi.nlm.nih.gov/ncicgap.
National Cancer Institute, Cancer Genome Anatomy Project (CGAP),
Tumor Gene Index
JOURNAL      Unpublished (1997)
COMMENT      Contact: Robert Strausberg, Ph.D.
              Email: cgapbs-remail.nih.gov
              CDNA Library Preparation: David B. Krizman, Ph.D.
              DNA Sequencing by: The I.M.A.G.E. Consortium/LLNL
              Clone distribution: NCI-CCAP clone distribution information can be
              found through the I.M.A.G.E. Consortium/LLNL, send email to:
              info@image.llnl.gov
              Seq primer: -40UP from Gibco.
              Location/Qualifiers
              1..76
                /organism="Homo sapiens"
                /db_xref="taxon:9606"
                /clone="IMAGE:4204320"
                /clone_1lb="NCI-CCAP-Co29"
                /tissue_type="tubulovillous adenoma"
                /lab_host="DH10B"
                /note="Organ: colon; Vector: pAMP1; mRNA made from colonic
                adenoma, cDNA made by oligo-dT priming. Directionally
                cloned into UDG sites. Size-selected on agarose gel,
                average insert size 300 bp. Primary library. CDNA library
                preparation: David B. Krizman, Ph.D. Reference: Krizman
                et al. (1996) Cancer Research 56:5380-5383."
BASE COUNT   22 a      20 c      14 g      20 t
ORIGIN
Query Match      65.7%; Score 13.8; DB 12; Length 76;
Best Local Similarity 88.2%; Pred. No. 3.7e+04;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      2 GATTCTAGCAATTCAA 18
        || ||| ||||| |||||
Db      24 GAATTCGAGCAATTCAA 8

RESULT 14
LOCUS      BG151684      82 bp      mRNA      linear      EST 05-FEB-2001
DEFINITION nag63b11.x1 NCI-CCAP-Co26 Homo sapiens CDNA clone IMAGE:4226252 3',
            mRNA sequence.
ACCESSION  BG151684
VERSION     BG151684.1  GI:12663714
KEYWORDS    EST.
SOURCE      human.
ORGANISM    Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
REFERENCE   1 (bases 1 to 82)
NCI-CCAP http://www.ncbi.nlm.nih.gov/ncicgap.
National Cancer Institute, Cancer Genome Anatomy Project (CGAP),
Tumor Gene Index
JOURNAL      Unpublished (1997)
COMMENT      Contact: Robert Strausberg, Ph.D.
              Email: cgapbs-remail.nih.gov
              CDNA Library Preparation: David B. Krizman, Ph.D.
              DNA Sequencing by: The I.M.A.G.E. Consortium/LLNL
              Clone distribution: NCI-CCAP clone distribution information can be
              found through the I.M.A.G.E. Consortium/LLNL, send email to:
              info@image.llnl.gov
              Seq primer: -40UP from Gibco.
              Location/Qualifiers
              1..76
                /organism="Homo sapiens"
                /db_xref="taxon:9606"
                /clone="IMAGE:4226252"
                /clone_1lb="NCI-CCAP-Co26"
                /tissue_type="normal colonic mucosa"
                /lab_host="DH10B"
                /note="Organ: colon; Vector: pAMP1; mRNA made from normal
                colonic mucosa, cDNA made by oligo-dT priming.
                Directionally cloned into UDG sites. Size-selected on
                agarose gel, average insert size 300 bp. Primary library.
                CDNA library preparation: David B. Krizman, Ph.D.
                Reference: Krizman et al. (1996) Cancer Research
                56:5380-5383."
BASE COUNT   23 a      23 c      17 g      25 t
ORIGIN
Query Match      65.7%; Score 13.8; DB 12; Length 88;
Best Local Similarity 88.2%; Pred. No. 3.7e+04;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```

FEATURES

source

```

1..82
  /organism="Homo sapiens"
  /db_xref="taxon:9606"
  /clone="IMAGE:4226252"
  /clone_1lb="NCI-CCAP-Co26"
  /tissue_type="normal colonic mucosa"
  /lab_host="DH10B"
  /note="Organ: colon; Vector: pAMP1; mRNA made from normal
  colonic mucosa, cDNA made by oligo-dT priming.
  Directionally cloned into UDG sites. Size-selected on
  agarose gel, average insert size 300 bp. Primary library.
  CDNA library preparation: David B. Krizman, Ph.D.
  Reference: Krizman et al. (1996) Cancer Research
  56:5380-5383."
BASE COUNT   22 a      21 c      14 g      24 t      1 others
ORIGIN
Query Match      65.7%; Score 13.8; DB 12; Length 82;
Best Local Similarity 88.2%; Pred. No. 3.7e+04;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      2 GATTCTAGCAATTCAA 18
        || ||| ||||| |||||
Db      40 GAATTCGAGCAATTCAA 24

RESULT 15
LOCUS      BG151856      88 bp      mRNA      linear      EST 05-FEB-2001
DEFINITION nag65405.x1 NCI-CCAP-Co26 Homo sapiens CDNA clone IMAGE:4226360 3',
            mRNA sequence.
ACCESSION  BG151856
VERSION     BG151856.1  GI:12663886
KEYWORDS    EST.
SOURCE      human.
ORGANISM    Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
REFERENCE   1 (bases 1 to 88)
NCI-CCAP http://www.ncbi.nlm.nih.gov/ncicgap.
National Cancer Institute, Cancer Genome Anatomy Project (CGAP),
Tumor Gene Index
JOURNAL      Unpublished (1997)
COMMENT      Contact: Robert Strausberg, Ph.D.
              Email: cgapbs-remail.nih.gov
              CDNA Library Preparation: David B. Krizman, Ph.D.
              DNA Sequencing by: The I.M.A.G.E. Consortium/LLNL
              Clone distribution: NCI-CCAP clone distribution information can be
              found through the I.M.A.G.E. Consortium/LLNL, send email to:
              info@image.llnl.gov
              Seq primer: -40UP from Gibco.
              Location/Qualifiers
              1..88
                /organism="Homo sapiens"
                /db_xref="taxon:9606"
                /clone="IMAGE:4226360"
                /clone_1lb="NCI-CCAP-Co26"
                /tissue_type="normal colonic mucosa"
                /lab_host="DH10B"
                /note="Organ: colon; Vector: pAMP1; mRNA made from normal
                colonic mucosa, cDNA made by oligo-dT priming.
                Directionally cloned into UDG sites. Size-selected on
                agarose gel, average insert size 300 bp. Primary library.
                CDNA library preparation: David B. Krizman, Ph.D.
                Reference: Krizman et al. (1996) Cancer Research
                56:5380-5383."
BASE COUNT   23 a      23 c      17 g      25 t
ORIGIN
Query Match      65.7%; Score 13.8; DB 12; Length 88;
Best Local Similarity 88.2%; Pred. No. 3.7e+04;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```

Fri Dec 27 17:38:55 2002

us-09-744-875-1.rst

Page 8

Oy 2 GATTCTAGGAATTCAA 18
| | | | | | | | | |
Db 35 GAATTCGAGGAATTCAA 19

Search completed: December 25, 2002, 12:30:48
Job time : 2991 secs

GenCore version 5.1.3
Copyright (c) 1993 - 2002 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: December 25, 2002, 14:02:35 ; Search time 54 Seconds
(without alignments)
67.706 Million cell updates/sec

Title: SCHMIDT875
Perfect score: 9
Sequence: 1 ttcnngaa 9

Scoring table: IDENTITY_NUC
Gapop 10.0, Gapext 1.0

Searched: 363474 seqs, 203117208 residues

Total number of hits satisfying chosen parameters: 221248

Minimum DB seq length: 0
Maximum DB seq length: 100

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database: Published Applications, NA:*

- 1: /cgn2_6/ptodata/1/pubppa/US07_PUBCOMB.seq:*
- 2: /cgn2_6/ptodata/1/pubppa/PTCT_NEM_PUB.seq:*
- 3: /cgn2_6/ptodata/1/pubppa/US06_NEM_PUB.seq:*
- 4: /cgn2_6/ptodata/1/pubppa/US06_PUBCOMB.seq:*
- 5: /cgn2_6/ptodata/1/pubppa/US07_NEM_PUB.seq:*
- 6: /cgn2_6/ptodata/1/pubppa/PTCT_NEM_PUB.seq:*
- 7: /cgn2_6/ptodata/1/pubppa/US08_PUBCOMB.seq:*
- 8: /cgn2_6/ptodata/1/pubppa/US08_PUBCOMB.seq:*
- 9: /cgn2_6/ptodata/1/pubppa/US09_PUBCOMB.seq:*
- 10: /cgn2_6/ptodata/1/pubppa/US09_PUBCOMB.seq:*
- 11: /cgn2_6/ptodata/1/pubppa/US10_NEM_PUB.seq:*
- 12: /cgn2_6/ptodata/1/pubppa/US10_PUBCOMB.seq:*
- 13: /cgn2_6/ptodata/1/pubppa/US06_PUBCOMB.seq:*
- 14: /cgn2_6/ptodata/1/pubppa/US06_PUBCOMB.seq:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	66.7	9	9	US-10-136-224-13	Sequence 13, App1
2	66.7	9	9	US-10-136-224-13	Sequence 13, App1
3	66.7	9	9	US-09-842-761-4	Sequence 4, App1
4	66.7	9	9	US-09-842-761-4	Sequence 4, App1
5	66.7	9	9	US-09-816-763-112	Sequence 112, App
6	66.7	9	9	US-09-816-763-112	Sequence 112, App
7	66.7	11	9	US-10-113-877-21	Sequence 21, App1
8	66.7	11	9	US-10-113-877-21	Sequence 21, App1
9	66.7	11	9	US-10-113-877-25	Sequence 25, App1
10	66.7	11	9	US-10-113-877-25	Sequence 25, App1
11	66.7	12	9	US-10-113-877-23	Sequence 23, App1
12	66.7	12	9	US-10-113-877-23	Sequence 23, App1
13	66.7	12	9	US-10-113-877-24	Sequence 24, App1
14	66.7	12	9	US-10-113-877-24	Sequence 24, App1
15	66.7	15	10	US-09-504-231A-366	Sequence 366, App
16	66.7	15	10	US-09-504-231A-366	Sequence 366, App
17	66.7	15	10	US-09-504-231A-367	Sequence 367, App
18	66.7	15	10	US-09-504-231A-367	Sequence 367, App
19	66.7	15	10	US-09-504-231A-935	Sequence 935, App

C 20	6	66.7	15	10	US-09-504-231A-935	Sequence 935, App
C 21	6	66.7	15	10	US-09-504-231A-936	Sequence 936, App
C 22	6	66.7	15	10	US-09-504-231A-936	Sequence 936, App
C 23	6	66.7	15	10	US-09-504-231A-981	Sequence 981, App
C 24	6	66.7	15	10	US-09-504-231A-981	Sequence 981, App
C 25	6	66.7	15	10	US-09-504-231A-982	Sequence 982, App
C 26	6	66.7	15	10	US-09-504-231A-982	Sequence 982, App
C 27	6	66.7	15	10	US-09-504-231A-1096	Sequence 1096, App
C 28	6	66.7	15	10	US-09-504-231A-1096	Sequence 1096, App
C 29	6	66.7	15	10	US-09-504-231A-1097	Sequence 1097, App
C 30	6	66.7	15	10	US-09-504-231A-1097	Sequence 1097, App
C 31	6	66.7	15	10	US-09-504-231A-1098	Sequence 1098, App
C 32	6	66.7	15	10	US-09-504-231A-1098	Sequence 1098, App
C 33	6	66.7	15	10	US-09-504-231A-366	Sequence 366, App
C 34	6	66.7	15	10	US-09-274-553D-366	Sequence 366, App
C 35	6	66.7	15	10	US-09-274-553D-367	Sequence 367, App
C 36	6	66.7	15	10	US-09-274-553D-367	Sequence 367, App
C 37	6	66.7	15	10	US-09-274-553D-935	Sequence 935, App
C 38	6	66.7	15	10	US-09-274-553D-935	Sequence 935, App
C 39	6	66.7	15	10	US-09-274-553D-936	Sequence 936, App
C 40	6	66.7	15	10	US-09-274-553D-936	Sequence 936, App
C 41	6	66.7	15	10	US-09-274-553D-981	Sequence 981, App
C 42	6	66.7	15	10	US-09-274-553D-981	Sequence 981, App
C 43	6	66.7	15	10	US-09-274-553D-982	Sequence 982, App
C 44	6	66.7	15	10	US-09-274-553D-982	Sequence 982, App
C 45	6	66.7	15	10	US-09-274-553D-1096	Sequence 1096, App

ALIGNMENTS

RESULT 1
US-10-136-224-13 Application US/10136224
Sequence 13, App1
Patent No. US20020174448A1
GENERAL INFORMATION:
APPLICANT: AUERNHAMER, CHRISTOPH J.
TITLE OF INVENTION: SUPPRESSOR OF CYTOKINE SIGNALING
TITLE OF INVENTION: (SOCG) - 3 PROMOTER AND METHODS FOR ITS USE IN GENETIC THERAPY
FILE REFERENCE: P07 42591
CURRENT APPLICATION NUMBER: US/10/136,224
PRIOR FILING DATE: 2002-04-29
PRIOR APPLICATION NUMBER: US/09/327,138
PRIOR FILING DATE: 1999-06-07
NUMBER OF SEQ ID NOS: 30
SOFTWARE: FASTSEQ for Windows Version 3.0
SEQ ID NO 13
LENGTH: 9
TYPE: DNA
ORGANISM: MURINE
FEATURE:
NAME/KEY: promoter
LOCATION: (-74)...(-66)
OTHER INFORMATION: STAT-BINDING SITE AT -74 TO -66
FEATURE:
NAME/KEY: promoter
LOCATION: (0)...(0)
FEATURE:
NAME/KEY: mutation
LOCATION: (0)...(0)
OTHER INFORMATION: STAT-BINDING SITE AT -74 TO 66
US-10-136-224-13

Query Match 66.7%: Score 6; DB 9; Length 9;
Best local similarity 66.7%: Pred. No. 4.3e+07;
Matches 6; Conservative 0; Mismatches 3; Indels 0;

QY 1 TTCNNNGAA 9
||| |||
DB 1 TTCGAGGAA 9

RESULT 2

```

US-10-136-224-13/C
; Sequence 13, Application US/10136224
; Patent No. US20020174448A1
; GENERAL INFORMATION:
; APPLICANT: AUERNHAMMER, CHRISTOPH J.
; APPLICANT: MELMED, SHLOMO
; TITLE OF INVENTION: SUPPRESSOR OF CYTOKINE SIGNALING
; TITLE OF INVENTION: (SOCS)-3 PROMOTER AND METHODS FOR ITS USE IN GENETIC THERAPY
; TITLE OF INVENTION: IN HUMANS
; FILE REFERENCE: P07 42591
; CURRENT APPLICATION NUMBER: US/10/136,224
; CURRENT FILING DATE: 2002-04-29
; PRIOR APPLICATION NUMBER: US/09/327,138
; PRIOR FILING DATE: 1999-06-07
; NUMBER OF SEQ ID NOS: 30
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 13
; LENGTH: 9
; TYPE: DNA
; ORGANISM: MURINE
; FEATURE:
; NAME/KEY: Promoter
; LOCATION: (-74)...(-66)
; OTHER INFORMATION: STAT-BINDING SITE AT -74 TO -66
; FEATURE:
; NAME/KEY: Promoter
; LOCATION: (0)...(0)
; FEATURE:
; NAME/KEY: mutation
; LOCATION: (0)...(0)
; OTHER INFORMATION: STAT-BINDING SITE AT -74 TO 66
US-10-136-224-13

```

Query Match 66.7%; Score 6; DB 9; Length 9;
 Best Local Similarity 66.7%; Pred. No. 4.3e+07;

Matches 6; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

```

QY 1 TTCNNNGAA 9
   ||| |||
Db 9 TTCGCGGAA 1

```

RESULT 3

```

US-09-842-761-4
; Sequence 4, Application US/09842761
; Patent No. US20020081602A1
; GENERAL INFORMATION:
; APPLICANT: Bealey, Lee
; TITLE OF INVENTION: Method for the Detection of Compounds
; TITLE OF INVENTION: that Modulate the Effects of the Obese (OB) Protein
; FILE REFERENCE: P31648-C1
; CURRENT APPLICATION NUMBER: US/09/842,761
; CURRENT FILING DATE: 2001-04-26
; PRIOR APPLICATION NUMBER: 09/297,442
; PRIOR FILING DATE: 1999-06-18
; NUMBER OF SEQ ID NOS: 4
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 4
; LENGTH: 9
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-842-761-4

```

Query Match 66.7%; Score 6; DB 10; Length 9;
 Best Local Similarity 66.7%; Pred. No. 4.3e+07;
 Matches 6; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

```

QY 1 TTCNNNGAA 9
   ||| |||
Db 1 TTCGCGGAA 9

```

RESULT 4

```

US-09-842-761-4/C
; Sequence 4, Application US/09842761
; Patent No. US20020081602A1
; GENERAL INFORMATION:
; APPLICANT: Bealey, Lee
; TITLE OF INVENTION: Method for the Detection of Compounds
; TITLE OF INVENTION: that Modulate the Effects of the Obese (OB) Protein
; FILE REFERENCE: P31648-C1
; CURRENT APPLICATION NUMBER: US/09/842,761
; CURRENT FILING DATE: 2001-04-26
; PRIOR APPLICATION NUMBER: 09/297,442
; PRIOR FILING DATE: 1999-06-18
; NUMBER OF SEQ ID NOS: 4
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 4
; LENGTH: 9
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-842-761-4

```

Query Match 66.7%; Score 6; DB 10; Length 9;
 Best Local Similarity 66.7%; Pred. No. 4.3e+07;
 Matches 6; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

```

QY 1 TTCNNNGAA 9
   ||| |||
Db 9 TTCGCGGAA 1

```

RESULT 5

```

US-09-816-763-112
; Sequence 112, Application US/09816763
; Patent No. US20020110814A1
; GENERAL INFORMATION:
; APPLICANT: Remacle, Jose
; APPLICANT: Renard, Patricia
; APPLICANT: Art, Muriel
; TITLE OF INVENTION: METHOD AND KIT FOR THE SCREENING, THE
; TITLE OF INVENTION: DETECTION AND/OR THE QUANTIFICATION OF TRANSCRIPTIONAL
; TITLE OF INVENTION: FACTORS
; FILE REFERENCE: VANM212.001AUS
; CURRENT APPLICATION NUMBER: US/09/816,763
; CURRENT FILING DATE: 2001-03-23
; PRIOR APPLICATION NUMBER: EP 00870057.7
; PRIOR FILING DATE: 2000-03-24
; NUMBER OF SEQ ID NOS: 150
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 112
; LENGTH: 9
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Consensus sequence for transcriptional factor STAT
; NAME/KEY: misc_feature
; LOCATION: (1)...(9)
; OTHER INFORMATION: n = A,T,C or G
US-09-816-763-112

```

Query Match 66.7%; Score 6; DB 10; Length 9;
 Best Local Similarity 100.0%; Pred. No. 4.3e+07;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

QY 1 TTCNNNGAA 9
   ||| ||| ||| |||
Db 1 TTCNNNGAA 9

```

RESULT 6

```

US-09-816-763-112/C
; Sequence 112, Application US/09816763
; Patent No. US20020110814A1

```

```
;; GENERAL INFORMATION:
;; APPLICANT: Remacle, Jose
;; APPLICANT: Renard, Patricia
;; APPLICANT: Atl, Muriel
;; TITLE OF INVENTION: METHOD AND KIT FOR THE SCREENING, THE
;; TITLE OF INVENTION: DETECTION AND/OR THE QUANTIFICATION OF TRANSCRIPTIONAL
;; FILE REFERENCE: VANM212.001AUS
;; CURRENT APPLICATION NUMBER: US/09/816,763
;; CURRENT FILING DATE: 2001-03-23
;; PRIOR APPLICATION NUMBER: EP 00870057.7
;; PRIOR FILING DATE: 2000-03-24
;; NUMBER OF SEQ ID NOS: 150
;; SOFTWARE: FastSeq for Windows Version 4.0
;; SEQ ID NO 112
;; LENGTH: 9
;; TYPE: DNA
;; ORGANISM: Artificial Sequence
;; FEATURE:
;; OTHER INFORMATION: Consensus sequence for transcriptional factor STAT
;; NAME/KEY: misc_feature
;; LOCATION: (1)...(9)
;; OTHER INFORMATION: n = A,T,C or G
US-09-816-763-112
```

```
Query Match          66.7%; Score 6; DB 10; Length 9;
Best Local Similarity 100.0%; Pred. No. 4.3e+07;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
OY      1 TTCNNNGAA 9
        ||| ||| |||
Db       9 TTCNNNGAA 1
```

```
RESULT 7
US-10-113-877-21
;; Sequence 21, Application US/10113877
;; Patent No. US20020177218A1
;; GENERAL INFORMATION:
;; APPLICANT: Fang, Yu
;; APPLICANT: Wang, Xiao-Yang
;; APPLICANT: Turpin, Pierre
;; TITLE OF INVENTION: Methods of detecting multiple DNA
;; TITLE OF INVENTION: binding protein and DNA interactions in a sample, and
;; FILE REFERENCE: CLON-071
;; CURRENT APPLICATION NUMBER: US/10/113,877
;; CURRENT FILING DATE: 2002-03-29
;; PRIOR APPLICATION NUMBER: 60/280,658
;; PRIOR FILING DATE: 2001-03-30
;; PRIOR APPLICATION NUMBER: 60/314,330
;; PRIOR FILING DATE: 2001-08-20
;; NUMBER OF SEQ ID NOS: 192
;; SOFTWARE: FastSeq for Windows Version 4.0
;; SEQ ID NO 21
;; LENGTH: 11
;; TYPE: DNA
;; ORGANISM: Artificial Sequence
;; FEATURE:
;; OTHER INFORMATION: oligonucleotide
US-10-113-877-21
```

```
Query Match          66.7%; Score 6; DB 9; Length 11;
Best Local Similarity 66.7%; Pred. No. 2.9e+04;
Matches 6; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

```
OY      1 TTCNNNGAA 9
        ||| ||| |||
Db       1 TTCTGGGAA 9
```

```
RESULT 8
US-10-113-877-21/c
```

```
;; Sequence 21, Application US/10113877
;; Patent No. US20020177218A1
;; GENERAL INFORMATION:
;; APPLICANT: Fang, Yu
;; APPLICANT: Wang, Xiao-Yang
;; APPLICANT: Turpin, Pierre
;; TITLE OF INVENTION: Methods of detecting multiple DNA
;; TITLE OF INVENTION: binding protein and DNA interactions in a sample, and
;; FILE REFERENCE: CLON-071
;; CURRENT APPLICATION NUMBER: US/10/113,877
;; CURRENT FILING DATE: 2002-03-29
;; PRIOR APPLICATION NUMBER: 60/280,658
;; PRIOR FILING DATE: 2001-03-30
;; PRIOR APPLICATION NUMBER: 60/314,330
;; PRIOR FILING DATE: 2001-08-20
;; NUMBER OF SEQ ID NOS: 192
;; SOFTWARE: FastSeq for Windows Version 4.0
;; SEQ ID NO 21
;; LENGTH: 11
;; TYPE: DNA
;; ORGANISM: Artificial Sequence
;; FEATURE:
;; OTHER INFORMATION: oligonucleotide
US-10-113-877-21
```

```
Query Match          66.7%; Score 6; DB 9; Length 11;
Best Local Similarity 66.7%; Pred. No. 2.9e+04;
Matches 6; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

```
OY      1 TTCNNNGAA 9
        ||| ||| |||
Db       9 TTCCGAGAA 1
```

```
RESULT 9
US-10-113-877-25
;; Sequence 25, Application US/10113877
;; Patent No. US20020177218A1
;; GENERAL INFORMATION:
;; APPLICANT: Fang, Yu
;; APPLICANT: Wang, Xiao-Yang
;; APPLICANT: Turpin, Pierre
;; TITLE OF INVENTION: Methods of detecting multiple DNA
;; TITLE OF INVENTION: binding protein and DNA interactions in a sample, and
;; FILE REFERENCE: CLON-071
;; CURRENT APPLICATION NUMBER: US/10/113,877
;; CURRENT FILING DATE: 2002-03-29
;; PRIOR APPLICATION NUMBER: 60/280,658
;; PRIOR FILING DATE: 2001-03-30
;; PRIOR APPLICATION NUMBER: 60/314,330
;; PRIOR FILING DATE: 2001-08-20
;; NUMBER OF SEQ ID NOS: 192
;; SOFTWARE: FastSeq for Windows Version 4.0
;; SEQ ID NO 25
;; LENGTH: 11
;; TYPE: DNA
;; ORGANISM: Artificial Sequence
;; FEATURE:
;; OTHER INFORMATION: oligonucleotide
US-10-113-877-25
```

```
Query Match          66.7%; Score 6; DB 9; Length 11;
Best Local Similarity 66.7%; Pred. No. 2.9e+04;
Matches 6; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

```
OY      1 TTCNNNGAA 9
        ||| ||| |||
Db       2 TTCCGAGAA 10
```

```
RESULT 10
```

```
US-10-113-877-25/c
; Sequence 25, Application US/10113877
; Patent No. US20020177218A1
; GENERAL INFORMATION:
; APPLICANT: Fang, Yu
; APPLICANT: Wang, Xiao-Yang
; APPLICANT: Turpin, Pierre
; TITLE OF INVENTION: Methods of detecting multiple DNA
; TITLE OF INVENTION: binding protein and DNA interactions in a sample, and
; FILE REFERENCE: CLON-071
; CURRENT APPLICATION NUMBER: US/10/113,877
; CURRENT FILING DATE: 2002-03-29
; PRIOR APPLICATION NUMBER: 60/280,658
; PRIOR FILING DATE: 2001-03-30
; PRIOR APPLICATION NUMBER: 60/314,330
; PRIOR FILING DATE: 2001-08-20
; NUMBER OF SEQ ID NOS: 192
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 25
; LENGTH: 11
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: oligonucleotide
US-10-113-877-25
```

```
Query Match          66.7%; Score 6; DB 9; Length 11;
Best Local Similarity 66.7%; Pred. No. 2.9e+04;
Matches 6; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

```
QY      1 TTCNNNGAA 9
        ||| |||
Db       10 TTCGCGGAA 2
```

```
RESULT 11
US-10-113-877-23
; Sequence 23, Application US/10113877
; Patent No. US20020177218A1
; GENERAL INFORMATION:
; APPLICANT: Fang, Yu
; APPLICANT: Wang, Xiao-Yang
; APPLICANT: Turpin, Pierre
; TITLE OF INVENTION: Methods of detecting multiple DNA
; TITLE OF INVENTION: binding protein and DNA interactions in a sample, and
; FILE REFERENCE: CLON-071
; CURRENT APPLICATION NUMBER: US/10/113,877
; CURRENT FILING DATE: 2002-03-29
; PRIOR APPLICATION NUMBER: 60/280,658
; PRIOR FILING DATE: 2001-03-30
; PRIOR APPLICATION NUMBER: 60/314,330
; PRIOR FILING DATE: 2001-08-20
; NUMBER OF SEQ ID NOS: 192
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 23
; LENGTH: 12
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: oligonucleotide
US-10-113-877-23
```

```
Query Match          66.7%; Score 6; DB 9; Length 12;
Best Local Similarity 66.7%; Pred. No. 2.9e+04;
Matches 6; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

```
QY      1 TTCNNNGAA 9
        ||| |||
Db       2 TTCGCGGAA 10
```

```
RESULT 12
US-10-113-877-23/c
; Sequence 23, Application US/10113877
; Patent No. US20020177218A1
; GENERAL INFORMATION:
; APPLICANT: Fang, Yu
; APPLICANT: Wang, Xiao-Yang
; APPLICANT: Turpin, Pierre
; TITLE OF INVENTION: Methods of detecting multiple DNA
; TITLE OF INVENTION: binding protein and DNA interactions in a sample, and
; FILE REFERENCE: CLON-071
; CURRENT APPLICATION NUMBER: US/10/113,877
; CURRENT FILING DATE: 2002-03-29
; PRIOR APPLICATION NUMBER: 60/280,658
; PRIOR FILING DATE: 2001-03-30
; PRIOR APPLICATION NUMBER: 60/314,330
; PRIOR FILING DATE: 2001-08-20
; NUMBER OF SEQ ID NOS: 192
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 23
; LENGTH: 12
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: oligonucleotide
US-10-113-877-23
```

```
Query Match          66.7%; Score 6; DB 9; Length 12;
Best Local Similarity 66.7%; Pred. No. 2.9e+04;
Matches 6; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

```
QY      1 TTCNNNGAA 9
        ||| |||
Db       10 TTCGCGGAA 2
```

```
RESULT 13
US-10-113-877-24
; Sequence 24, Application US/10113877
; Patent No. US20020177218A1
; GENERAL INFORMATION:
; APPLICANT: Fang, Yu
; APPLICANT: Wang, Xiao-Yang
; APPLICANT: Turpin, Pierre
; TITLE OF INVENTION: Methods of detecting multiple DNA
; TITLE OF INVENTION: binding protein and DNA interactions in a sample, and
; FILE REFERENCE: CLON-071
; CURRENT APPLICATION NUMBER: US/10/113,877
; CURRENT FILING DATE: 2002-03-29
; PRIOR APPLICATION NUMBER: 60/280,658
; PRIOR FILING DATE: 2001-03-30
; PRIOR APPLICATION NUMBER: 60/314,330
; PRIOR FILING DATE: 2001-08-20
; NUMBER OF SEQ ID NOS: 192
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 24
; LENGTH: 12
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: oligonucleotide
US-10-113-877-24
```

```
Query Match          66.7%; Score 6; DB 9; Length 12;
Best Local Similarity 66.7%; Pred. No. 2.9e+04;
Matches 6; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

```
QY      1 TTCNNNGAA 9
        ||| |||
Db       2 TTCCTTGAA 10
```

RESULT 14

US-10-113-877-24/C
 ; Sequence 24, Application US/10113877
 ; Patent No. US20020177218A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Fang, Yu
 ; APPLICANT: Wang, Xiao-Yang
 ; APPLICANT: Turpin, Pierre
 ; TITLE OF INVENTION: Methods of detecting multiple DNA
 ; TITLE OF INVENTION: binding protein and DNA interactions in a sample, and
 ; TITLE OF INVENTION: devices, systems and kits for practicing the same.
 ; FILE REFERENCE: CLON-071
 ; CURRENT APPLICATION NUMBER: US/10/113,877
 ; CURRENT FILING DATE: 2002-03-29
 ; PRIOR APPLICATION NUMBER: 60/280,658
 ; PRIOR FILING DATE: 2001-03-30
 ; PRIOR APPLICATION NUMBER: 60/314,330
 ; PRIOR FILING DATE: 2001-08-20
 ; NUMBER OF SEQ ID NOS: 192
 ; SOFTWARE: FastSeq for Windows Version 4.0
 ; SEQ ID NO 24
 ; LENGTH: 12
 ; TYPE: DNA
 ; ORGANISM: Artificial Sequence
 ; FEATURE:
 ; OTHER INFORMATION: oligonucleotide
 US-10-113-877-24

Query Match

Best Local Similarity 66.7%; Score 6; DB 9; Length 12;
 Matches 6; Conservative 0; Mismatches 3; Indels 0;

QY 1 TTCNNNGAA 9
 ||| |||
 Db 10 TTCACGAA 2

RESULT 15

US-09-504-231A-366
 ; Sequence 366, Application US/09504231A
 ; Patent No. US20020013458A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Blatt, Lawrence
 ; APPLICANT: McSwiggen, James
 ; APPLICANT: Roberts, Beth
 ; APPLICANT: Pavco, Pamela
 ; APPLICANT: Macejak, Dennis
 ; TITLE OF INVENTION: ENZYMATIC NUCLEIC ACID TREATMENT OF DISEASES OR CONDITIONS RELATE
 ; TITLE OF INVENTION: HEPATITIS C VIRUS INFECTION
 ; FILE REFERENCE: rpl 247/282
 ; CURRENT APPLICATION NUMBER: US/09/504,231A
 ; CURRENT FILING DATE: 2000-02-15
 ; PRIOR APPLICATION NUMBER: 09/274,553
 ; PRIOR FILING DATE: 1999-03-23
 ; PRIOR APPLICATION NUMBER: 09/257,608
 ; PRIOR FILING DATE: 1999-02-24
 ; PRIOR APPLICATION NUMBER: 60/100,842
 ; PRIOR FILING DATE: 1998-09-18
 ; PRIOR APPLICATION NUMBER: 60/083,217
 ; PRIOR FILING DATE: 1998-04-27
 ; NUMBER OF SEQ ID NOS: 3242
 ; SOFTWARE: PatentIn version 3.0
 ; SEQ ID NO 366
 ; LENGTH: 15
 ; TYPE: RNA
 ; ORGANISM: Artificial Sequence
 ; FEATURE:
 ; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid Target
 US-09-504-231A-366

Matches 4; Conservative 2; Mismatches 3; Indels 0; Gaps 0;

QY 1 TTCNNNGAA 9
 :|| |||
 Db 7 UUCACCGAA 15

Search completed: December 25, 2002, 22:45:49
 Job time : 55 secs

Query Match 66.7%; Score 6; DB 10; Length 15;
 Best Local Similarity 44.4%; Pred. No. 3e+04;

GenCore version 5.1.3
Copyright (c) 1993 - 2002 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: December 25, 2002, 12:30:59 : Search time 1971 seconds

(without alignments)
73.952 Million cell updates/sec

Title: SCHMIDT875

Perfect score: 9

Sequence: 1 ttcnngaa 9

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 16154066 seqs, 8097743376 residues

Total number of hits satisfying chosen parameters: 357874

Minimum DB seq length: 0

Maximum DB seq length: 100

Post-processing: Maximum Match 0%

Listing first 45 summaries

Database :

EST:*
1: em_estba:*
2: em_esthum:*
3: em_estlin:*
4: em_estmu:*
5: em_estov:*
6: em_estpl:*
7: em_estro:*
8: em_hic:*
9: gb_est1:*
10: gb_est2:*
11: gb_hic:*
12: gb_est3:*
13: gb_est4:*
14: gb_est5:*
15: em_estum:*
16: em_estom:*
17: gb_gss:*
18: em_gss_hum:*
19: em_gss_inv:*
20: em_gss_pln:*
21: em_gss_vtc:*
22: em_gss_fun:*
23: em_gss_man:*
24: em_gss_mus:*
25: em_gss_other:*
26: em_gss_pro:*
27: em_gss_rod:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	6	66.7	19	17	AZ835621 2M0129L21
2	6	66.7	19	17	AZ835621 2M0129L21
3	6	66.7	20	13	BM400102 5009-0-66
4	6	66.7	20	13	BM400102 5009-0-66
5	6	66.7	21	17	AZ360212 1M0103K04
6	6	66.7	21	17	AZ360212 1M0103K04

7	6	66.7	21	17	AZ484782
8	6	66.7	22	17	AZ484782
9	6	66.7	22	17	AZ430664
10	6	66.7	22	17	AZ430664
11	6	66.7	22	17	AZ508843
12	6	66.7	22	17	AZ508843
13	6	66.7	22	17	AZ508843
14	6	66.7	22	17	AZ816374
15	6	66.7	22	17	AZ816374
16	6	66.7	22	17	TA196602P
17	6	66.7	23	9	AU012492
18	6	66.7	23	9	AU012492
19	6	66.7	23	17	AZ305600
20	6	66.7	23	17	AZ305600
21	6	66.7	23	17	AZ388663
22	6	66.7	23	17	AZ388663
23	6	66.7	23	17	AZ424145
24	6	66.7	23	17	AZ424145
25	6	66.7	23	17	AZ424145
26	6	66.7	23	17	AZ847801
27	6	66.7	23	17	AZ847801
28	6	66.7	24	14	L32040
29	6	66.7	24	17	AZ357286
30	6	66.7	24	17	AZ357286
31	6	66.7	24	17	AZ829302
32	6	66.7	24	17	AZ829302
33	6	66.7	24	17	TA196602P
34	6	66.7	24	17	TA196602P
35	6	66.7	24	17	TA256C04P
36	6	66.7	24	17	TA256C04P
37	6	66.7	24	17	TA273G07Q
38	6	66.7	24	17	TA273G07Q
39	6	66.7	25	9	AI247983
40	6	66.7	25	9	AI247983
41	6	66.7	25	17	BH863680
42	6	66.7	25	17	BH863680
43	6	66.7	26	17	AZ822697
44	6	66.7	26	17	AZ822697
45	6	66.7	27	14	L32053

ALIGNMENTS

RESULT 1
AZ835621
LOCUS 19 bp DNA linear GSS 20-FEB-2001
DEFINITION 2M0129L21R Mouse 10kb plasmid JUNGCM library Mus musculus genomic
clone JUNG2M0129L21 R. DNA sequence.
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
GSS
house mouse.
Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
1 (bases 1 to 19)
A835621.1 GI:13005529

TITLE

JOURNAL COMMENT

Unpublished (2000)
Contract: Robert B. Weiss
University of Utah Genome Center
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunne@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00

Plate: 0129 row: L column: 21
 Seq primer: CACACAGAAACGCTATGACC
 Class: plasmid ends
 High quality sequence stop: 19.
 Location/Qualifiers
 1..19

FEATURES
 source
 /organism="Mus musculus"
 /strain="C57BL/6J"
 /db_xref="taxon:10090"
 /clone="UUCG2M0129L21"
 /clone_1lb="Mouse 10kb plasmid UUCGCM library"
 /sex="Male"
 /lab_host="E. coli strain XL10-Gold, T1-resistant, F-"
 /note="Vector: PMD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adapted DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of PMD42 (q1473211419b)AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adapted mouse DNA was annealed to adapted vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

BASE COUNT
 6 a 3 c 3 g 7 t
 ORIGIN

Query Match 66.7%; Score 6; DB 17; Length 19;
 Best Local Similarity 66.7%; Pred. No. 4.4e+05;
 Matches 6; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1 TTCNNNGAA 9
 ||| |||
 Db 2 TTCTGTGAA 10

RESULT 2
 A2835621/c 19 bp DNA linear GSS 20-FEB-2001
 LOCUS 2M0129L21R Mouse 10kb plasmid UUCGCM library Mus musculus genomic
 DEFINITION clone UUCG2M0129L21 R. DNA sequence.
 ACCESSION A2835621
 VERSION A2835621.1 GI:13005529
 KEYWORDS GSS.
 SOURCE house mouse.
 ORGANISM Mus musculus
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathia; Muridae; Mus.
 1 (bases 1 to 19)
 Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamill,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tingy,A., von Niederhausen,A. and Wright,D., Weiss,R.
 Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts
 Unpublished (2000)
 Contact: Robert B. Weiss
 University of Utah Genome Center
 University of Utah
 Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA
 Tel: 801 585 5606
 Fax: 801 585 7177
 Email: ddunn@genetics.utah.edu
 Insert length: 10000 Std Error: 0.00

Plate: 0129 row: L column: 21
 Seq primer: CACACAGAAACGCTATGACC
 Class: plasmid ends
 High quality sequence stop: 19.
 Location/Qualifiers
 1..19

FEATURES
 source
 /organism="Mus musculus"
 /strain="C57BL/6J"
 /db_xref="taxon:10090"
 /clone="UUCG2M0129L21"
 /clone_1lb="Mouse 10kb plasmid UUCGCM library"
 /sex="Male"
 /lab_host="E. coli strain XL10-Gold, T1-resistant, F-"
 /note="Vector: PMD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adapted DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of PMD42 (q1473211419b)AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adapted mouse DNA was annealed to adapted vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

BASE COUNT
 6 a 3 c 3 g 7 t
 ORIGIN

Query Match 66.7%; Score 6; DB 17; Length 19;
 Best Local Similarity 66.7%; Pred. No. 4.4e+05;
 Matches 6; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1 TTCNNNGAA 9
 ||| |||
 Db 10 TTCACAGAA 2

RESULT 3
 BM400102 20 bp mRNA linear EST 17-JAN-2002
 LOCUS 5009-0-66-D02.t.2 ChllocaT/Turkewitz CDNA (large fraction)
 DEFINITION Tetrahymena thermophila cDNA, mRNA sequence.
 ACCESSION BM400102
 VERSION BM400102.1 GI:18200155
 KEYWORDS EST.
 SOURCE Tetrahymena thermophila.
 ORGANISM Tetrahymena thermophila.
 Eukaryota; Alveolata; Ciliophora; Oligohymenophorea; Hymenostomatida; Tetrahymenina; Tetrahymena.
 1 (bases 1 to 20)
 Turkewitz,A.P., Karier,K.M., Jahn,C., Orias,E., Kirk,K.E., Frankel,J. and Klobutcher,L.
 EST from Tetrahymena thermophila, strain CU428.1, growing cells
 Unpublished (2002)
 Contact: Turkewitz AP
 Molecular Genetics and Cell Biology
 University of Chicago
 920 E. 58th Street, Chicago, IL 60637, USA
 Tel: 773 702 4374
 Fax: 773 702 3172
 Email: apturkew@midway.uchicago.edu
 Seq primer: T3.

FEATURES
 source
 1..20
 /organism="Tetrahymena thermophila"
 /strain="CU428.1"


```

/db_xref="taxon:5911"
/clone_id="Chilcoat/Turkewitz cDNA (large fraction)"
/Note="Vector: Bluescript2 SK+; Details on library
preparation can be found in Chilcoat and Turkewitz (2001)
Proc. Natl. Acad. Sci USA, 98: 8709-8713."
BASE COUNT      4 a      3 c      8 g      5 t
ORIGIN

Query Match      66.7%; Score 6; DB 13; Length 20;
Best Local Similarity 66.7%; Pred. No. 4.5e+05;
Matches 6; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      1 TTCNNNGAA 9
        ||| |||
        20 TTCCCGGAA 12

RESULT 4
BM400102/c      20 bp      mRNA      linear      EST 17-JAN-2002
LOCUS      BM400102
DEFINITION      5009-0-66-D02.t.2 Chilcoat/Turkewitz cDNA (large fraction)
Tetrahymena thermophila cDNA, mRNA sequence.
ACCESSION      BM400102
VERSION      BM400102.1 GI:18200155
KEYWORDS      EST.
SOURCE      Tetrahymena thermophila.
ORGANISM      Tetrahymena thermophila.
REFERENCE      Eukaryota; Alveolata; Ciliophora; Oligohymenophorea;
AUTHORS      Hymenostomatida; Tetrahymena.
1 (bases 1 to 20)
Turkewitz A.P., Karrer, K.M., Jahn, C., Orias, E., Kirk, K.E., Frankel
J., and Klobutcher, L.
EST from Tetrahymena thermophila, strain CU428.1, growing cells
Unpublished (2002)
JOURNAL      Contact: Turkewitz AP
COMMENT      Molecular Genetics and Cell Biology
University of Chicago
920 E. 58th Street, Chicago, IL 60637, USA
Tel: 773 702 4374
Fax: 773 702 3172
Email: apturkew@midway.uchicago.edu
Seq primer: T3.
FEATURES
Source      Location/Qualifiers
1..20
/organism="Tetrahymena thermophila"
/strain="CU428.1"
/db_xref="taxon:5911"
/clone_id="Chilcoat/Turkewitz cDNA (large fraction)"
/Note="Vector: Bluescript2 SK+; Details on library
preparation can be found in Chilcoat and Turkewitz (2001)
Proc. Natl. Acad. Sci USA, 98: 8709-8713."
BASE COUNT      4 a      3 c      8 g      5 t
ORIGIN

Query Match      66.7%; Score 6; DB 13; Length 20;
Best Local Similarity 66.7%; Pred. No. 4.5e+05;
Matches 6; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      1 TTCNNNGAA 9
        ||| |||
        20 TTCCCGGAA 12

RESULT 5
A2360212
LOCUS      A2360212      21 bp      DNA      linear      GSS 02-OCT-2000
DEFINITION      M0103K04F Mouse 10Kb plasmid UUC1M library Mus musculus genomic
clone UUC1M0103K04 F, DNA sequence.
ACCESSION      A2360212
VERSION      A2360212.1 GI:10473912
KEYWORDS      GSS.
SOURCE      house mouse.
ORGANISM      Mus musculus

```

```

REFERENCE      Mammalia; Euteria; Rodentia; Sclerognathi; Muridae; Murinae; Mus.
1 (bases 1 to 21)
Dunn, D., Aoyagi, A., Barber, M., Beacorn, T., Duval, B., Hamill, C.,
Islam, H., Longacre, S., Mahmood, M., Meenen, E., Pedersen, T., Reilly
M., Rose, M., Rose, R., Stokes, R., Tinney, A., von Niederhausern, A.
and Wright, D., Weiss, R.
Mouse whole genome scaffolding with paired end reads from 10kb
plasmid inserts
TITLE      Unpublished (2000)
JOURNAL      Contact: Robert B. Weiss
COMMENT      University of Utah Genome Center
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0103 row: K column: 04
Seq primer: CATTGTAAACGACGCGCAGT
Class: Plasmid ends
High quality sequence stop: 21.
FEATURES
Source      Location/Qualifiers
1..21
/organism="Mus musculus"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone_id="UUC1M0103K04"
/sex="Male"
/lab_host="E. coli strain XL10-Gold, T1-resistant, F-'"
/Note="Vector: pMD207; Purified genomic DNA from M.
musculus C57BL/6J (male) was obtained from the Jackson
Laboratory Mouse DNA Resource
(http://www.jax.org/resources/documents/dnares/). The DNA
was hydrodynamically sheared by repeated passage through a
0.005 inch orifice at constant velocity. The sheared DNA
was blunt end-repaired with T4 DNA polymerase and T4
polynucleotide kinase. Adaptor oligonucleotides were
ligated to the blunt ends in high molar excess. The
adapted DNA was purified and size-selected for a 9.5 to
10.5 kb range using preparative agarose gel
electrophoresis. Vector DNA was prepared from a derivative
of pMD42 (g1473214|gb|AF129072.1), a copy-number
inducible derivative of plasmid R1. The vector was ligated
with adaptors complementary to the insert adaptors and
purified. The sheared, adapted mouse DNA was annealed to
chemically-competent E. coli XL10-Gold (Stratagene) cells
and selected for ampicillin resistance."
BASE COUNT      6 a      7 c      5 g      3 t
ORIGIN

Query Match      66.7%; Score 6; DB 17; Length 21;
Best Local Similarity 66.7%; Pred. No. 4.5e+05;
Matches 6; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      1 TTCNNNGAA 9
        ||| |||
        7 TTCTGGGAA 15

RESULT 6
A2360212/c
LOCUS      A2360212      21 bp      DNA      linear      GSS 02-OCT-2000
DEFINITION      M0103K04F Mouse 10Kb plasmid UUC1M library Mus musculus genomic
clone UUC1M0103K04 F, DNA sequence.
ACCESSION      A2360212
VERSION      A2360212.1 GI:10473912
KEYWORDS      GSS.
SOURCE      house mouse.
ORGANISM      Mus musculus

```

REFERENCE	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus; 1 (bases 1 to 21)			
AUTHORS	Dunn,D., Noyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tingley,A., von Niederhausern,A. and Wright,D., Weiss,R.			
TITLE	Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts			
JOURNAL	Unpublished (2000)			
COMMENT	Contact: Robert B. Weiss University of Utah Genome Center University of Utah Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA Tel: 801 585 5606 Fax: 801 585 7177 Email: ddunn@genetics.utah.edu Insert Length: 10000 Std Error: 0.00 Plate: 0103 row: K column: 04 Seq primer: CGTGTGTAACGACGCGCCAT Class: plasmid ends High quality sequence stop: 21. Location/Qualifiers 1. 21 /organism="Mus musculus" /strain="C57BL/6J" /db_xref="taxon:10090" /clone="UUCG1M0103K04" /clone_1lb="Mouse 10kb plasmid UUCG1M library" /sex="Male" /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-" /note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptor DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pMD2 (gi14732114 gb AF129072.1), a copy-number-inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptor mouse DNA was annealed to adaptor vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."			
BASE COUNT	6 a 5 g 3 t			
ORIGIN	7 c			
Query Match	66.78; Score 6; DB 17; Length 21;			
Best Local Similarity	65.78; P-adj. No. 4.5e+05;			
Matches	6; Conservative 0; Mismatches 3; Indels 0; Gaps 0;			
QY	1 TTCNNNGAA 9			
Db	15 TTCGCAGAA 7			
RESULT 7	A2484782 21 bp DNA linear GSS 05-OCT-2000			
LOCUS	A2484782			
DEFINITION	1M0311C05R Mouse 10kb plasmid UUCG1M library Mus musculus genomic clone UUCG1M0311C05 R, DNA sequence.			
ACCESSION	A2484782			
VERSION	A2484782.1 GI:10649960			
KEYWORDS	GSS.			
SOURCE	house mouse.			
ORGANISM	Mus musculus			

REFERENCE	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
AUTHORS	1 (bases 1 to 21) Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A. and Wright,D., Weiss,R.
TITLE	Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts
JOURNAL	Unpublished (2000)
COMMENT	Contact: Robert B. Weiss University of Utah Genome Center University of Utah Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLIC, UT 84112, USA Tel: 801 585 5606 Fax: 801 585 7177 Email: ddunn@genetics.utah.edu Insert Length: 10000 Std Error: 0.00 Plate: 0311 row: C column: 05 Seq primer: CACACGGAACAGCTATGACC Clas: plasmid ends High quality sequence stop: 21. Location/Qualifiers 1. . 21
FEATURES	source 1..21 /organism="Mus musculus" /strain="C57BL/6J" /db_xref="taxon:10090" /clone="MUGCM311C05" /clone_1lb="Mouse 10kb plasmid UMGCM library" /sex="Male" /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-" /note="Vector: PWD42ny; Purified genomic DNA from Mus musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptor DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of PWD42 (q114732114[gb AF129072.1]), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptor mouse DNA was annealed to adaptor vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."
BASE COUNT	7 a 3 c 4 g 7 t
ORIGIN	
Query Match	66.7%; Score 6; DB 17; Length 21;
Best Local Similarity	66.7%; Pred. No. 4.5e-05;
Matches	6; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY	1 TTCCNNNGAA 9
Db	1 TTCCGCTGAA 9
RESULT 8	
AZ484782/c	21 bp DNA linear GSS 05-OCT-2000
LOCUS	AZ484782
DEFINITION	IM0311C05R Mouse 10kb plasmid UMGCM library Mus musculus genomic
ACCESSION	clone UMGCM0311C05 R, DNA sequence.
VERSION	AZ484782.1 GI:10649960
KEYWORDS	GSS.
SOURCE	house mouse.
ORGANISM	Mus musculus

REFERENCE

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus. 1 (bases 1 to 21)

AUTHORS

Dunn, D., Aoyagi, A., Barber, M., Beacorn, T., Duval, B., Hamil, C., Islam, H., Longacre, S., Mahmoud, M., Meenen, E., Pedersen, T., Reilly, M., Rose, M., Rose, R., Stokes, R., Tingey, A., von Niederhausern, A. and Wright, D., Weiss, R.

TITLE

Mouse whole genome scaffolding with paired end reads from 10kb

JOURNAL

Unpublished (2000)

COMMENT

Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0311 row: C column: 05
Seq primer: CACACAGAAACGCTATGACC
Class: plasmid ends
High quality sequence stop: 21.

FEATURES

Location/Qualifiers

1..21

/organism="Mus musculus"

/strain="C57BL/6J"

/db_xref="taxon:10090"

/clone="UUCG1M0311C05"

/clone_1lb="Mouse 10kb plasmid UUCG1M library"

/sex="Male"

/lab_host="E. coli strain XL10-Gold, TI-resistant, F-"

/note="Vector: PMD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource

(http://www.jax.org/resources/documents/dnares/). The DNA

was hydrodynamically sheared by repeated passage through a

0.005 inch orifice at constant velocity. The sheared DNA

was blunt end-repaired with T4 DNA polymerase and T4

polynucleotide kinase. Adaptor oligonucleotides were

ligated to the blunt ends in high molar excess. The

adapted DNA was purified and size-selected for a 9.5 to

10.5 kb range using preparative agarose gel

electrophoresis. Vector DNA was prepared from a derivative

of PMD42 (g14732114|gb|AF129072.1), a copy-number

inducible derivative of plasmid R1. The vector was ligated

with adaptors complementary to the insert adaptors and

purified. The sheared, adapted mouse DNA was annealed to

chemically-competent E. coli XL10-Gold (Stratagene) cells

and selected for ampicillin resistance."

BASE COUNT

7 a 3 c 4 g 7 t

ORIGIN

Query Match 66.7%; Score 6; DB 17; Length 21;

Best Local Similarity 66.7%; Pred. No. 4.5e+05;

Matches 6; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 1 TTCNNNGAA 9

Db 9 TTCACCGAA 1

RESULT 9

LOCUS

DEFINITION

ACCESSION

VERSION

KEYWORDS

SOURCE

ORGANISM

AZ430664
1M0215D17F Mouse 10kb plasmid UUCG1M library Mus musculus genomic
clone UUCG1M0215D17 F, DNA sequence.
GI:10554677
house mouse.
Mus musculus

REFERENCE

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus. 1 (bases 1 to 22)

AUTHORS

Dunn, D., Aoyagi, A., Barber, M., Beacorn, T., Duval, B., Hamil, C., Islam, H., Longacre, S., Mahmoud, M., Meenen, E., Pedersen, T., Reilly, M., Rose, M., Rose, R., Stokes, R., Tingey, A., von Niederhausern, A. and Wright, D., Weiss, R.

TITLE

Mouse whole genome scaffolding with paired end reads from 10kb

JOURNAL

Unpublished (2000)

COMMENT

Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0215 row: D column: 17
Seq primer: CGTTGTAAACGACGCGCAGT
Class: plasmid ends
High quality sequence stop: 22.

FEATURES

Location/Qualifiers

1..22

/organism="Mus musculus"

/strain="C57BL/6J"

/db_xref="taxon:10090"

/clone="UUCG1M0215D17"

/clone_1lb="Mouse 10kb plasmid UUCG1M library"

/sex="Male"

/lab_host="E. coli strain XL10-Gold, TI-resistant, F-"

/note="Vector: PMD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource

(http://www.jax.org/resources/documents/dnares/). The DNA

was hydrodynamically sheared by repeated passage through a

0.005 inch orifice at constant velocity. The sheared DNA

was blunt end-repaired with T4 DNA polymerase and T4

polynucleotide kinase. Adaptor oligonucleotides were

ligated to the blunt ends in high molar excess. The

adapted DNA was purified and size-selected for a 9.5 to

10.5 kb range using preparative agarose gel

electrophoresis. Vector DNA was prepared from a derivative

of PMD42 (g14732114|gb|AF129072.1), a copy-number

inducible derivative of plasmid R1. The vector was ligated

with adaptors complementary to the insert adaptors and

purified. The sheared, adapted mouse DNA was annealed to

chemically-competent E. coli XL10-Gold (Stratagene) cells

and selected for ampicillin resistance."

BASE COUNT

6 a 4 c 3 g 9 t

ORIGIN

Query Match 66.7%; Score 6; DB 17; Length 22;

Best Local Similarity 66.7%; Pred. No. 4.6e+05;

Matches 6; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 1 TTCNNNGAA 9

Db 13 TTCTGGCAA 21

RESULT 10

LOCUS

DEFINITION

ACCESSION

VERSION

KEYWORDS

SOURCE

ORGANISM

AZ430664/c
1M0215D17F Mouse 10kb plasmid UUCG1M library Mus musculus genomic
clone UUCG1M0215D17 F, DNA sequence.
GI:10554677
house mouse.
Mus musculus

REFERENCE 1 (bases 1 to 22)
 AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamill,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausen,A. and Wright,D., Weiss,R.
 TITLE Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts
 JOURNAL Unpublished (2000)
 COMMENT Contact: Robert B. Weiss
 University of Utah
 Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA
 Tel: 801 585 5606
 Fax: 801 585 7177
 Email: ddunn@genetics.utah.edu
 Insert Length: 10000 Std Error: 0.00
 Plate: 0215 row: D column: 17
 Seq primer: CGTTGTAAACGACGCGCAGT
 Class: plasmid ends
 High quality sequence stop: 22.
 Location/Qualifiers
 1..22
 /organism="Mus musculus"
 /strain="C57BL/6J"
 /db_xref="taxon:10090"
 /clone="U08C1M0215D17"
 /clone_1lb="Mouse 10kb plasmid U08C1M library"
 /sex="Male"
 /lab_host="E. coli strain XL10-Gold, T1-resistant, F-"
 /note="Vector: PMD42nv. Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adapted DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of PMD42 (g14732114|9b|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adapted mouse DNA was annealed to adapted vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

BASE COUNT 6 a 4 c 3 g 9 t
 ORIGIN
 Query Match 66.7%; Score 6; DB 17; Length 22;
 Best Local Similarity 66.7%; Pred. No. 4.6e+05;
 Matches 6; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1 TTCNNNGAA 9
 ||| |||
 Db 21 TTCCAGGAA 13

RESULT 11
 A2508843
 LOCUS 22 bp DNA linear GSS 05-OCT-2000
 DEFINITION IM0351E06R Mouse 10kb plasmid U08C1M library Mus musculus genomic
 clone U08C1M0351E06 R, DNA sequence.
 ACCESSION A2508843
 VERSION A2508843.1 GI:10690159
 KEYWORDS GSS.
 SOURCE house mouse.
 ORGANISM Mus musculus

REFERENCE 1 (bases 1 to 22)
 AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamill,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausen,A. and Wright,D., Weiss,R.
 TITLE Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts
 JOURNAL Unpublished (2000)
 COMMENT Contact: Robert B. Weiss
 University of Utah
 Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA
 Tel: 801 585 5606
 Fax: 801 585 7177
 Email: ddunn@genetics.utah.edu
 Insert Length: 10000 Std Error: 0.00
 Plate: 0351 row: E column: 06
 Seq primer: CACACAGAAACACGTATGAC
 Class: plasmid ends
 High quality sequence stop: 22.
 Location/Qualifiers
 1..22
 /organism="Mus musculus"
 /strain="C57BL/6J"
 /db_xref="taxon:10090"
 /clone="U08C1M0351E06"
 /clone_1lb="Mouse 10kb plasmid U08C1M library"
 /sex="Male"
 /lab_host="E. coli strain XL10-Gold, T1-resistant, F-"
 /note="Vector: PMD42nv. Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adapted DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of PMD42 (g14732114|9b|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adapted mouse DNA was annealed to adapted vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

BASE COUNT 6 a 5 c 3 g 8 t
 ORIGIN
 Query Match 66.7%; Score 6; DB 17; Length 22;
 Best Local Similarity 66.7%; Pred. No. 4.6e+05;
 Matches 6; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1 TTCNNNGAA 9
 ||| |||
 Db 7 TTCAAGTGA 15

RESULT 12
 A2508843/c
 LOCUS 22 bp DNA linear GSS 05-OCT-2000
 DEFINITION IM0351E06R Mouse 10kb plasmid U08C1M library Mus musculus genomic
 clone U08C1M0351E06 R, DNA sequence.
 ACCESSION A2508843
 VERSION A2508843.1 GI:10690159
 KEYWORDS GSS.
 SOURCE house mouse.
 ORGANISM Mus musculus

REFERENCE
AUTHORS

Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
1 (bases 1 to 22)
Dunn, D., Aoyagi, A., Barber, M., Beacorn, T., Duval, B., Hamil, C.,
Islam, H., Longacre, S., Mahmoud, M., Meenen, E., Pedersen, T., Rellily
, M., Rose, M., Rose, R., Stokes, R., Tingey, A., von Niederhausen, A.
and Wright, D., Weiss, R.

TITLE

Mouse whole genome scaffolding with paired end reads from 10kb
plasmid inserts

JOURNAL
COMMENT

Unpublished (2000)
Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0351 row: E column: 06
Seq primer: CACACAGAAACGCTATGACC
Class: plasmid ends
High quality sequence stop: 22.

FEATURES

SOURCE

Location/Qualifiers

1..22

/organism="Mus musculus"

/strain="C57BL/6J"

/db_xref="taxon:10090"

/clone="UUGC1M0351E05"

/clone_1lb="Mouse 10kb plasmid UUGC1M library"

/sex="Male"

/lab_host="E. coli strain XL10-Gold, TI-resistant, F-"
/note="Vector: PMD42nv; Purified genomic DNA from M.
musculus C57BL/6J (male) was obtained from the Jackson
Laboratory Mouse DNA Resource
(http://www.jax.org/resources/documents/dnares/). The DNA
was hydrodynamically sheared by repeated passage through a
0.005 inch orifice at constant velocity. The sheared DNA
was blunt end-repaired with T4 DNA polymerase and T4
polynucleotide kinase. Adaptor oligonucleotides were
ligated to the blunt ends in high molar excess. The
adapted DNA was purified and size-selected for a 9.5 to
10.5 kb range using preparative agarose gel
electrophoresis. Vector DNA was prepared from a derivative
of PMD42 (g114732114|gb|AF129072.1), a copy-number
inducible derivative of plasmid R1. The vector was ligated
with adaptors complementary to the insert adaptors and
purified. The sheared, adapted mouse DNA was annealed to
adapted vector DNA, and transformed into
chemically-competent E. coli XL10-Gold (Stratagene) cells
and selected for ampicillin resistance."

BASE COUNT
ORIGIN

6 a 5 c 3 g 8 t

Query Match

Best Local Similarity 66.7%; Score 6; DB 17; Length 22;
Pred. No. 4.6e+05;

Matches 6; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1 TTCNNNGAA 9

Db 15 TTCACGAA 7

RESULT 13

AZ816374

LOCUS AZ816374 22 bp DNA linear GSS 20-FEB-2001
DEFINITION 2M0085005F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
clone UUGC2M0085005 F, DNA sequence.

ACCESSION AZ816374
VERSION AZ816374.1 GI:12986282

KEYWORDS GSS.

SOURCE house mouse.

ORGANISM Mus musculus

REFERENCE
AUTHORS

Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
1 (bases 1 to 22)
Dunn, D., Aoyagi, A., Barber, M., Beacorn, T., Duval, B., Hamil, C.,
Islam, H., Longacre, S., Mahmoud, M., Meenen, E., Pedersen, T., Rellily
, M., Rose, M., Rose, R., Stokes, R., Tingey, A., von Niederhausen, A.
and Wright, D., Weiss, R.

TITLE

Mouse whole genome scaffolding with paired end reads from 10kb
plasmid inserts

JOURNAL
COMMENT

Unpublished (2000)
Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0085 row: O column: 05
Seq primer: CGTGTAAACGACGCGCAGT
Class: plasmid ends
High quality sequence stop: 22.

FEATURES

SOURCE

Location/Qualifiers

1..22

/organism="Mus musculus"

/strain="C57BL/6J"

/db_xref="taxon:10090"

/clone="UUGC2M0085005"

/clone_1lb="Mouse 10kb plasmid UUGC1M library"

/sex="Male"

/lab_host="E. coli strain XL10-Gold, TI-resistant, F-"
/note="Vector: PMD42nv; Purified genomic DNA from M.
musculus C57BL/6J (male) was obtained from the Jackson
Laboratory Mouse DNA Resource
(http://www.jax.org/resources/documents/dnares/). The DNA
was hydrodynamically sheared by repeated passage through a
0.005 inch orifice at constant velocity. The sheared DNA
was blunt end-repaired with T4 DNA polymerase and T4
polynucleotide kinase. Adaptor oligonucleotides were
ligated to the blunt ends in high molar excess. The
adapted DNA was purified and size-selected for a 9.5 to
10.5 kb range using preparative agarose gel
electrophoresis. Vector DNA was prepared from a derivative
of PMD42 (g114732114|gb|AF129072.1), a copy-number
inducible derivative of plasmid R1. The vector was ligated
with adaptors complementary to the insert adaptors and
purified. The sheared, adapted mouse DNA was annealed to
adapted vector DNA, and transformed into
chemically-competent E. coli XL10-Gold (Stratagene) cells
and selected for ampicillin resistance."

BASE COUNT
ORIGIN

8 a 2 c 8 g 4 t

Query Match

Best Local Similarity 66.7%; Score 6; DB 17; Length 22;
Pred. No. 4.6e+05;

Matches 6; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1 TTCNNNGAA 9

Db 3 TTCCTAGAA 11

RESULT 14

AZ816374/c

LOCUS AZ816374 22 bp DNA linear GSS 20-FEB-2001
DEFINITION 2M0085005F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
clone UUGC2M0085005 F, DNA sequence.

ACCESSION AZ816374
VERSION AZ816374.1 GI:12986282

KEYWORDS GSS.

SOURCE house mouse.

ORGANISM Mus musculus

REFERENCE 1 (bases 1 to 22)
 AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamill,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausen,A. and Wright,D., Weiss,R.
 TITLE Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts
 JOURNAL Unpublished (2000)
 COMMENT Contact: Robert B. Weiss
 University of Utah
 Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA
 Tel: 801 585 5606
 Fax: 801 585 7177
 Email: ddunn@genetics.utah.edu
 Insert Length: 10000 Std Error: 0.00
 Plate: 0085 row: 0 column: 05
 Seq primer: CGTTGTAACGACGCGCCAGT
 Class: plasmid ends
 High quality sequence stop: 22.
 Location/Qualifiers
 1..22
 /organism="Mus musculus"
 /strain="C57BL/6J"
 /db_xref="taxon:10090"
 /clone="UUCG2M0085005"
 /clone_1ib="Mouse 10kb plasmid UUCG1M library"
 /sex="Male"
 /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
 /note="Vector: PMD42nv. Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adapted DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of PMD42 (g14732114[9b]AF129072.1), a copy-number inducible derivative of plasmid RL. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adapted mouse DNA was annealed to adapted vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

BASE COUNT 8 a 2 c 8 g 4 t
 ORIGIN
 Query Match 66.7%; Score 6; DB 17; Length 22;
 Best Local Similarity 66.7%; Pred. No. 4.6e+05;
 Matches 6; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 QY 1 TTCNNNGAA 9
 ||| |||
 DB 11 TTCCTGAGA 3

RESULT 15
 TAI96G02P 22 bp DNA linear GSS 13-DEC-2000
 LOCUS T. brucei sheared genomic DNA clone 196g02, forward sequence,
 DEFINITION genomic survey sequence.
 ACCESSION AL475949
 VERSION AL475949.1 GI:11842689
 KEYWORDS GSS.
 SOURCE Trypanosoma brucei.
 ORGANISM Trypanosoma brucei

REFERENCE 1 (bases 1 to 22)
 AUTHORS Hall,N., Bowman,S., Lennard,N.J., Doggett,J., Atkin,R., Chillingworth,C., Ormond,D., Harris,B., El-Sayed,N., Hou,L., Melville,S.E., Rajandream,M.A. and Barrell,B.G.
 TITLE Submitted (10-DEC-2000) Trypanosoma brucei genome sequencing project, Sanger Centre, The Wellcome Trust Genome Campus, Hinxton, Cambridge CB10 1SA, E-mail: barrell@sanger.ac.uk and nhlesanger.ac.uk
 COMMENT Constructed at the Institute for Genomic Research (TIGR), Rockville, MD. Genomic DNA isolated from a cloned population of Trypanosoma brucei (TREU927/4 GUTat 10.1) was mechanically sheared to give a tight size distribution (4 kb). The v + i method used for the library construction is described in detail in Smith, H. and Venter, J.C. (Making small insert libraries for whole genome shotgun sequencing projects. In Genome Sequencing: A Practical Approach, eds. M. Vaubin and B. Barrell, Oxford University Press, 1999).
 Email: nhlesayed@tigr.org
 Details of T. brucei sequencing at the Sanger Centre are available at http://www.sanger.ac.uk/Projects/T_brucei/.
 Location/Qualifiers
 1..22
 /organism="Trypanosoma brucei"
 /strain="TREU927"
 /db_xref="taxon:5691"
 /clone="196g02"
 4 a 5 c 6 g 7 t

BASE COUNT 4 a 5 c 6 g 7 t
 ORIGIN
 Query Match 66.7%; Score 6; DB 17; Length 22;
 Best Local Similarity 66.7%; Pred. No. 4.6e+05;
 Matches 6; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 QY 1 TTCNNNGAA 9
 ||| |||
 DB 2 TTCCTGAGA 10

Search completed: December 25, 2002, 20:55:16
 Job time : 1977 secs